Compositions and methods for delivery of pharmaceutical actives

Abstract

The present application provides compositions, excipient systems, methods, and dispensers for delivery of active pharmaceutical ingredients (APIs). In one example, a composition is provided comprising an active pharmaceutical ingredient; one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound. In another example, an excipient system is provided comprising one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof and a semi-fluorinated alkane compound. Dispensers containing the compositions are also provided and include glass and polyethylene terephthalate dispensers or containers. Methods of using the compositions are also provided and include a method for treating a condition in a subject comprising administering the compositions to the subject.

Description

[0001] ATTORNEY DOCKET NO.43081-0032WO1 COMPOSITIONS AND METHODS FOR DELIVERY OF PHARMACEUTICAL ACTIVES CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Application No. 63 / 656,461, filed on June 5, 2024, U.S. Application No.63 / 678,641, filed on August 2, 2024, and U.S. Application No.63 / 752,245, filed on January 31, 2025, the contents of which are hereby incorporated by reference. TECHNICAL FIELD This disclosure relates to compositions for delivery of active pharmaceutical ingredients (APIs), and methods for making and using the compositions. BACKGROUND Formulation of active pharmaceutical ingredients compounds (APIs) is an important step in delivering useful medicinal compounds to humans and animals in need and in making the compounds biologically available within the body, e.g., for treating and preventing various conditions or improving symptoms thereof. However, challenges with delivery formulations can limit the usability of the APIs, their activity and shelf life, and can in some instances result in systemic side effects. APIs are often formulated in aqueous formulations, however, many APIs can be insoluble in or degrade in aqueous formulations. Additionally, delivery needs, such as tissue type and preferences of the patient, among others, may make aqueous formulations less practical in some situations. A class of compounds, semi-fluorinated alkanes, has recently shown promise in formulating some APIs (Tsagogiorgas et al., “Semifluorinated Alkanes as New Drug Carriers-An Overview of Potential Medical and Clinical Applications,” Pharmaceutics, April 2023, 15(4):1211; Holm et al., “A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of ATTORNEY DOCKET NO.43081-0032WO1 poorly water-soluble drugs,” European Journal of Pharmaceutical Sciences, March 2011, 42(4):416-422), including in nonaqueous formulations. However, many APIs remain challenging to formulate. There remains a need for improved compositions for delivery of APIs. SUMMARY This disclosure relates to excipient systems and to compositions for delivery of active pharmaceutical ingredients (APIs). Applicant has surprisingly discovered an excipient system comprising semi- fluorinated alkanes (SFA) in combination with one or more excipient compounds that are oils with certain ester functionality can act as an ideal composition for formulating APIs, including difficult to formulate APIs. For example, in some instances, the one or more excipient compounds can be selected from hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof. While semi-fluorinated alkanes (SFA), which are amphiphilic nonaqueous organic liquids, have recently been shown to be useful as an excipient for, e.g., ocular and pulmonary uses, the use of SFAs as an API carrier seem to be limited due to the poor solubility of most APIs in SFAs (Holm et al., European Journal of Pharmaceutical Sciences, March 2011, 42(4):416-422). Applicant has surprisingly discovered that one or more of the excipient compound(s) can be mixed with semi- fluorinated alkanes to form stable, clear formulations, that allow solubility and / or suitable formulation of all of a wide range of classes of APIs. Applicant has also surprisingly discovered that the excipient system described herein and compositions described herein can provide improved delivery of an API to the cornea, e.g., by transcorneal absorption. In some instances, the compositions described herein are selectively transcorneally absorbed (e.g., compared with periorbital absorption). The improved delivery of the API to the cornea can allow for lower doses to be administered to a subject, and / or more frequent lower doses. Thus, the improved ATTORNEY DOCKET NO.43081-0032WO1 delivery of the API to the cornea reduces one or more adverse side effects of an API and can be used to treat ocular conditions in subjects highly sensitive to the API. In some instances, provided herein are compositions comprising: an active pharmaceutical ingredient (API); one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound. In some instances, provided herein is an excipient system for delivering an API to a subject comprising: one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound. This disclosure is based, at least in part, on a surprising realization that any API can be effectively formulated and delivered to humans or animals using the compositions described herein, and further that in some embodiments, the compositions can result in improved solubility of both water soluble and water insoluble APIs. This disclosure provides an excipient system for APIs comprising a semi- fluorinated alkane (SFA), one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof, and also provides compositions comprising a semi-fluorinated alkane (SFA), one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof, and an active pharmaceutical ingredient (API), and methods for making and using the compositions. The compositions described herein can provide improved delivery formulations for APIs. In some instances, the delivery can be topical delivery. In some instances, the delivery can be to ocular tissues, skin, mucosal membrane, oral tissue, esophageal tissue, or lung tissue. ATTORNEY DOCKET NO.43081-0032WO1 In one aspect, described herein is a composition comprising: an active pharmaceutical ingredient (API); one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound. In this and other instances, the compositions can optionally have the following features. The composition can be non-aqueous. The semi-fluorinated alkane compound can be selected from the group consisting of perfluorobutylpentane (F4H5), perfluorobutylhexane (F4H6), perfluorohexylbutane (F6H4), perfluorohexylhexane (F6H6), perfluorohexyloctane (F6H8), and perfluorohexyl decane (F6H10). The one or more excipient compound(s) can be selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof. The hydroxyalkyl ester of an aliphatic fatty acid can be a propylene glycol mono or di-ester of C4-C20 fatty acid, or a glycerol of 1, 2 or 1, 3 di-ester of C4-C20 fatty acid, or a glycerol of a mono ester of a C4-20 fatty acid. The fatty acid can be saturated or unsaturated, linear, or branched. The excipient compound(s) is a mixture of two or more different excipient compounds selected from hydroxyalkyl esters of an aliphatic fatty acid, hydroxyacid alkyl esters, alkyl esters of fatty acids, or combinations thereof. In these and other instances, the hydroxyalkyl ester of an aliphatic fatty acid is a compound of any one of Formulas (II)-(VIII):

[0002] ATTORNEY DOCKET NO.43081-0032WO1 ; ; ; ; ; ; and ; wherein: R6and R7can each, independently, be C3-C19 linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl; R can be H or an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-6 C atoms, optionally wherein one H atom on each carbon atom can independently be replaced with one -OH group; and n can be an integer from 1 to 12. In these and other instances, the hydroxyalkyl ester of an aliphatic fatty acid of any one of Formulas (II)-(VIII) can optionally have the following features. R6and R7can each, independently, be C7-C17 linear or branched alkyl. R can be an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-4 C atoms. The variable n can be selected from 2 or 3. In some instances, the alkyl ester of a fatty acid can be a compound of Formula (IX): ATTORNEY DOCKET NO.43081-0032WO1 , wherein: x can be an integer from 2 to 3; and y can be an integer from 4 to 7. In some instances, the hydroxyacid alkyl ester can be a medium-chain alkyl C12 to C15 lactate or glycolate. In some instances, In these and other instances, the hydroxyacid alkyl ester can be a compound of any one of Formulas (X)-(XII): ; ; and , wherein: R6and R7can each, independently, be C3-C19 linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl; R8can be C6-C20 linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl; and R can be H or an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-6 C atoms, optionally wherein one H atom on each carbon atom can independently be replaced with one -OH group. In these and other instances, the hydroxyacid alkyl ester can optionally have the following features. R8can be C12-C15 linear or branched alkyl. R can be an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-4 C atoms. In these and other instances, the excipient compound(s) can optionally have the following features. At least one or more of the one or more excipient compound(s) has a hydrophilic-lipophilic balance (HLB) value of less than or equal to 3.4 as calculated according to the formula: HLB = 20(1-(S / A)), wherein: S is number of ATTORNEY DOCKET NO.43081-0032WO1 ester saponification; and A is the acid number of the fatty acid. The excipient compound(s) can be present in a concentration of from about 0.1% to about 99% (w / w), from about 0.1% to about 80% (w / w), from about 0.1% to about 50% (w / w), from about 0.1% to about 30% (w / w), from about 0.1% to about 20% (w / w), from about 0.1% to about 15% (w / w), from about 0.1% to about 10% (w / w), from about 0.1% to about 5% (w / w), about 20% (w / w), about 15% (w / w), about 10% (w / w), about 5% (w / w), about 3% (w / w), or about 1% (w / w). The semi-fluorinated alkane compound can be present in a concentration of from about 1% to about 99.9% (w / w), from about 20% to about 99.9% (w / w), from about 50% to about 99.9% (w / w), from about 70% to about 99.9% (w / w), from about 80% to about 99.9% (w / w), from about 85% to about 99.9% (w / w), from about 90% to about 99.9% (w / w), from about 95% to about 99.9% (w / w), about 80% (w / w), about 85% (w / w), about 90% (w / w), about 95% (w / w), about 97% (w / w), or about 99% (w / w). The API can be present in a concentration of from about 0.001% to about 20%, from about 0.01% to 15% (w / w), from about 0.01% to 10% (w / w), from about 0.01% to 5% (w / w), from about 0.1% to 5% (w / w), or from about 0.1% to 4% (w / w). The API can be in a free base or salt form. The excipient compound(s) can be selected from 3-hydroxypropane-1,2-diyl bis(icosanoate); 3-hydroxypropane-1,2-diyl dinonadecanoate; 3-hydroxypropane-1,2- diyl distearate; 3-hydroxypropane-1,2-diyl diheptadecanoate; 3-hydroxypropane-1,2- diyl dipalmitate; 3-hydroxypropane-1,2-diyl dipentadecanoate; 3-hydroxypropane- 1,2-diyl ditetradecanoate; 3-hydroxypropane-1,2-diyl ditridecanoate; 3- hydroxypropane-1,2-diyl didodecanoate; 3-hydroxypropane-1,2-diyl diundecanoate; 3-hydroxypropane-1,2-diyl bis(decanoate); 3-hydroxypropane-1,2-diyl dinonanoate; 3-hydroxypropane-1,2-diyl dioctanoate; 1-(heptanoyloxy)-3-hydroxypropan-2-yl octanoate; 3-hydroxypropane-1,2-diyl diheptanoate; 2-(heptanoyloxy)-3- hydroxypropyl octanoate; 1-(hexanoyloxy)-3-hydroxypropan-2-yl heptanoate; 3- hydroxypropane-1,2-diyl dihexanoate; 1-hydroxy-3-(pentanoyloxy)propan-2-yl hexanoate; 1-(butyryloxy)-3-hydroxypropan-2-yl hexanoate; 1-(butyryloxy)-3- hydroxypropan-2-yl pentanoate; 3-hydroxypropane-1,2-diyl dibutyrate; 1- (butyryloxy)-3-hydroxypropan-2-yl octanoate; 2-(butyryloxy)-3-hydroxypropyl octanoate; 2-hydroxypropane-1,3-diyl bis(icosanoate); 2-hydroxypropane-1,3-diyl dinonadecanoate; 2-hydroxypropane-1,3-diyl distearate; 2-hydroxypropane-1,3-diyl diheptadecanoate; 2-hydroxypropane-1,3-diyl dipalmitate; 2-hydroxypropane-1,3-diyl dipentadecanoate; 2-hydroxypropane-1,3-diyl ditetradecanoate; 2-hydroxypropane- ATTORNEY DOCKET NO.43081-0032WO1 1,3-diyl ditridecanoate; 2-hydroxypropane-1,3-diyl didodecanoate; 2- hydroxypropane-1,3-diyl bis(decanoate); 2-hydroxy-3-(octanoyloxy)propyl decanoate; 2-hydroxypropane-1,3-diyl dioctanoate; 3-(hexanoyloxy)-2-hydroxypropyl octanoate; 2-hydroxypropane-1,3-diyl dihexanoate; 3-(hexanoyloxy)-2-hydroxypropyl octanoate; 3-(butyryloxy)-2-hydroxypropyl octanoate; 3-(butyryloxy)-2- hydroxypropyl hexanoate; 2-hydroxypropane-1,3-diyl dibutyrate; 2-hydroxyoctyl icosanoate; 2-hydroxyheptyl icosanoate; 2-hydroxyhexyl icosanoate; 2-hydroxypentyl icosanoate; 2-hydroxypentyl stearate; 2-hydroxypropyl stearate; 2-hydroxybutyl stearate; 2-hydroxybutyl palmitate; 2-hydroxypentyl palmitate; 2-hydroxypentyl tetradecanoate; 2-hydroxybutyl tetradecanoate; 2-hydroxypropyl tetradecanoate; 2- hydroxypentyl dodecanoate; 2-hydroxybutyl dodecanoate; 2-hydroxypropyl dodecanoate; 2-hydroxypropyl decanoate; 2-hydroxybutyl decanoate; 2- hydroxypentyl decanoate; 2-hydroxypentyl octanoate; 2-hydroxybutyl octanoate; 2- hydroxypropyl octanoate; 2-hydroxypropyl hexanoate; 2-hydroxypropyl butyrate; 2- hydroxybutyl butyrate; 1-hydroxyoctan-2-yl icosanoate; 1-hydroxyoctan-2-yl stearate; 1-hydroxyhexan-2-yl stearate; 1-hydroxypentan-2-yl stearate; 1-hydroxypentan-2-yl palmitate; 1-hydroxypropan-2-yl stearate; 1-hydroxypropan-2-yl palmitate; 1- hydroxypropan-2-yl tetradecanoate; 1-hydroxypropan-2-yl dodecanoate; 1- hydroxypropan-2-yl decanoate; 1-hydroxypropan-2-yl octanoate; 1-hydroxypropan-2- yl hexanoate; 1-hydroxypropan-2-yl butyrate; 1-hydroxybutan-2-yl butyrate; 1- hydroxypentan-2-yl butyrate; 1-hydroxyoctan-2-yl butyrate; 2-hydroxyethyl icosanoate; 2-hydroxyethyl stearate; 2-hydroxyethyl palmitate; 2-hydroxyethyl tetradecanoate; 2-hydroxyethyl dodecanoate; 2-hydroxyethyl decanoate; 2- hydroxyethyl octanoate; 2-hydroxyethyl hexanoate; 2-hydroxyethyl butyrate; 3- hydroxypropyl butyrate; 3-hydroxypropyl hexanoate; 3-hydroxypropyl pentanoate; 3- hydroxypropyl heptanoate; 3-hydroxypropyl octanoate; 3-hydroxypropyl decanoate; 3-hydroxypropyl dodecanoate; 3-hydroxypropyl tetradecanoate; 3-hydroxypropyl palmitate; 3-hydroxypropyl stearate; 3-hydroxypropyl icosanoate; pentadecyl 2- hydroxypropanoate; pentadecyl 2-hydroxyacetate; tetradecyl 2-hydroxypropanoate; tetradecyl 2-hydroxyacetate; tridecyl 2-hydroxyacetate; tridecyl 2- hydroxypropanoate; dodecyl 2-hydroxypropanoate; dodecyl 2-hydroxyacetate; decyl 2-hydroxyacetate; decyl 2-hydroxypropanoate; octyl 2-hydroxypropanoate; 2,3- dihydroxypropyl icosanoate; 2,3-dihydroxypropyl stearate; 2,3-dihydroxypropyl palmitate; 2,3-dihydroxypropyl tetradecanoate; 2,3-dihydroxypropyl dodecanoate; ATTORNEY DOCKET NO.43081-0032WO1 2,3-dihydroxypropyl decanoate; 2,3-dihydroxypropyl octanoate; 2,3-dihydroxypropyl hexanoate; 2,3-dihydroxypropyl butyrate; 1,3-dihydroxypropan-2-yl butyrate; 1,3- dihydroxypropan-2-yl pentanoate; 1,3-dihydroxypropan-2-yl hexanoate; 1,3- dihydroxypropan-2-yl heptanoate; 1,3-dihydroxypropan-2-yl octanoate; 1,3- dihydroxypropan-2-yl nonanoate; 1,3-dihydroxypropan-2-yl decanoate; 1,3- dihydroxypropan-2-yl dodecanoate; 1,3-dihydroxypropan-2-yl tetradecanoate; 1,3- dihydroxypropan-2-yl palmitate; 1,3-dihydroxypropan-2-yl stearate; 1,3- dihydroxypropan-2-yl icosanoate; 2,3-dihydroxypropyl nonanoate; 2,3- dihydroxypropyl heptanoate; 2,3-dihydroxypropyl pentanoate; dodecyl octanoate; tetradecyl octanoate; hexadecyl octanoate; octadecyl octanoate; octadecyl decanoate; hexadecyl decanoate; tetradecyl decanoate; and dodecyl decanoate; propane-1,2-diyl dibutyrate; 2-(butyryloxy)propyl pentanoate; propane-1,2-diyl dipentanoate; 2- (pentanoyloxy)propyl hexanoate; propane-1,2-diyl dihexanoate; 2- (hexanoyloxy)propyl heptanoate; 2-(heptanoyloxy)propyl octanoate; 2- (heptanoyloxy)propyl nonanoate; 2-(octanoyloxy)propyl nonanoate; propane-1,2-diyl dinonanoate; 2-(nonanoyloxy)propyl decanoate; propane-1,2-diyl bis(decanoate); 2- (decanoyloxy)propyl dodecanoate; propane-1,2-diyl didodecanoate; 2- (dodecanoyloxy)propyl tetradecanoate; propane-1,2-diyl ditetradecanoate; 1- (tetradecanoyloxy)propan-2-yl palmitate; propane-1,2-diyl dipalmitate; 1- (palmitoyloxy)propan-2-yl stearate; propane-1,2-diyl distearate; 2- (stearoyloxy)propyl icosanoate; propane-1,2-diyl bis(icosanoate); 2-methylpropane- 1,3-diyl bis(icosanoate); 2-methyl-3-(stearoyloxy)propyl icosanoate; 2- methylpropane-1,3-diyl distearate; 2-methyl-3-(palmitoyloxy)propyl stearate; 2- methylpropane-1,3-diyl dipalmitate; 2-methyl-3-(tetradecanoyloxy)propyl palmitate; 2-methylpropane-1,3-diyl ditetradecanoate; 3-(dodecanoyloxy)-2-methylpropyl tetradecanoate; 2-methylpropane-1,3-diyl didodecanoate; 3-(decanoyloxy)-2- methylpropyl dodecanoate; 2-methylpropane-1,3-diyl bis(decanoate); 2-methyl-3- (nonanoyloxy)propyl decanoate; 2-methylpropane-1,3-diyl dinonanoate; 2-methyl-3- (octanoyloxy)propyl nonanoate; 2-methylpropane-1,3-diyl dioctanoate; 3- (heptanoyloxy)-2-methylpropyl octanoate; 3-(hexanoyloxy)-2-methylpropyl octanoate; 3-(hexanoyloxy)-2-methylpropyl heptanoate; 2-methyl-3- (pentanoyloxy)propyl hexanoate; 3-(butyryloxy)-2-methylpropyl pentanoate; 2- methylpropane-1,3-diyl dibutyrate; a cetostearyl alcohol; a cetyl alcohol; docosanol; ethylhexyl hydroxystearate; glyceryl 1-stearate; glyceryl dibehenate; glyceryl ATTORNEY DOCKET NO.43081-0032WO1 distearate; glycerylricinoleate; lauryl lactate; a lauroyl polyoxylglyceride; a myristyl alcohol; octyldodecanol; polyoxyl 35 castor oil; polyoxyl 40 hydrogented castor oil; polyoxyl 40 stearate; sorbitan monolaurate; sorbitan monooleate; sorbitan monopalmitate; sorbitan monostearate; sorbitan sesquioleate; sorbitan trioleate; sorbitan tristearate; trihydroxystearin; and combinations of two or more thereof. In these and other instances, the compositions can optionally have the following features. The semi-fluorinated alkane can be perfluorohexyloctane (F6H8). The semi-fluorinated alkane can be perfluorobutylpentane (F4H5). The API in the composition can be chemically stable for at least 6 months, at least 1 year, at least 18 months, at least 2 years or longer. The API can be selected from alpha agonists, antibiotics, corticosteroids, antinicotinic agents, antiglaucoma agents, antihistamines, antivirals, cycloplegics / mydriatics, mast cell stabilizers, miotics, ophthalmic NSAIDs, cyclosporine, riboflavin 5'-phosphate ophthalmic compounds, and VEGF inhibitors and VEGF receptor inhibitors. In these and other instances, the compositions can optionally have the following features. The API can be selected from the group consisting of aceclidine, pilocarpine, bethanechol, cevimeline, methacholine, xanomeline, and aprolidine, optionally wherein the API is in free base form. The API can be riboflavin or a riboflavin derivative, optionally the API can be selected from riboflavin, riboflavin tetraacetate, riboflavin tetrapropionate, riboflavin tetrabutyrate, riboflavin tetrapalmitate, or combinations thereof. The API can be a multikinase inhibitor, optionally wherein the multikinase inhibitor is selected from afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib, or combinations thereof. The API can be a co-drug selected from the group consisting of (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5-yl)amino)-4,5- dihydro-lH-imidazole-lcarbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl ATTORNEY DOCKET NO.43081-0032WO1 acetate; (2R,3S)-3-(2-((4-bromo-lHbenzo[d]imidazol-5-yl)amino)-4,5-dihydro-lH- imidazole-l-carbonyl)-2-((l-methyl-1Himidazol-5-yl)methyl)pentyl propionate; (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5- yl)amino)-4,5-dihydro-lH- imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)- 3-(2-((4-bromo-lH-benzo[d]imidazol-5-yl)amino)-4,5-dihydro-lH-imidazolel- carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3- (2-((4-bromo-lH-benzo[d]imidazol-5-yl)amino)-4,5-dihydro-lH- imidazole-l-carbonyl)-2-((lmethyl-lH-imidazol-5-yl)methyl)pentyl oleate; (2R,3S)-3- (2-((4-bromo-lH-benzo[d]imidazol-5- yl)amino)-4,5-dihydro-lH-imidazole-l- carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl (9Z,12Z)-octadeca-9,12- dienoate; (2R,3S)-3-(2-((5-bromoquinoxalin-6-yl)amino)-4,5-dihydrolH-imidazole-l- carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2- ((5- bromoquinoxalin-6-yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl- lHimidazol-5-yl)methyl)pentyl propionate; (2R,3S)-3-(2-((5-bromoquinoxalin-6- yl)amino)-4,5- dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl butyrate; (2R,3S)-3-(2-((5-bromoquinoxalin-6-yl)amino)-4,5- dihydro-lH-imidazole-l-carbonyl)-2-((lmethyl-lH-imidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((5- bromoquinoxalin-6-yl)amino)-4,5- dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lHimidazol-5-yl)methyl)pentyl oleate; (2R,3S)-3-(2-((5-bromoquinoxalin-6-yl)amino)-4,5-dihydrolH-imidazole-l-carbonyl)- 2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl (9Z,12Z)-octadeca- 9,12-dienoate; (2R,3S)-3-(2-((4-amino-2,6-dichlorophenyl)amino)-4,5-dihydro-lH-imidazole- lcarbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2-((4- amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l- methyl-lH-imidazol-5- yl)methyl)pentyl propionate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydrolH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2- ((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl- ATTORNEY DOCKET NO.43081-0032WO1 lHimidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5- yl)methyl)pentyl oleate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lHimidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl (9Z,12Z)-octadeca-9, 12-dienoate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2- ((l-methyl-lH- imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2-((2,6-dichlorophenyl)amino)- 4,5- dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl propionate; (2R,3S)-3-(2-((2,6-dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l- carbonyl)-2- ((l-methyl-lH-imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)- 4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazolel-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl oleate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)-4,5- dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl (9Z,12Z)-octadeca-9,12-dienoate; and (2R,3S)-3-((Z)-2-((5-bromoquinoxalin-6- yl)imino)imidazolidine-1-carbonyl)-2-((1-methyl-1H-imidazol-5-yl)methyl)pentyl pivalate, or combinations thereof. The composition can be in the form of a solution, suspension, emulsion, or implant. In some instances, the compositions can optionally comprise: from about 0.001% to about 20% of the (w / w) active pharmaceutical ingredient (API); from about 0.1% to about 40% (w / w) of the one or more excipient compound(s); and from about 60% to about 99.9% (w / w) of the semi-fluorinated alkane compound. In some instances, the compositions can optionally comprise; from about 0.001% to about 10% (w / w) of the one or more excipient compound(s); and from about 80% to about 99.9% (w / w) of the semi-fluorinated alkane compound. ATTORNEY DOCKET NO.43081-0032WO1 In some instances, the compositions can optionally consist of or consist essentially of: the (w / w) active pharmaceutical ingredient (API); the excipient compound(s); and the semi-fluorinated alkane compound. In some instances, the API can be in a free base form. In some instances, the API can optionally have a logP less than or equal to 4.3, optionally less than or equal to 2.0. In another aspect, provided herein are methods for delivering an API to a subject comprising dissolving the API in a composition comprising: one or more of the excipient compound(s); and a semi-fluorinated alkane compound, to form an API composition, and administering the API composition to the subject. In this and other instances, the methods can optionally have the following features. The method can comprise dissolving the API in one or more of the excipient compound(s) compound to form a first composition; and mixing the first composition with the semi-fluorinated alkane compound, to form the API composition. The API can be selected from alpha agonists, antibiotics, corticosteroids, anticholinergic agents, antiglaucoma agents, antihistamines, antivirals, cycloplegics / mydriatics, mast cell stabilizers, miotics, ophthalmic NSAIDs, cyclosporine, riboflavin 5'-phosphate ophthalmic compounds, and VEGF inhibitors and VEGF receptor inhibitors. Administering the API composition to the subject comprises administering the API composition to skin or mucosal membrane of a subject, to an eye of the subject, or to a lung of the subject. In another aspect, provided herein is a method for delivering an API to a target tissue of a subject, wherein the target tissue is selected from skin, mucosal membrane, eye tissue, lung tissue, or a tissue of the oral cavity or esophagus, comprising administering any one of the compositions described herein to said target tissue of the subject. In this and other instances, the method can optionally have the following features. The API can be selected from alpha agonists, antibiotics, corticosteroids, ATTORNEY DOCKET NO.43081-0032WO1 anticholinergic agents, antiglaucoma agents, antihistamines, antivirals, cycloplegics / mydriatics, mast cell stabilizers, miotics, ophthalmic NSAIDs, cyclosporine, riboflavin 5'-phosphate ophthalmic compounds, and VEGF inhibitors and VEGF receptor inhibitors. In another aspect, a method is provided for treating, slowing the progression of, or reducing one or more symptoms of a condition in a subject, or inducing one or more symptoms of miosis in a subject comprising administering a composition described herein to the subject. In another aspect, a method is provided for treating, slowing the progression of, or reducing one or more symptoms of an ocular condition in a subject, or inducing one or more symptoms of miosis in a subject comprising administering a composition described herein to an eye of the subject. In this and other instances, the method can optionally have the following features. The ocular condition can be selected from neurotrophic keratitis, glaucoma, elevated intraocular pressure, ocular hypertension, presbyopia, myopia, ocular rosacea, dry eye disease, meibomian gland dysfunction, blepharitis, allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, pterygium, pinguecula, corneal transplant rejection, graft versus host disease, ocular allergy, uveitis, anterior uveitis, Behcet's disease, Sjogren's syndrome, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, chronic ocular surface inflammation caused by viral infection, herpes simplex keratitis, atopic conjunctivitis, Lyell’s syndrome, neovascularization induced by viral, bacterial, fungal, or parasitic infection, contact lens induced neovascularization, ulceration, alkali burns, stem cell deficiency, neovascular glaucoma, Steven Johnson syndrome, tumor in the eye, aphakia, pseudophakia, astigmatism, blepharospasm, cataract, conjunctival diseases, corneal diseases, corneal ulcer, eyelid diseases, lacrimal apparatus diseases, pupil disorders, refractive disorders, and strabismus. ATTORNEY DOCKET NO.43081-0032WO1 In another aspect, a method is provided for slowing myopia progression in a subject or for relieving vitreous floater symptoms in a subject, comprising administering a composition described herein to an eye of the subject, wherein the API is a muscarinic receptor antagonist. In this and other instances, the API can optionally be selected from atropine, an atropine mimetic or analog, or a free base or salt form thereof. In another aspect, a method is provided for treating, slowing the progression of, or reducing one or more symptoms of presbyopia or glaucoma in a subject, or for inducing miosis in a subject, comprising administering a composition described herein to an eye of the subject, wherein the API comprises a muscarinic cholinergic receptor agonist. In these and other instances, the methods can optionally have the following features. The API can be selected from the group consisting of aceclidine, pilocarpine, bethanechol, cevimeline, methacholine, xanomeline, and aprolidine. The API can be riboflavin or a riboflavin derivative, optionally the API can be selected from riboflavin, riboflavin tetraacetate, riboflavin tetrapropionate, riboflavin tetrabutyrate, riboflavin tetrapalmitate, or combinations thereof. The API can be a multikinase inhibitor, optionally wherein the multikinase inhibitor is selected from afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib, or combinations thereof. The API can be a co-drug selected from the group consisting of (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5- yl)amino)-4,5-dihydro-lH-imidazole-lcarbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl acetate; (2R,3S)-3-(2-((4-bromo-lHbenzo[d]imidazol-5-yl)amino)- 4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-1Himidazol-5-yl)methyl)pentyl ATTORNEY DOCKET NO.43081-0032WO1 propionate; (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5- yl)amino)-4,5-dihydro- lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5-yl)amino)-4,5-dihydro-lH- imidazolel-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3- (2-((4-bromo-lH-benzo[d]imidazol-5-yl)amino)- 4,5-dihydro-lH-imidazole-l-carbonyl)-2-((lmethyl-lH-imidazol-5-yl)methyl)pentyl oleate; (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5- yl)amino)-4,5-dihydro-lH- imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl (9Z,12Z)- octadeca-9,12-dienoate; (2R,3S)-3-(2-((5-bromoquinoxalin-6-yl)amino)-4,5- dihydrolH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2- ((5-bromoquinoxalin-6-yl)amino)-4,5-dihydro-lH-imidazole-l- carbonyl)-2-((l-methyl-lHimidazol-5-yl)methyl)pentyl propionate; (2R,3S)-3-(2-((5- bromoquinoxalin-6-yl)amino)-4,5- dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2-((5-bromoquinoxalin-6- yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((lmethyl-lH-imidazol-5- yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((5- bromoquinoxalin-6- yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lHimidazol-5- yl)methyl)pentyl oleate; (2R,3S)-3-(2-((5-bromoquinoxalin-6-yl)amino)-4,5- dihydrolH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl (9Z,12Z)-octadeca- 9,12-dienoate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-lcarbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5- yl)methyl)pentyl propionate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydrolH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2- ((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl- lHimidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((4-amino-2,6- ATTORNEY DOCKET NO.43081-0032WO1 dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5- yl)methyl)pentyl oleate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lHimidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl (9Z,12Z)-octadeca-9, 12-dienoate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2- ((l-methyl-lH- imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2-((2,6-dichlorophenyl)amino)- 4,5- dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl propionate; (2R,3S)-3-(2-((2,6-dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l- carbonyl)-2- ((l-methyl-lH-imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)- 4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazolel-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl oleate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)-4,5- dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl (9Z,12Z)-octadeca-9,12-dienoate; and (2R,3S)-3-((Z)-2-((5-bromoquinoxalin-6- yl)imino)imidazolidine-1-carbonyl)-2-((1-methyl-1H-imidazol-5-yl)methyl)pentyl pivalate, or combinations thereof. The composition can be in the form of a solution, suspension, emulsion, or implant. In another aspect, a method is provided for crosslinking collagen in a tissue of a subject, comprising: administering to the tissue of the subject a composition described herein, wherein the API is a compound of Formula (I): ATTORNEY DOCKET NO.43081-0032WO1 wherein: R1, R2, and R3 are each independently selected from hydrogen or -C(O)R5; R4 is selected from hydrogen, -C(O)R5, a phosphate, or a salt thereof; and R5 is a linear or branched or cyclic alkyl having 1 to 26 carbon atoms; and irradiating the tissue with UV radiation or blue light. In another aspect, a method is provided for crosslinking a structural protein, comprising: contacting the structural protein or a biological tissue containing the structural protein with a composition described herein, wherein the API is a compound of Formula (I): wherein: R1, R2, and R3 are each independently selected from hydrogen or -C(O)R5; R4 is selected from hydrogen, -C(O)R5, a phosphate, or a salt thereof; and R5 is a linear or branched or cyclic alkyl having 1 to 26 carbon atoms; and irradiating the structural protein or the tissue with UV radiation or blue light. ATTORNEY DOCKET NO.43081-0032WO1 In these and other methods, the API can optionally be selected from riboflavin, riboflavin tetraacetate, riboflavin tetrapropionate, riboflavin tetrabutyrate, riboflavin tetrapalmitate, or combinations thereof. In another aspect, an excipient system is provided for delivering an API to a subject comprising: one or more of the excipient compound(s); and a semi- fluorinated alkane compound. In another aspect, a method is provided for making a composition described herein, comprising dissolving the API in a composition comprising: one or more of the excipient compound(s); and a semi-fluorinated alkane compound. In this and other instances, the method can optionally have the following features. The method can comprise dissolving the API in the one or more of the excipient compound(s) compound to form a first composition; and mixing the first composition with the semi-fluorinated alkane compound. In another aspect, a dispenser is provided, comprising: a container portion comprising an interior wall defining an interior volume and adapted to contact and store a liquid within at least a portion of the interior volume; and a composition or excipient system described herein contained within the interior volume. In this and other instances, the dispenser can optionally have the following features. The interior wall can comprise less than about 10% of one or more of low density polyethylene (LDPE) or polypropylene (PP). The interior wall does not comprise low density polyethylene (LDPE) or polypropylene (PP). The interior wall can comprise glass or polyethylene terephthalate. The interior wall can consist essentially of glass or polyethylene terephthalate (PET). A concentration of the API can remain more than 90% of an initial API concentration after storage in the dispenser for a period of at least 6 months, or a concentration of the API can remain more than 90% of an initial API concentration after storage in the dispenser for a period of at least 12 months or a concentration of the API can remain more than 90% of an initial API concentration after storage in the dispenser for at least a period of 24 ATTORNEY DOCKET NO.43081-0032WO1 months. The dispenser can further comprise: a dispensing portion adapted to dispense one or more drops of a liquid out of the container portion; and wherein the container portion and the dispensing portion each, independently, consist essentially of glass or polyethylene terephthalate (PET). The dispenser can further comprise: a dispensing portion adapted to dispense one or more drops of a liquid out of the container portion; and wherein the volume of the one or more drops each independently is from about 5 µl to about 40 µl. In another aspect, the disclosure provides a method of administering to a subject a topical ophthalmological composition for selective transcorneal absorption, the method comprising administering to an eye of the subject a composition described herein; optionally wherein the composition is non-aqueous; and optionally wherein the API is in free base form. In some instances, the API is selectively absorbed transcorneally in the eye as compared to periorbitally. In some instances, the composition is non-aqueous; optionally wherein the composition is an emulsion. In some instances, the API is in a free base form. In some instances, the API can have a logP less than or equal to 4.3 or less than or equal to 2.0. In some instances, the composition is non-aqueous, and the composition is administered at a dose 5-10%, 5- 15%, 5-20%, 5-25%, 5-30%, 10-30%, 10-40%, 10-50%, 10-60%, 10-70%, 20-30%, 20-40%, 20-50%, 20-60%, 20-70%, 30-40%, 30-50%, 30-60%, 30-70%, 40-50%, 40- 60%, 40-70%, or 50-70% less than a dose of an aqueous composition comprising the API used for the same purpose (e.g., if the administering is for treating an ocular condition, the dose is compared to the dose of an aqueous composition comprising the API used for treating the ocular condition). In some instances, the composition is administered to the subject: (i) every about 6 to about 8 hours or three times a day, (ii) once a day, or (iii) twice a day. In another aspect, the disclosure provides a method of treating an ocular condition in a subject, the method comprising: (a) (i) selecting a subject in need of transcorneal absorption of an API; or (ii) selecting a subject having an ocular ATTORNEY DOCKET NO.43081-0032WO1 condition, wherein the ocular condition is in need of transcorneal absorption of an API; and (b) administering to an eye of the subject a composition described herein; optionally wherein the composition is non-aqueous; and optionally wherein the API is in free base form. In some instances, the API is selectively absorbed transcorneally in the eye as compared to periorbitally. In some instances, the composition is non- aqueous; optionally wherein the composition is an emulsion. In some instances, the API is in a free base form. In some instances, the API can have a logP less than or equal to 4.3 or less than or equal to 2.0. In some instances, the composition is non- aqueous, and wherein the composition is administered at a dose 5-10%, 5-15%, 5- 20%, 5-25%, 5-30%, 10-30%, 10-40%, 10-50%, 10-60%, 10-70%, 20-30%, 20-40%, 20-50%, 20-60%, 20-70%, 30-40%, 30-50%, 30-60%, 30-70%, 40-50%, 40-60%, 40- 70%, or 50-70% less than a dose of an aqueous composition comprising the API for the ocular condition. In some instances, the composition is administered to the subject: (i) every about 6 to about 8 hours or three times a day, (ii) once a day, or (iii) twice a day. In another aspect, the disclosure provides a method of selectively delivering an API to a cornea of an eye of a subject, the method comprising administering to the eye of the subject a composition described herein; optionally wherein the composition is non-aqueous; and optionally wherein the API is in free base form. In some instances, the API is absorbed transcorneally in the eye. In some instances, the API is selectively absorbed transcorneally in the eye as compared to periorbitally. In some instances, the composition is non-aqueous; optionally wherein the composition is an emulsion. In some instances, the API is in a free base form. In some instances, the API can have a logP less than or equal to 4.3 or less than or equal to 2.0. In some instances, the composition is non-aqueous, and wherein the composition is administered at a dose 5-10%, 5-15%, 5-20%, 5-25%, 5-30%, 10-30%, 10-40%, 10- 50%, 10-60%, 10-70%, 20-30%, 20-40%, 20-50%, 20-60%, 20-70%, 30-40%, 30- 50%, 30-60%, 30-70%, 40-50%, 40-60%, 40-70%, or 50-70% less than a dose of an ATTORNEY DOCKET NO.43081-0032WO1 aqueous composition comprising the API used for the same purpose (e.g., if the administering is for treating an ocular condition, the dose is compared to the dose of an aqueous composition comprising the API used for treating the ocular condition). In some instances, the composition is administered to the subject: (i) every about 6 to about 8 hours or three times a day, (ii) once a day, or (iii) twice a day. In another aspect, the disclosure provides a method of formulating a topical ophthalmological composition for transcorneal absorption, the method comprising combining an active pharmaceutical ingredient (API), one or more of the excipient compound(s), and a semi-fluorinated alkane compound. In some instances of the compositions and methods described herein, the API can be Brimonidine or pharmaceutically acceptable salts or free base forms thereof, and at least one excipient compound can optionally be a propylene glycol dilaurate or a propylene glycol dicaprylate. In some instances of the compositions and methods described herein, the API can be lifitegrast, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof and at least one excipient compound can optionally be a propylene glycol dilaurate or a propylene glycol dicaprylate. In some instances of the compositions and methods described herein, the API can be aceclidine, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, and at least one excipient compound can optionally be a coco-caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate. In some instances of the compositions and methods described herein, the API can be axitinib, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, and at least one excipient compound can optionally be a coco-caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate. ATTORNEY DOCKET NO.43081-0032WO1 In some instances of the compositions and methods described herein, the API can be atropine, or an atropine mimetic or analog, or a free base, hydrate, solvate, or salt form thereof, and at least one excipient compound can optionally be a coco- caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate. In some instances of the compositions and methods described herein, the API can be (2R,3S)-3-((Z)-2-((5-bromoquinoxalin-6-yl)imino)imidazolidine-1-carbonyl)- 2-((1-methyl-1H-imidazol-5-yl)methyl)pentyl pivalate, or a free base, hydrate, solvate, or salt form thereof, and at least one excipient compound can optionally be a coco-caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate. In some instances, the compositions and methods provided herein can provide several advantages. First, in some instances, the compositions provided herein can provide increased solubility of the API. In some instances, the compositions provided herein can provide increased solubility of the API in non-aqueous formulations, for example increased solubility of the API in an SFA. This is especially beneficial in instances where the API cannot achieve desired solubility in SFA alone. Without being bound by theory, it is believed that the unique dual properties of the perfluorinated moiety and the ester moiety of the excipient compound(s) can act as a solubilizer or carrier to solubilize and / or emulsify APIs, including even difficult to solubilize, in an SFA, thus leading to a robust composition for carrying and delivery of an API. Second, in some instances of the compositions and methods provided herein, the compositions can surprisingly provide better stability of the API as compared to, e.g., aqueous or other standard formulations of the API. This provides several additional advantages, including, in some instances, the possibility to use certain APIs that were previously difficult to formulate for use, or the prevention of formation of API-based impurities, or improved shelf life and storage time as compared to other standard formulations or aqueous formulations of the API. ATTORNEY DOCKET NO.43081-0032WO1 Third, in some instances, the compositions described herein can be made into nanoemulsions having droplet sizes below 500 nm, 100 nm, 50 nm, 15 nm, 10 nm, and even 5 nm, or microemulsion, or an emulsion solution. Without being bound by theory, it is believed the smaller droplet sizes can lead to improved longer term stability of the API in the formulation as compared to aqueous formulations, as well as increased availability of the API, improved tissue penetration and distribution of the API, and improved residence time in ocular tissues. Fourth, in some instances, the dispenser provided herein can provide increased compatibility with the compositions described herein, e.g., compositions comprising excipient compound(s) and SFA. The increased compatibility of the dispensers can lead to better stability of the compositions and of the API in the compositions, longer shelf life for the compositions, and improved delivery of the prescribed or desired amount of API to a patient’s or subject’s eye or ocular tissue. Fifth, in some instances, where the compositions described herein are emulsions, it is believed, without being bound by theory, that in some instances, the excipient compound(s) can provide a dual role of both solubilizing the API, and acting on its own in a manner to stabilize a micro- or nano-emulsion, emulsion solution, or suspension, thus potentially eliminating the need for an added surfactant and thereby eliminating potential toxic complications from such surfactants. In some instances, this can lead to stability of the compositions and stability of the API in the compositions without added surfactants. In some instances, additional surfactant may be added for desired stability, but the presence of one or more of the excipient compound(s)can, in some instances, allow for decreased amounts of surfactant to achieve desired stability. Sixth, the compatibility of one or more of the excipient compound(s) with SFA can allow for useful compositions (e.g., with desired solubility of API in SFA) without undesirable effects to the compositions or the API. ATTORNEY DOCKET NO.43081-0032WO1 Seventh, in some instances, the compositions (e.g., topical ophthalmological compositions) described herein can provide improved delivery of the API to the cornea, e.g., by transcorneal absorption, e.g., as compared to an aqueous composition comprising the API or an aqueous composition comprising a salt of the API, and, surprisingly, sustained ocular efficacy. In some instances, the compositions described herein are selectively transcorneally absorbed (e.g., compared with periorbital absorption). The improved delivery of the API to the cornea can allow for lower doses to be administered to a subject, and / or more frequent lower doses. Thus, the improved delivery of the API to the cornea reduces one or more adverse side effects of an API and can be used to treat ocular conditions in subjects highly sensitive to the API. Thus, in some instances, the disclosure provides a method of administering to a subject a composition (e.g., a topical ophthalmological composition) for selective transcorneal absorption, the method comprising administering to an eye of the subject a composition described herein; optionally wherein the composition is non-aqueous; and optionally wherein the API is in free base form. In some instances, the disclosure provides a method of treating an ocular condition in a subject, the method comprising: (a) (i) selecting a subject in need of transcorneal absorption of an API; or (ii) selecting a subject having an ocular condition, wherein the ocular condition is in need of transcorneal absorption of an API; and (b) administering to an eye of the subject the composition of any one of claims 1-16; optionally wherein the composition is non-aqueous; and optionally wherein the API is in free base form. Subjects can be in need of transcorneal absorption of an API include subjects having high sensitivity to an API, subjects in need of a lower dose of an API, subjects having one or more adverse effects of an aqueous API (e.g., an adverse effect attributed to the API and not attributed to another component or feature of the composition comprising the API, e.g., pH or a preservative), subjects in need of ATTORNEY DOCKET NO.43081-0032WO1 treatment with an API having a target receptor in one or more of the cornea, the aqueous humor, or the iris, and subjects in need of treatment with an API that is associated with one or more adverse events in one or more of conjunctival, scleral, and ciliary body. In some instances, the disclosure provides a method of selectively delivering an API to a cornea of an eye of a subject, the method comprising administering to the eye of the subject a composition described herein; optionally wherein the composition is non-aqueous; and optionally wherein the API is in free base form. In some instances, the API can have a logP less than or equal to 4.3 or less than or equal to 2.0. In some instances, the API is absorbed transcorneally in the eye. In some instances, the API is selectively absorbed transcorneally in the eye as compared to periorbitally. In some instances, the composition is non-aqueous. In some instances, the composition is an emulsion. In some instances, the composition is non-aqueous, and the composition is administered at a dose 5-10%, 5-15%, 5-20%, 5-25%, 5-30%, 10-30%, 10-40%, 10- 50%, 10-60%, 10-70%, 20-30%, 20-40%, 20-50%, 20-60%, 20-70%, 30-40%, 30- 50%, 30-60%, 30-70%, 40-50%, 40-60%, 40-70%, or 50-70% less than a dose of an aqueous composition comprising the API or a salt thereof for the same purpose. For example, in some instances of a method of treating an ocular condition, the composition is administered at a dose 30% less than a dose of an aqueous composition comprising the API or a salt thereof for treating the ocular condition. In some instances, the composition is administered to the subject: (i) every about 6 to about 8 hours or three times a day, (ii) once a day, or (iii) twice a day. In some instances, the API is in a free base form. Other features and advantages of the present application will be apparent from the following detailed description and figures, and from the claims. ATTORNEY DOCKET NO.43081-0032WO1 BRIEF DESCRIPTION OF THE DRAWINGS FIG.1 is an exploded, schematic cross-sectional view of an exemplary embodiment of a dispenser as described herein. DETAILED DESCRIPTION Provided herein are compositions for delivery of active pharmaceutical ingredients (APIs), comprising medium chain a semi-fluorinated alkane (SFA); one or more excipient compound(s) that are oils with certain ester functionality, such as one or more excipient compounds selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and an active pharmaceutical ingredient (API), and methods for making and using the compositions, such as methods for treating or slowing the progression of, or reducing one or more symptoms of a condition in a subject, or inducing one or more symptoms of miosis in a subject. Also provided herein are dispensers or containers comprising the compositions. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present application belongs. Methods and materials are described herein for use in the present application; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. As used herein, the term “about” means “approximately” (e.g., plus or minus approximately 10% of the indicated value). As used herein, the term “contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, “contacting” the eye tissue with a compound of the invention includes the ATTORNEY DOCKET NO.43081-0032WO1 administration of a compound of the present invention to an individual or patient, such as a human, having the eye tissue in need of treatment, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the ocular tissue. As used herein, the term “individual”, “patient”, or “subject” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans. In some embodiment, a human subject may be of any age, for example, from 0 to 100 years old. As used herein, “pediatric subject” and “child” are used interchangeably and refer to subjects from 0 to 18 years old, for example, 1, 2, 5, 10, 12, or 14 years old. As used herein, the phrase “effective amount” or “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor, or other clinician. As used herein the term “treating” or “treatment” refers to 1) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and / or symptomatology), or 2) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and / or symptomatology). The term “alkyl,” as used herein, refers to saturated, monovalent hydrocarbon moieties having linear or branched moieties or combinations thereof and containing the specified (e.g., 1 to 26) carbon atoms. The term “alkenyl,” as used herein, refers to aliphatic hydrocarbon moieties having linear or branched moieties or combinations thereof, containing at least one ATTORNEY DOCKET NO.43081-0032WO1 carbon-carbon double bond and having one of its hydrogen atoms replaced with a bond, and containing the specified (e.g., 1 to 26) carbon atoms. The term “cycloalkyl,” as used herein, refers to a monovalent or divalent group of, e.g., 3 to 8 carbon atoms, derived from a saturated cyclic hydrocarbon. Cycloalkyl groups can be monocyclic or polycyclic. The term “hydroxyalkyl,” as used herein, refers to an alkyl group as defined above, wherein one or more of the alkyl group's hydrogen atoms have been replaced with an —OH group. The term “hydroxyalkenyl,” as used herein, refers to an alkenyl group as defined above, wherein one or more of the alkenyl group's hydrogen atoms have been replaced with an —OH group. The formula “H”, as used herein, represents a hydrogen atom. The formula “O”, as used herein, represents an oxygen atom. The formula “P”, as used herein, represents a phosphorus atom. The term “compound” as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted, including racemic mixtures. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified. In some instances, provided herein are compositions comprising an active pharmaceutical ingredient (API), one or more of the excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof, and a semi-fluorinated alkane compound. In some instances of the compositions described herein, the composition is non-aqueous. In some instances of the compositions described herein, the composition is an oil-in-oil emulsion. In some instances of the compositions described herein, the composition is an emulsion solution. ATTORNEY DOCKET NO.43081-0032WO1 The compositions described herein can include an active pharmaceutical ingredient (API) compound. APIs, their analogs, their salts, and their free base forms (where applicable) are included within the scope of the present invention. Such solvates include for example hydrates, alcoholates (e.g., ethanol solvate), and the like. APIs can exist in different polymorphic forms. Such forms are intended to be included within the scope of the present disclosure. Based on the information disclosed herein, one skilled in the art will understand that the excipient system can be adjusted to more favorably accommodate specific APIs. For example, an excipient system with more polar characteristics can be chosen to formulate an API having more polar characteristic, particularly if larger amounts of API are desired in the final formulation. Similarly, an excipient system with less polar characteristics can be chosen to formulate an API having non-polar characteristic, particularly if larger amounts of API are desired in the final formulation. In some instances, the excipient compounds may be heated in order to solubilize the API. In some instances, where a particular API is not soluble in a particular excipient compound, heated or at room temperature or lower, that excipient compound may still be used in the formulation or excipient system. For example, in some instances, the API may be soluble and / or emulsified in the combination of the excipient compound and the SFA. As another example, the API may be soluble in a mixture of excipient compounds that includes an excipient compound that the API is not ordinarily soluble in alone, heated, at room temperature, or a lower temperature. In some instances, the API can have a certain logP value, as estimated using the PubChem “Explore Chemistry” database hosted by the National Institutes of Health (NIH), accessible at https: / / pubchem.ncbi.nlm.nih.gov / . In some instances, the API can have a logP of less than or equal to 5.0, less than or equal to 4.9, less than or equal to 4.8, less than or equal to 4.7, less than or equal to 4.6, less than or equal to 4.5, less than or equal to 4.4, less than or equal to 4.3, less than or equal to 4.2, less than or equal to 4.1, less than or equal to 4.0, less than or equal to 3.9, less than or ATTORNEY DOCKET NO.43081-0032WO1 equal to 3.8, less than or equal to 3.7, less than or equal to 3.6, less than or equal to 3.5, less than or equal to 3.4, less than or equal to 3.3, less than or equal to 3.2, less than or equal to 3.1, less than or equal to 3.0, less than or equal to 2.9, less than or equal to 2.8, less than or equal to 2.7, less than or equal to 2.6, less than or equal to 2.5, less than or equal to 2.4, less than or equal to 2.3, less than or equal to 2.2, less than or equal to 2.1, or less than or equal to 2.0. In some instances, the API can have a logP from about 0.5 to about 5.0, from about 1.0 to about 5.0, from about 1.5 to about 4.5, from about 0.5 to about 4.4, from about 0.5 to about 4.3, from about 0.5 to about 2.0, from about 1.0 to about 2.0, from about 1.0 to about 4.5, from about 1.0 to about 4.3, 0.8 to about 5.0, from about 0.8 to about 4.5, from about 0.8 to about 4.4, from about 0.8 to about 4.3, from about 0.8 to about 2.0, from about 0.8 to about 2.5, from about 0.8 to about 3.0, from about 0.8 to about 3.2, from about 0.8 to about 4.0. Exemplary, non-limiting APIs useful in the compositions described herein can include alpha agonists, antibiotics, corticosteroids, anticholinergic agents (e.g., antimuscarinics and antinicotinics), antiglaucoma agents (e.g., alpha agonists, beta- blockers, carbonic anhydrase inhibitors, miotics, prostaglandin agonists, and the like), antihistamines, antivirals, cycloplegics / mydriatics, mast cell stabilizers, miotics (e.g., cholinesterase inhibitors, direct-acting miotics, and the like), ophthalmic non-steroidal anti-inflammatory drugs (NSAIDs), cyclosporine, riboflavin 5'-phosphate ophthalmic compounds, and vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors. Exemplary, nonlimiting antibiotics can include Moxifloxacin, Levofloxacin, Ofloxacin, Besifloxacin, Gatifloxacin, Azithromycin, Tobramycin, Erythromycin, Bacitracin, Neomycin-Polymyxin B-Gramicidin, Neomycin-Polymyxin B-Bacitracin, Bacitracin-Polymyxin B, and Sulfacetamide. Exemplary, nonlimiting anti-parasitics can include formamidine parasiticides or isooxazoline parasiticides, such as but not limited to fluralaner, sarolaner, lotilaner, afoxolaner, and / or fluxametamide. ATTORNEY DOCKET NO.43081-0032WO1 An additional exemplary, nonlimiting anti-parasitic is ivermectin (e.g., ivermectin B1a, ivermectin B1b, or a combination thereof). In some instances, the anti-parasitic is ivermectin (e.g., ivermectin B1a, ivermectin B1b, or a combination thereof), or a derivative, analogue, and L- and D-isomer thereof, including but not limited to enantiomers, compositions comprising racemic mixtures, and enantiomerically pure compositions. In some instances, the anti-parasitic comprises a mixture of ivermectin B1 homologues (e.g., a mixture of ivermectin B1a and ivermectin B1b). In some instances, the anti-parasitic comprises a mixture of ivermectin B1a and ivermectin B1b. Ivermectin B1a has the structure of Compound (I): Ivermectin B1b has the structure of Compound (II): (Compound (II)). In some instances, the anti-parasitic comprises a mixture of ivermectin B1a and ivermectin B1b at a ivermectin B1a:ivermectin B1b ratio of about 1000:1, about 500:1, about 400:1, about 300:1, about 200:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 10:1, about 5:1, about 4:1, about 2:1, or about 1:1. In some instances, the anti-parasitic comprises a mixture of ivermectin B1a and ivermectin B1b, wherein the amount of ivermectin B1a in the anti-parasitic is about 1-, about 1.25-, about 1.5-, about 2-, about 3-, about 4-, about 5-, about 6-, about 7-, about 10-, about 11-, about 12-, about 13-, about 14-, about 15-, about 20-, about 25-, about 30-, about 35-, about 40-, about ATTORNEY DOCKET NO.43081-0032WO1 45-, about 50-, about 55-, about 60-, about 70-, about 80-, about 90-, about 100-, about 200-, about 300-, about 400-, about 500-, about 750-, or about 1000- fold higher than the amount of ivermectin B1b in the anti-parasitic. Exemplary, nonlimiting steroids and NSAIDs can include Fluorometholone, Loteprednol, Rimexolone, Prednisolone, and Difluprednate. Exemplary, nonlimiting antimicrobials can include Natamycin, Ganciclovir, Trifluiridine, and Cysteamine. Exemplary, nonlimiting pressure regulators can include Brimonidine, Apraclonidine Iopidine, Dorzolamide, Brinzolamide, Azopt, Timolol, Timoptic / Istalol / Betimol, Betaxolol, Betoptic, Levobunolol, Betagan, Metipranolol, Optipranolol, Latanoprost, Xalatan Green, Bimatoprost, Lumigan, Tafluprost, Zioptan, Latanoprostene, Vyzulta Turquoise, Pilocarpine, Carbachol, Isopto Carbachol, Netarsudil, and Rhopressa. Exemplary, nonlimiting dilation and cycloplegia agents include Atropine, Isopto Atropine, Atropisol, Scopolamine, Isopto Hyoscine Red, Cyclopentolate, Cyclogyl, AK Pentolate, Tropicamide, Mydriacyl, Tropicacyl, and Phenylephrine. In some instances, the API can be a muscarinic receptor agonist. Exemplary non-limiting muscarinic receptor agonists can include acetylcholine, arecoline, oxotremorine, muscarine, carbachol, nebracetam, bethanechol, pilocarpine, and desmethylclozapine, or a pharmaceutically acceptable salt thereof. Suitable examples of muscarinic receptor antagonists include atropine, hyoscyamine, scopolamine, diphenhydramine, dimenhydrinate, dicycloverine, tolterodine, oxybutynin, ipratropium, pirenzepine, telenzepine, tripitramine, gallamine, methoctramine, darifenacin, tiotropium, chlorpromazine, and haloperidol, a free base form, or a pharmaceutically acceptable salt thereof. In some instances, the API can be a muscarinic receptor antagonist. Exemplary non-limiting muscarinic receptor antagonists can include atropine, hyoscyamine, scopolamine, diphenhydramine, dimenhydrinate, dicycloverine, tolterodine, ATTORNEY DOCKET NO.43081-0032WO1 oxybutynin, ipratropium, pirenzepine, telenzepine, tripitramine, gallamine, methoctramine, darifenacin, tiotropium, chlorpromazine, and haloperidol, a free base form, or a pharmaceutically acceptable salt thereof. In some instances, the API is in a free base form. In some instances, the API is in a free acid form. In some instances, provided herein are compositions comprising a therapeutically effective amount of anti-parasitic compound as an active pharmaceutical ingredient; one or more of the excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound. The compositions can, in some instances, be topical ophthalmological compositions. Anti-parasitic compounds can, in some instances, aid in eradication or reduction of parasite infestations of the eyes, ocular tissue, skin, eyelashes, or other body hair. In some instances, this can temporarily or permanently treat or reduce or relieve symptoms of certain diseases or conditions, such as ocular, skin, vector-borne, or other diseases cause by parasites. In some instances, anti-parasitic compounds can temporarily or permanently treat or reduce or relieve symptoms of certain ocular diseases or conditions, such as blepharitis, meibomian gland disfunction, or rosacea caused by parasites such as Demodex mites. In some instances, anti-parasitic compounds can temporarily or permanently treat or reduce or relieve symptoms of eyelid margin redness caused by Demodex mites, or improve eyelash health in a subject. In some instances, anti-parasitic compounds can temporarily or permanently eradicate, reduce the population of, treat or reduce or relieve symptoms of lice, scabies, or bed bugs and associated skin, hair, scalp, or follicular conditions. In some instances, the anti-parasitic compound can be an isooxazoline parasiticide or a formamidine parasiticide. In some instances, the anti-parasitic compound can be an isooxazoline parasiticide selected from fluralaner, sarolaner, lotilaner, afoxolaner, and / or fluxametamide, including derivatives, analogues, and L- and D-isomers thereof, including but not limited to enantiomers, compositions comprising racemic ATTORNEY DOCKET NO.43081-0032WO1 mixtures, and enantiomerically pure compositions. In some instances, the anti- parasitic compound can be ivermectin (e.g., ivermectin B1a, ivermectin B1b, or a combination thereof), or a derivative, analogue, isomer thereof, including but not limited to enantiomers, compositions comprising racemic mixtures, and enantiomerically pure compositions. In some instances, the anti-parasitic compound comprises a mixture of ivermectin B1 homologues (e.g., a mixture of ivermectin B1a and ivermectin B1b). In some instances, the anti-parasitic compound can be in free base form. In some instances, the anti-parasitic compound can be present in an amount of from about 0.1% to about 5% (w / w), from about 0.1% to about 2.5% (w / w), from about 0.1% to about 2% (w / w), from about 0.1% to about 1.5% (w / w), from about 0.1% to about 1% (w / w), from about 0.1% to about 0.5% (w / w), from about 0.1% to about 0.45% (w / w), from about 0.1% to about 0.4% (w / w), from about 0.1% to about 0.35% (w / w), from about 0.1% to about 0.3% (w / w), from about 0.1% to about 0.25% (w / w), from about 0.1% to about 0.2% (w / w), from about 0.15% to about 0.5% (w / w), from about 0.15% to about 0.45% (w / w), from about 0.15% to about 0.4% (w / w), from about 0.15% to about 0.35% (w / w), from about 0.15% to about 0.3% (w / w), from about 0.15% to about 0.25% (w / w), from about 0.15% to about 0.2% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.7% (w / w), from about 0.1% to about 2% (w / w), from about 0.3% to about 2% (w / w), from about 0.5% to about 2% (w / w), from about 0.7% to about 2% (w / w), from about 1% to about 2% (w / w), from about 1.3% to about 2% (w / w), from about 1.5% to about 2% (w / w), from about 1.7% to about 2% (w / w), from about 0.3% to about 1% (w / w), from about 0.3% to about 1.3% (w / w), from about 0.3% to about 1% (w / w), from about 0.5% to about 1% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.5% to about 1% (w / w), from about 0.5 to about 1.5% (w / w), from about 0.5% to about 2% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.7% to about 1% (w / w), from about 1% to about 1.3 % (w / w), ATTORNEY DOCKET NO.43081-0032WO1 from about 1.3% to about 1.5% (w / w), from about 1.5% to about 2% (w / w), about 0.1% (w / w), about 0.2% (w / w), about 0.3% (w / w), about 0.4% (w / w), about 0.5% (w / w), about 0.6% (w / w), about 0.7% (w / w), about 0.8% (w / w), about 0.9% (w / w), about 1% (w / w), about 1.3% (w / w), about 1.5% (w / w), about 1.7% (w / w), or about 2% (w / w). In some instances, the anti-parasitic compound can be present in an amount of from about 1% to about 5% (w / w), In some instances, the anti-parasitic compound can be lotilaner or TP-03. In some instances, the lotilaner or TP-03 can be in a form including derivatives, analogues, and L- and D-isomers thereof, including but not limited to enantiomers, compositions comprising racemic mixtures, and enantiomerically pure compositions. In some instances, the lotilaner or TP-03 can be in free base form. In some instances, the lotilaner or TP-03 can be present in an amount of from about 0.1% to about 5% (w / w), from about 0.1% to about 2.5% (w / w), from about 0.1% to about 2% (w / w), from about 0.1% to about 1.5% (w / w), from about 0.1% to about 1% (w / w), from about 0.1% to about 0.5% (w / w), from about 0.1% to about 0.45% (w / w), from about 0.1% to about 0.4% (w / w), from about 0.1% to about 0.35% (w / w), from about 0.1% to about 0.3% (w / w), from about 0.1% to about 0.25% (w / w), from about 0.1% to about 0.2% (w / w), from about 0.15% to about 0.5% (w / w), from about 0.15% to about 0.45% (w / w), from about 0.15% to about 0.4% (w / w), from about 0.15% to about 0.35% (w / w), from about 0.15% to about 0.3% (w / w), from about 0.15% to about 0.25% (w / w), from about 0.15% to about 0.2% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.7% (w / w), from about 0.1% to about 2% (w / w), from about 0.3% to about 2% (w / w), from about 0.5% to about 2% (w / w), from about 0.7% to about 2% (w / w), from about 1% to about 2% (w / w), from about 1.3% to about 2% (w / w), from about 1.5% to about 2% (w / w), from about 1.7% to about 2% (w / w), from about 0.3% to about 1% (w / w), from about 0.3% to about 1.3% (w / w), from about 0.3% to about 1% (w / w), from about 0.5% to about 1% (w / w), from about 0.5% to about 0.7% (w / w), ATTORNEY DOCKET NO.43081-0032WO1 from about 0.5% to about 1% (w / w), from about 0.5 to about 1.5% (w / w), from about 0.5% to about 2% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.7% to about 1% (w / w), from about 1% to about 1.3 % (w / w), from about 1.3% to about 1.5% (w / w), from about 1.5% to about 2% (w / w), about 0.1% (w / w), about 0.2% (w / w), about 0.3% (w / w), about 0.4% (w / w), about 0.5% (w / w), about 0.6% (w / w), about 0.7% (w / w), about 0.8% (w / w), about 0.9% (w / w), about 1% (w / w), about 1.3% (w / w), about 1.5% (w / w), about 1.7% (w / w), or about 2% (w / w). In some instances, the anti-parasitic compound can be ivermectin (e.g., ivermectin B1a, ivermectin B1b, or a combination thereof). In some instances, the ivermectin can be in a form including derivatives, analogues, and L- and D-isomers thereof, including but not limited to enantiomers, compositions comprising racemic mixtures, and enantiomerically pure compositions. In some instances, the ivermectin can be a mixture of ivermectin B1a and ivermectin B1b. In some instances, the ivermectin (e.g., a mixture of ivermectin B1a and ivermectin B1b) can be present in an amount of from about 0.1% to about 5% (w / w), from about 0.1% to about 2.5% (w / w), from about 0.1% to about 2% (w / w), from about 0.1% to about 1.5% (w / w), from about 0.1% to about 1% (w / w), from about 0.1% to about 0.5% (w / w), from about 0.1% to about 0.45% (w / w), from about 0.1% to about 0.4% (w / w), from about 0.1% to about 0.35% (w / w), from about 0.1% to about 0.3% (w / w), from about 0.1% to about 0.25% (w / w), from about 0.1% to about 0.2% (w / w), from about 0.15% to about 0.5% (w / w), from about 0.15% to about 0.45% (w / w), from about 0.15% to about 0.4% (w / w), from about 0.15% to about 0.35% (w / w), from about 0.15% to about 0.3% (w / w), from about 0.15% to about 0.25% (w / w), from about 0.15% to about 0.2% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.7% (w / w), from about 0.1% to about 2% (w / w), from about 0.3% to about 2% (w / w), from about 0.5% to about 2% (w / w), from about 0.7% to about 2% (w / w), from about 1% to about 2% (w / w), from about 1.3% to about 2% (w / w), from about 1.5% to about 2% (w / w), from about 1.7% to ATTORNEY DOCKET NO.43081-0032WO1 about 2% (w / w), from about 0.3% to about 1% (w / w), from about 0.3% to about 1.3% (w / w), from about 0.3% to about 1% (w / w), from about 0.5% to about 1% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.5% to about 1% (w / w), from about 0.5 to about 1.5% (w / w), from about 0.5% to about 2% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.7% to about 1% (w / w), from about 1% to about 1.3 % (w / w), from about 1.3% to about 1.5% (w / w), from about 1.5% to about 2% (w / w), about 0.1% (w / w), about 0.2% (w / w), about 0.3% (w / w), about 0.4% (w / w), about 0.5% (w / w), about 0.6% (w / w), about 0.7% (w / w), about 0.8% (w / w), about 0.9% (w / w), about 1% (w / w), about 1.3% (w / w), about 1.5% (w / w), about 1.7% (w / w), or about 2% (w / w). In some instances, the ivermectin (e.g., a mixture of ivermectin B1a and ivermectin B1b) can be present in an amount of from about 1% to about 5% (w / w). In some instances, the anti-parasitic compound can be ivermectin (e.g., ivermectin B1a, ivermectin B1b, or a combination thereof), or a derivative, analogue, and L- and D-isomer thereof, including but not limited to enantiomers, compositions comprising racemic mixtures, and enantiomerically pure compositions. In some instances, the anti-parasitic compound comprises a mixture of ivermectin B1 homologues (e.g., a mixture of ivermectin B1a and ivermectin B1b). In some instances, the anti-parasitic compound comprises a mixture of ivermectin B1a and ivermectin B1b. In some instances, the anti-parasitic comprises a mixture of ivermectin B1a and ivermectin B1b at a ivermectin B1a:ivermectin B1b ratio of about 1000:1, about 500:1, about 400:1, about 300:1, about 200:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 10:1, about 5:1, about 4:1, about 2:1, or about 1:1. In some instances, the anti- parasitic comprises a mixture of ivermectin B1a and ivermectin B1b, wherein the amount of ivermectin B1a in the anti-parasitic is about 1-, about 1.25-, about 1.5-, about 2-, about 3-, about 4-, about 5-, about 6-, about 7-, about 10-, about 11-, about 12-, about 13-, about 14-, about 15-, about 20-, about 25-, about 30-, about 35-, about 40-, about 45-, about 50-, about 55-, about 60-, about 70-, about 80-, about 90-, about ATTORNEY DOCKET NO.43081-0032WO1 100-, about 200-, about 300-, about 400-, about 500-, about 750-, or about 1000- fold higher than the amount of ivermectin B1b in the anti-parasitic. In some instances, provided herein are compositions comprising a therapeutically effective amount of lifitegrast or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof as an active pharmaceutical ingredient; one or more of the excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semifluorinated alkane compound. The compositions can, in some instances, be topical ophthalmological compositions. Lifitegrast is an N-acyl-L-alpha-amino acid obtained by formal condensation of the carboxy group of N-[2-(1-benzofuran-6-carbonyl)]-5,7-dichloro-1,2,3,4- tetrahydroisoquinoline-6-carboxylic acid with the amino group of 3- (methanesulfonyl)-L-phenylalanine. Lifitegrast can reduce inflammation by inhibiting inflammatory cell binding through inhibition of an integrin, lymphocyte function- associated antigen 1 (LFA-1), from binding to intercellular adhesion molecule 1 (ICAM-1). Lifitegrast, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, can, in some instances, aid in treatment of dry eye syndrome, or keratoconjunctivitis sicca. In some instances, lifitegrast or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, can slow the progression of, treat, or reduce or relieve symptoms of certain ocular diseases or conditions, such as dry eye syndrome or keratoconjunctivitis sicca, dry eye disease, inflammatory dry eye, redness, or meibomian gland disfunction. In some instances, the lifitegrast or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, can be present in an amount of from about 0.1% to about 10% (w / w), from ATTORNEY DOCKET NO.43081-0032WO1 about 0.1% to about 9% (w / w), from about 0.1% to about 8% (w / w), from about 0.1% to about 7% (w / w), from about 0.1% to about 6% (w / w), from about 0.1% to about 5% (w / w), from about 0.2% to about 10% (w / w), from about 0.3% to about 10% (w / w), from about 0.4% to about 10% (w / w), from about 0.5% to about 10% (w / w), from about 0.6% to about 10% (w / w), from about 0.7% to about 10% (w / w), from about 0.8% to about 10% (w / w), from about 0.9% to about 10% (w / w), from about 1% to about 10% (w / w), from about 1.5% to about 10% (w / w), from about 2% to about 10% (w / w), from about 2.5% to about 10% (w / w), from about 3% to about 10% (w / w), from about 3.5% to about 10% (w / w), from about 4% to about 10% (w / w), from about 4.5% to about 10% (w / w), from about 5% to about 10% (w / w), from about 5.5% to about 10% (w / w), from about 6% to about 10% (w / w), from about 6.5% to about 10% (w / w), from about 7% to about 10% (w / w), from about 7.5% to about 10% (w / w), from about 8% to about 10% (w / w), from about 8.5% to about 10% (w / w), from about 9% to about 10% (w / w), from about 9.5% to about 10% (w / w), from about 1% to about 5% (w / w), from about 2% to about 8% (w / w), from about 3% to about 9% (w / w), from about 4% to about 9% (w / w),from about 0.1% to about 2.5% (w / w), from about 0.1% to about 2% (w / w), from about 0.1% to about 1.5% (w / w), from about 0.1% to about 1% (w / w), from about 0.1% to about 0.5% (w / w), from about 0.1% to about 0.45% (w / w), from about 0.1% to about 0.4% (w / w), from about 0.1% to about 0.35% (w / w), from about 0.1% to about 0.3% (w / w), from about 0.1% to about 0.25% (w / w), from about 0.1% to about 0.2% (w / w), from about 0.15% to about 0.5% (w / w), from about 0.15% to about 0.45% (w / w), from about 0.15% to about 0.4% (w / w), from about 0.15% to about 0.35% (w / w), from about 0.15% to about 0.3% (w / w), from about 0.15% to about 0.25% (w / w), from about 0.15% to about 0.2% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.7% (w / w), from about 0.1% to about 2% (w / w), from about 0.3% to about 2% (w / w), from about 0.5% to about 2% (w / w), from about 0.7% to about 2% (w / w), from about 1% to about 2% (w / w), from about ATTORNEY DOCKET NO.43081-0032WO1 1.3% to about 2% (w / w), from about 1.5% to about 2% (w / w), from about 1.7% to about 2% (w / w), from about 0.3% to about 1% (w / w), from about 0.3% to about 1.3% (w / w), from about 0.3% to about 1% (w / w), from about 0.5% to about 1% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.5% to about 1% (w / w), from about 0.5 to about 1.5% (w / w), from about 0.5% to about 2% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.7% to about 1% (w / w), from about 1% to about 1.3 % (w / w), from about 1.3% to about 1.5% (w / w), from about 1.5% to about 2% (w / w), about 0.1% (w / w), about 0.2% (w / w), about 0.3% (w / w), about 0.4% (w / w), about 0.5% (w / w), about 0.6% (w / w), about 0.7% (w / w), about 0.8% (w / w), about 0.9% (w / w), about 1% (w / w), about 1.3% (w / w), about 1.5% (w / w), about 1.7% (w / w), about 2% (w / w), about 2.5% (w / w), about 3% (w / w), about 3.5% (w / w), about 4% (w / w), about 4.5% (w / w), about 5% (w / w), or about 5.5% (w / w). In some instances, provided herein are compositions comprising a therapeutically effective amount of a TRPM8 agonist (e.g., menthol or AR-15512 ((1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl) cyclohexanecarboxamide)), or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, or combinations thereof, as an active pharmaceutical ingredient; one or more of the excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound. The compositions can, in some instances, be topical ophthalmological compositions. TRPM8 agonists, such as AR-15512 and menthol, can act as potent and selective agonists of the TRPM8 (transient receptor potential melastatin 8) cold thermoreceptor. TRPM8 is a calcium-permeable ion channel, serves as a detector of cold in humans, and is involved in the regulation of blink rate and tear production. Stimulation of this receptor can lead to restoration of tear film volume and a reduction of ocular discomfort in patients suffering from dry eye symptoms or dry eye ATTORNEY DOCKET NO.43081-0032WO1 syndrome. An exemplary TRPM8 agonist is AR-15512 ((1R,2S,5R)-N-(4- methoxyphenyl)-5-methyl-2-(1-methylethyl) cyclohexanecarboxamide), or a derivative, analogue, racemic mixture, or diastereomer or enantiomer thereof. Another exemplary TRPM8 agonist is menthol (e.g., 5-Methyl-2-(propan-2-yl)cyclohexan-1- ol), or a derivative, analogue, racemic mixture, or diastereomer or enantiomer thereof. Other non-limiting exemplary TRPM8 agonists include eucalyptol (1,3,3-Trimethyl- 2-oxabicyclo[2.2.2]octane); Cryosim-3 or IVW-1001 (diisopropyl(nonyl)phosphine oxide); Icilin (3-(2-Hydroxyphenyl)-6-(3-nitrophenyl)-3,4-dihydropyrimidin-2(1H)- one); Dendreon D3263 (3-(2-aminoethyl)-1-((1R,2S,5R)-2-isopropyl-5- methylcyclohexane-1-carbonyl)-5-methoxy-1,3-dihydro-2H-benzo[d]imidazol-2-one hydrochloride); Borneol (rel -(1 R ,2 S ,4 R )-1,7,7-Trimethylbicyclo[2.2.1]heptan-2- ol); WS-5 (ethyl ((1R,2S,5R)-2-isopropyl-5-methylcyclohexane-1- carbonyl)carbamate), structure shown below: CPS369 (ethyl ((1R,2S,5R)-2-isopropyl-5-methylcyclohexane-1-carbonyl)alaninate), structure shown below: CPS368 (methyl ((1R,2S,5R)-2-isopropyl-5-methylcyclohexane-1-carbonyl)alaninate; CPS125 ((1R,2S,5R)-2-isopropyl-5-methyl-N-(4-(N-(pyrimidin-2- yl)sulfamoyl)phenyl)cyclohexane-1-carboxamide), structure shown below: ATTORNEY DOCKET NO.43081-0032WO1 Frescolat ML ((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 2-hydroxypropanoate), structure shown below: Frescolat MGA (((5S,6S,9R)-6-isopropyl-9-methyl-1,4-dioxaspiro[4.5]decan-2- yl)methanol), structure shown below: WS-3 (N-ethyl-2-isopropyl-5-methylcyclohexane-1-carboxamide), structure shown below: WS-23 (3-isopropyl-N,2,4-trimethylpentanamide), structure shown below: ATTORNEY DOCKET NO.43081-0032WO1 Rotundifolone ((1S,6S)-6-methyl-3-(propan-2-ylidene)-7-oxabicyclo[4.1.0]heptan-2- one), structure shown below: Cubebol ((3S,3aR,3bR,4S,7R,7aR)-4-isopropyl-3,7-dimethyloctahydro-1H- cyclopenta[1,3]cyclopropa[1,2]benzen-3-ol), structure shown below: (1S,3R,6S)-6-isopropyl-3-methyl-2-methylenecyclohexan-1-ol, structure shown below: 4-(3,5-dimethoxyphenyl)-1-((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)-1H-1,2,3- triazole, structure shown below: ATTORNEY DOCKET NO.43081-0032WO1 (1R,2S,5R)-N-((S)-2-(2-aminoacetamido)-2-phenylethyl)-2-isopropyl-5- methylcyclohexane-1-carboxamide, structure shown below: (R)-2-((1R,2S,5R)-2-isopropyl-5-methylcyclohexane-1-carboxamido)-1-phenylethyl glycinate, structure shown below: (1R,2S,5R)-N-((S)-2-((R)-2-aminopropanamido)-2-phenylethyl)-2-isopropyl-5- methylcyclohexane-1-carboxamide, structure shown below: (1R,2S,5R)-2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl)cyclohexane-1- carboxamide, structure shown below: ATTORNEY DOCKET NO.43081-0032WO1 3-(((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)oxy)propane-1,2-diol, structure shown below: 4-((1S,2S)-2-(4-allyl-2,6-dimethoxyphenoxy)-1-ethoxypropyl)-2-methoxyphenol, 4-(2-(4-allyl-2,6-dimethoxyphenoxy)-1-(((1S,2R,5S)-2-isopropyl-5- methylcyclohexyl)oxy)propyl)-2-methoxyphenol, structure shown below: di-sec-butyl(pentyl)phosphine oxide, structure shown below: ATTORNEY DOCKET NO.43081-0032WO1 ethyl 5-oxo-1,2,3,4,4a,10b,11,12a-octahydrospiro[naphtho[1,2-c]chromene-12,2'- [1,3]dithiolane]-4b(5H)-carboxylate, structure shown below: 10b-((2-mercaptoethyl)thio)-1,3,4,10b-tetrahydro-6H-spiro[pyrido[2,1-a]isoindole- 2,2'-[1,3]dithian]-6-one, structure shown below: 5-(cyclohex-1-en-1-yl)-1,5-dimethyl-3-(2-oxo-2-(pyridin-3-yl)ethyl)pyrimidine- 2,4,6(1H,3H,5H)-trione, structure shown below: ATTORNEY DOCKET NO.43081-0032WO1 5-((1S,2R,4R)-bicyclo[2.2.1]heptan-2-yl)-3-(2-(3-hydroxyphenyl)-2-oxoethyl)-1,5- dimethylimidazolidine-2,4-dione, structure shown below: (S)-2-cyclohexyl-N-methyl-N-(2-oxo-2-phenylethyl)propanamide, structure shown below: N-(1H-pyrazol-3-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, structure shown below: 2-((2,3-dihydro-1H-inden-5-yl)oxy)-N-(1H-pyrazol-3-yl)-N-(thiophen-2- ylmethyl)acetamide, structure shown below: ATTORNEY DOCKET NO.43081-0032WO1 (E)-N-(1H-pyrazol-3-yl)-N-(thiophen-2-ylmethyl)-3-(p-tolyl)acrylamide, structure shown below: (S)-2-(cyclohexanecarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin- 4-one aka Praziquantel, structure shown below: Tacrolimus ((-)-(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,26aS)-8-allyl- 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3- {(E)-2-[(1R,3R,4R)-4-hydroxy-3-methylcyclohexyl]-1-methylvinyl}-14,16- dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-3H-pyrido[2,1-c] [1,4]oxaazacyclotricosane-1,7,20,21(4H,23H)-tetrone), structure shown below: ATTORNEY DOCKET NO.43081-0032WO1 CPS-113 ((1R,2S,5R)-N-(4-fluorophenyl)-2-isopropyl-5-methylcyclohexane-1- carboxamide), structure shown below: 6-(3-chlorophenyl)-3-(2-hydroxyphenyl)-3,4-dihydropyrimidin-2(1H)-one, structure shown below: ethyl ((1R,2S,5R)-2-isopropyl-5-methylcyclohexane-1-carbonyl)glycinate, structure shown below: ATTORNEY DOCKET NO.43081-0032WO1 (1R,2S,5R)-N-(1-(2-aminoethyl)-3-phenyl-1H-pyrazol-5-yl)-2-isopropyl-5- methylcyclohexane-1-carboxamide, structure shown below: (1R,2S,5R)-N-((S)-2-(2-aminoethoxy)-2-phenylethyl)-2-isopropyl-5- methylcyclohexane-1-carboxamide, structure shown below: and derivatives, analogues, racemic mixtures, or diastereomers or enantiomers thereof. The compositions described herein can also include combinations of two or more TRPM8 agonists. TRPM8 agonists (e.g., menthol and AR-15512), or combinations thereof, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, can, in some instances, aid in treatment of dry eye syndrome, or keratoconjunctivitis sicca. In some instances, TRPM8 agonists (e.g., menthol and AR-15512), or combinations thereof, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, can slow the progression of, treat, or reduce or relieve symptoms of certain ocular diseases or conditions, such as dry eye syndrome or keratoconjunctivitis sicca, dry eye disease, inflammatory dry eye, redness, or meibomian gland disfunction. In some instances, the TRPM8 agonists (e.g., menthol and AR-15512), or combinations thereof, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, can be present in ATTORNEY DOCKET NO.43081-0032WO1 an amount of from about 0.0001% to about 5% (w / w), from about 0.1% to about 2.5% (w / w), from about 0.1% to about 2% (w / w), from about 0.1% to about 1.5% (w / w), from about 0.1% to about 1% (w / w), from about 0.001% to about 0.01% (w / w), from about 0.001% to about 0.009% (w / w), from about 0.001% to about 0.008% (w / w), from about 0.001% to about 0.007% (w / w), from about 0.001% to about 0.006% (w / w), from about 0.001% to about 0.005% (w / w), from about 0.001% to about 0.004% (w / w), from about 0.001% to about 0.003% (w / w), from about 0.001% to about 0.002% (w / w), from about 0.0001% to about 0.001% (w / w), from about 0.0001% to about 0.0009% (w / w), from about 0.0001% to about 0.0008% (w / w), from about 0.0001% to about 0.0007% (w / w), from about 0.0001% to about 0.0006% (w / w), from about 0.0001% to about 0.0005% (w / w), from about 0.0001% to about 0.0004% (w / w), from about 0.0001% to about 0.0003% (w / w), from about 0.0001% to about 0.0002% (w / w), from about 0.15% to about 0.5% (w / w), from about 0.15% to about 0.45% (w / w), from about 0.15% to about 0.4% (w / w), from about 0.15% to about 0.35% (w / w), from about 0.15% to about 0.3% (w / w), from about 0.15% to about 0.25% (w / w), from about 0.15% to about 0.2% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.5% (w / w), from about 0.1% to about 0.45% (w / w), from about 0.1% to about 0.4% (w / w), from about 0.1% to about 0.35% (w / w), from about 0.1% to about 0.3% (w / w), from about 0.1% to about 0.25% (w / w), from about 0.1% to about 0.2% (w / w), from about 0.15% to about 0.5% (w / w), from about 0.15% to about 0.45% (w / w), from about 0.15% to about 0.4% (w / w), from about 0.15% to about 0.35% (w / w), from about 0.15% to about 0.3% (w / w), from about 0.15% to about 0.25% (w / w), from about 0.15% to about 0.2% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.7% (w / w), from about 0.1% to about 2% (w / w), from about 0.3% to about 2% (w / w), from about 0.5% to about 2% (w / w), from about 0.7% to about 2% (w / w), from about 1% to about 2% (w / w), from about 1.3% to about 2% (w / w), from about 1.5% to about 2% (w / w), from about 1.7% ATTORNEY DOCKET NO.43081-0032WO1 to about 2% (w / w), from about 0.3% to about 1% (w / w), from about 0.3% to about 1.3% (w / w), from about 0.3% to about 1% (w / w), from about 0.5% to about 1% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.5% to about 1% (w / w), from about 0.5 to about 1.5% (w / w), from about 0.5% to about 2% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.7% to about 1% (w / w), from about 1% to about 1.3 % (w / w), from about 1.3% to about 1.5% (w / w), from about 1.5% to about 2% (w / w), about 0.1% (w / w), about 0.2% (w / w), about 0.3% (w / w), about 0.4% (w / w), about 0.5% (w / w), about 0.6% (w / w), about 0.7% (w / w), about 0.8% (w / w), about 0.9% (w / w), about 1% (w / w), about 1.3% (w / w), about 1.5% (w / w), about 1.7% (w / w), about 2% (w / w), about 2.5% (w / w), about 3% (w / w), about 3.5% (w / w), about 4% (w / w), about 4.5% (w / w), about 5% (w / w), about 5.5% (w / w), about 0.001%(w / w), about 0.002% (w / w), about 0.003%(w / w), about 0.004% (w / w), about 0.005%(w / w), about 0.0011% (w / w), about 0.0012% (w / w), about 0.0013% (w / w), about 0.0014% (w / w), about 0.0015% (w / w), about 0.0016% (w / w), about 0.0017% (w / w), about 0.0018% (w / w), about 0.0019% (w / w), about 0.002% (w / w), about 0.0021% (w / w), about 0.0022% (w / w), about 0.0023% (w / w), about 0.0024% (w / w), about 0.0025% (w / w), about 0.0026% (w / w), about 0.0027% (w / w), about 0.0028% (w / w), about 0.0029% (w / w), about 0.0030% (w / w), about 0.0031% (w / w), about 0.0032% (w / w), about 0.0033% (w / w), about 0.0034% (w / w), about 0.0035% (w / w), about 0.0036% (w / w), about 0.0037% (w / w), about 0.0038% (w / w), about 0.0039% (w / w), about 0.0001% (w / w), about 0.0002% (w / w), about 0.0003% (w / w), about 0.0004% (w / w), about 0.0005% (w / w), about 0.0006% (w / w), about 0.0007% (w / w), about 0.0008% (w / w), or about 0.0009% (w / w). In some instances, the TRPM8 agonists (e.g., menthol and AR-15512), or combinations thereof, or a derivative, analogue, racemic mixture, or diastereomer or enantiomer thereof, can be present in an amount of from about 0.0001% to about 0.1% (w / w). In some instances, the TRPM8 agonists (e.g., menthol and AR-15512), or combinations thereof, or a derivative, analogue, racemic mixture, or diastereomer or enantiomer thereof, can be ATTORNEY DOCKET NO.43081-0032WO1 present in an amount of from about 0.001% to about 0.01% (w / w). In some instances, the TRPM8 agonists (e.g., menthol and AR-15512), or combinations thereof, or a derivative, analogue, racemic mixture, or diastereomer or enantiomer thereof, can be present in an amount of about 0.003% (w / w). In some instances, the compositions described herein include enantiomers or diastereomers of the TRPM8 agonists. For example, nonlimiting exemplary enantiomers or diastereomers of AR-15512 include (1S,2R,5S)-N-(4- methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide or (1S,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(1- methylethyl)cyclohexanecarboxamide. In some instances, the compositions described herein include derivatives of the TRPM8 agonists (e.g., menthol and AR- 15512). In some instances, provided herein are compositions comprising a therapeutically effective amount of cyclosporine, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof as an active pharmaceutical ingredient; one or more of the excipient compound(s) selected from hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound. The compositions can, in some instances, be topical ophthalmological compositions. Cyclosporine, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, can, in some instances, aid in treatment of dry eye syndrome, or keratoconjunctivitis sicca. In some instances, cyclosporine or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, can slow the progression of, treat, or reduce or relieve symptoms of certain ocular diseases or conditions, such as dry eye syndrome or keratoconjunctivitis sicca, dry eye disease, inflammatory dry eye, redness, or meibomian gland disfunction. In some instances, the cyclosporine or a derivative, analogue, ATTORNEY DOCKET NO.43081-0032WO1 pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, can be present in an amount of from about 0.0001% to about 5% (w / w), from about 0.1% to about 2.5% (w / w), from about 0.1% to about 2% (w / w), from about 0.1% to about 1.5% (w / w), from about 0.1% to about 1% (w / w), from about 0.001% to about 0.01% (w / w), from about 0.001% to about 0.009% (w / w), from about 0.001% to about 0.008% (w / w), from about 0.001% to about 0.007% (w / w), from about 0.001% to about 0.006% (w / w), from about 0.001% to about 0.005% (w / w), from about 0.001% to about 0.004% (w / w), from about 0.001% to about 0.003% (w / w), from about 0.001% to about 0.002% (w / w), from about 0.0001% to about 0.001% (w / w), from about 0.0001% to about 0.0009% (w / w), from about 0.0001% to about 0.0008% (w / w), from about 0.0001% to about 0.0007% (w / w), from about 0.0001% to about 0.0006% (w / w), from about 0.0001% to about 0.0005% (w / w), from about 0.0001% to about 0.0004% (w / w), from about 0.0001% to about 0.0003% (w / w), from about 0.0001% to about 0.0002% (w / w), from about 0.15% to about 0.5% (w / w), from about 0.15% to about 0.45% (w / w), from about 0.15% to about 0.4% (w / w), from about 0.15% to about 0.35% (w / w), from about 0.15% to about 0.3% (w / w), from about 0.15% to about 0.25% (w / w), from about 0.15% to about 0.2% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.5% (w / w), from about 0.1% to about 0.45% (w / w), from about 0.1% to about 0.4% (w / w), from about 0.1% to about 0.35% (w / w), from about 0.1% to about 0.3% (w / w), from about 0.1% to about 0.25% (w / w), from about 0.1% to about 0.2% (w / w), from about 0.15% to about 0.5% (w / w), from about 0.15% to about 0.45% (w / w), from about 0.15% to about 0.4% (w / w), from about 0.15% to about 0.35% (w / w), from about 0.15% to about 0.3% (w / w), from about 0.15% to about 0.25% (w / w), from about 0.15% to about 0.2% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.7% (w / w), from about 0.1% to about 2% (w / w), from about 0.3% to about 2% (w / w), from about 0.5% to about 2% (w / w), from about 0.7% to ATTORNEY DOCKET NO.43081-0032WO1 about 2% (w / w), from about 1% to about 2% (w / w), from about 1.3% to about 2% (w / w), from about 1.5% to about 2% (w / w), from about 1.7% to about 2% (w / w), from about 0.3% to about 1% (w / w), from about 0.3% to about 1.3% (w / w), from about 0.3% to about 1% (w / w), from about 0.5% to about 1% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.5% to about 1% (w / w), from about 0.5 to about 1.5% (w / w), from about 0.5% to about 2% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.7% to about 1% (w / w), from about 1% to about 1.3 % (w / w), from about 1.3% to about 1.5% (w / w), from about 1.5% to about 2% (w / w), about 0.1% (w / w), about 0.2% (w / w), about 0.3% (w / w), about 0.4% (w / w), about 0.5% (w / w), about 0.6% (w / w), about 0.7% (w / w), about 0.8% (w / w), about 0.9% (w / w), about 1% (w / w), about 1.3% (w / w), about 1.5% (w / w), about 1.7% (w / w), about 2% (w / w), about 2.5% (w / w), about 3% (w / w), about 3.5% (w / w), about 4% (w / w), about 4.5% (w / w), about 5% (w / w), about 5.5% (w / w), about 0.001%(w / w), about 0.002% (w / w), about 0.003%(w / w), about 0.004% (w / w), about 0.005%(w / w), about 0.0011% (w / w), about 0.0012% (w / w), about 0.0013% (w / w), about 0.0014% (w / w), about 0.0015% (w / w), about 0.0016% (w / w), about 0.0017% (w / w), about 0.0018% (w / w), about 0.0019% (w / w), about 0.002% (w / w), about 0.0021% (w / w), about 0.0022% (w / w), about 0.0023% (w / w), about 0.0024% (w / w), about 0.0025% (w / w), about 0.0026% (w / w), about 0.0027% (w / w), about 0.0028% (w / w), about 0.0029% (w / w), about 0.0030% (w / w), about 0.0031% (w / w), about 0.0032% (w / w), about 0.0033% (w / w), about 0.0034% (w / w), about 0.0035% (w / w), about 0.0036% (w / w), about 0.0037% (w / w), about 0.0038% (w / w), about 0.0039% (w / w), about 0.0001% (w / w), about 0.0002% (w / w), about 0.0003% (w / w), about 0.0004% (w / w), about 0.0005% (w / w), about 0.0006% (w / w), about 0.0007% (w / w), about 0.0008% (w / w), or about 0.0009% (w / w). In some instances, provided herein are compositions comprising a therapeutically effective amount of a pressure regulator, such as Brimonidine, Apraclonidine Iopidine, Dorzolamide, Brinzolamide, Azopt, Timolol, ATTORNEY DOCKET NO.43081-0032WO1 Timoptic / Istalol / Betimol, Betaxolol, Betoptic, Levobunolol, Betagan, Metipranolol, Optipranolol, Latanoprost, Xalatan Green, Bimatoprost, Lumigan, Tafluprost, Zioptan, Latanoprostene, Vyzulta Turquoise, Pilocarpine, Carbachol, Isopto Carbachol, Netarsudil, and Rhopressa, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof as an active pharmaceutical ingredient; one or more of the excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound. The compositions can, in some instances, be topical ophthalmological compositions. Pressure regulators, can, in some instances, aid in treatment of glaucoma. In some instances, pressure regulators can slow the progression of, treat, or reduce or relieve symptoms of certain ocular diseases or conditions, such as glaucoma, ocular hypertension, or high fluid pressure in an eye of a subject. In some instances, pressure regulators can lower fluid pressure in an eye of a subject. In some instances, the pressure regulator, such as Brimonidine or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, can be present in an amount of from about 0.0001% to about 5% (w / w), from about 0.1% to about 2.5% (w / w), from about 0.1% to about 2% (w / w), from about 0.1% to about 1.5% (w / w), from about 0.002% to about 0.3% (w / w), from about 0.0025% to about 0.25% (w / w), from about 0.1% to about 1% (w / w), from about 0.001% to about 0.01% (w / w), from about 0.001% to about 0.009% (w / w), from about 0.001% to about 0.008% (w / w), from about 0.001% to about 0.007% (w / w), from about 0.001% to about 0.006% (w / w), from about 0.001% to about 0.005% (w / w), from about 0.001% to about 0.004% (w / w), from about 0.001% to about 0.003% (w / w), from about 0.001% to about 0.002% (w / w), from about 0.0001% to about 0.001% (w / w), from about 0.0001% to about 0.0009% (w / w), from about 0.0001% to about 0.0008% (w / w), from about 0.0001% to about ATTORNEY DOCKET NO.43081-0032WO1 0.0007% (w / w), from about 0.0001% to about 0.0006% (w / w), from about 0.0001% to about 0.0005% (w / w), from about 0.0001% to about 0.0004% (w / w), from about 0.0001% to about 0.0003% (w / w), from about 0.0001% to about 0.0002% (w / w), from about 0.15% to about 0.5% (w / w), from about 0.15% to about 0.45% (w / w), from about 0.15% to about 0.4% (w / w), from about 0.15% to about 0.35% (w / w), from about 0.15% to about 0.3% (w / w), from about 0.15% to about 0.25% (w / w), from about 0.15% to about 0.2% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.5% (w / w), from about 0.1% to about 0.45% (w / w), from about 0.1% to about 0.4% (w / w), from about 0.1% to about 0.35% (w / w), from about 0.1% to about 0.3% (w / w), from about 0.1% to about 0.25% (w / w), from about 0.1% to about 0.2% (w / w), from about 0.15% to about 0.5% (w / w), from about 0.15% to about 0.45% (w / w), from about 0.15% to about 0.4% (w / w), from about 0.15% to about 0.35% (w / w), from about 0.15% to about 0.3% (w / w), from about 0.15% to about 0.25% (w / w), from about 0.15% to about 0.2% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.7% (w / w), from about 0.1% to about 2% (w / w), from about 0.3% to about 2% (w / w), from about 0.5% to about 2% (w / w), from about 0.7% to about 2% (w / w), from about 1% to about 2% (w / w), from about 1.3% to about 2% (w / w), from about 1.5% to about 2% (w / w), from about 1.7% to about 2% (w / w), from about 0.3% to about 1% (w / w), from about 0.3% to about 1.3% (w / w), from about 0.3% to about 1% (w / w), from about 0.5% to about 1% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.5% to about 1% (w / w), from about 0.5 to about 1.5% (w / w), from about 0.5% to about 2% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.7% to about 1% (w / w), from about 1% to about 1.3 % (w / w), from about 1.3% to about 1.5% (w / w), from about 1.5% to about 2% (w / w), about 0.1% (w / w), about 0.2% (w / w), about 0.3% (w / w), about 0.4% (w / w), about 0.5% (w / w), about 0.6% (w / w), about 0.7% (w / w), about 0.8% (w / w), about 0.9% (w / w), about 1% (w / w), about 1.3% (w / w), about 1.5% (w / w), about 1.7% ATTORNEY DOCKET NO.43081-0032WO1 (w / w), about 2% (w / w), about 2.5% (w / w), about 3% (w / w), about 3.5% (w / w), about 4% (w / w), about 4.5% (w / w), about 5% (w / w), about 5.5% (w / w), about 0.001%(w / w), about 0.002% (w / w), about 0.003%(w / w), about 0.004% (w / w), about 0.005%(w / w), about 0.0011% (w / w), about 0.0012% (w / w), about 0.0013% (w / w), about 0.0014% (w / w), about 0.0015% (w / w), about 0.0016% (w / w), about 0.0017% (w / w), about 0.0018% (w / w), about 0.0019% (w / w), about 0.002% (w / w), about 0.0021% (w / w), about 0.0022% (w / w), about 0.0023% (w / w), about 0.0024% (w / w), about 0.0025% (w / w), about 0.0026% (w / w), about 0.0027% (w / w), about 0.0028% (w / w), about 0.0029% (w / w), about 0.0030% (w / w), about 0.0031% (w / w), about 0.0032% (w / w), about 0.0033% (w / w), about 0.0034% (w / w), about 0.0035% (w / w), about 0.0036% (w / w), about 0.0037% (w / w), about 0.0038% (w / w), about 0.0039% (w / w), about 0.0001% (w / w), about 0.0002% (w / w), about 0.0003% (w / w), about 0.0004% (w / w), about 0.0005% (w / w), about 0.0006% (w / w), about 0.0007% (w / w), about 0.0008% (w / w), or about 0.0009% (w / w). In some instances, provided herein are compositions comprising a therapeutically effective amount of a muscarinic cholinergic receptor agonist as an active pharmaceutical ingredient; one or more of the excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof and a semi-fluorinated alkane compound. The compositions can, in some instances, be topical ophthalmological compositions. Muscarinic cholinergic receptor agonists can, in some instances, cause pupil contraction to alter the focusing depth of field of an eye. In some instances, this can temporarily relieve symptoms of certain eye diseases or conditions such as presbyopia. In some instances, through the muscarinic cholinergic receptors, the agonists can lower intraocular pressure (IOP). This mechanism can, in some instances, be used to treat glaucoma. In some instances, the muscarinic cholinergic receptor agonist can be selected from the group consisting of aceclidine, pilocarpine, ATTORNEY DOCKET NO.43081-0032WO1 bethanechol, cevimeline, methacholine, xanomeline, and aprolidine, or combinations thereof. In some instances, the muscarinic cholinergic receptor agonist can be in salt form. In some instances, the muscarinic cholinergic receptor agonist can be in free base form. In some instances, the muscarinic cholinergic receptor agonist can be present in an amount of from about 0.1% to about 5% (w / w), from about 0.1% to about 2.5% (w / w), from about 0.1% to about 2% (w / w), from about 0.1% to about 1.5% (w / w), from about 0.1% to about 1% (w / w), from about 0.1% to about 0.5% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.7% (w / w), from about 0.1% to about 2% (w / w), from about 0.3% to about 2% (w / w), from about 0.5% to about 2% (w / w), from about 0.7% to about 2% (w / w), from about 1% to about 2% (w / w), from about 1.3% to about 2% (w / w), from about 1.5% to about 2% (w / w), from about 1.7% to about 2% (w / w), from about 0.3% to about 1% (w / w), from about 0.3% to about 1.3% (w / w), from about 0.3% to about 1% (w / w), from about 0.5% to about 1% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.5% to about 1% (w / w), from about 0.5 to about 1.5% (w / w), from about 0.5% to about 2% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.7% to about 1% (w / w), from about 1% to about 1.3 % (w / w), from about 1.3% to about 1.5% (w / w), from about 1.5% to about 2% (w / w), about 0.1% (w / w), about 0.2% (w / w), about 0.3% (w / w), about 0.4% (w / w), about 0.5% (w / w), about 0.6% (w / w), about 0.7% (w / w), about 0.8% (w / w), about 0.9% (w / w), about 1% (w / w), about 1.3% (w / w), about 1.5% (w / w), about 1.7% (w / w), or about 2% (w / w). In some instances, the muscarinic cholinergic receptor agonist can be aceclidine. In some instances, the aceclidine can be in salt form, such as, for example aceclidine sulfate. In some instances, the aceclidine can be in salt form, such as, for example aceclidine hydrochloride. In some instances, the aceclidine can be in free base form. In some instances, the aceclidine can be present in an amount of from about 0.01% to about 10% (w / w), from about 0.01% to about 9% (w / w), from about ATTORNEY DOCKET NO.43081-0032WO1 0.01% to about 8% (w / w), from about 0.01% to about 7% (w / w), from about 0.01% to about 6% (w / w), from about 0.01% to about 5% (w / w), from about 0.01% to about 4% (w / w), from about 0.01% to about 3% (w / w), from about 0.01% to about 2% (w / w), from about 0.01% to about 1% (w / w), from about 0.01% to about 0.9% (w / w), from about 0.01% to about 0.8% (w / w), from about 0.01% to about 0.7% (w / w), from about 0.01% to about 0.6% (w / w), from about 0.01% to about 0.5% (w / w), from about 0.01% to about 0.4% (w / w), from about 0.01% to about 0.3% (w / w), from about 0.01% to about 0.2% (w / w), from about 0.01% to about 0.1% (w / w), from about 1% to about 10% (w / w), from about 1% to about 9% (w / w), from about 1% to about 8% (w / w), from about 1% to about 7% (w / w), from about 1% to about 6% (w / w), from about 1% to about 5% (w / w), from about 1% to about 4% (w / w), from about 1% to about 3% (w / w), from about 1% to about 2% (w / w), from about 0.01% to about 1%, 0.01% to about 0.95% (w / w), 0.01% to about .9% (w / w), 0.01% to about 0.85% (w / w), 0.01% to about 0.8% (w / w), 0.01% to about 0.75% (w / w), 0.01% to about 0.7% (w / w), 0.01% to about 0.65% (w / w), 0.01% to about 0.6% (w / w), 0.01% to about 0.55% (w / w), 0.01% to about 0.5% (w / w), 0.01% to about 0.45% (w / w), 0.01% to about 0.4% (w / w), 0.01% to about 0.35% (w / w), 0.01% to about 0.3% (w / w), 0.01% to about 0.25% (w / w), 0.01% to about 0.2% (w / w), 0.01% to about 0.15% (w / w), 0.01% to about 0.1% (w / w), 0.01% to about 0.09% (w / w), 0.01% to about 0.08% (w / w), 0.01% to about 0.07% (w / w), 0.01% to about 0.06% (w / w), 0.01% to about 0.05% (w / w), 0.01% to about 0.04% (w / w), 0.01% to about 0.03% (w / w), 0.01% to about 0.02% (w / w), from about 0.1% to about 5% (w / w), from about 0.1% to about 2.5% (w / w), from about 0.1% to about 2% (w / w), from about 0.1% to about 1.5% (w / w), from about 0.1% to about 1% (w / w), from about 0.1% to about 0.5% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.7% (w / w), from about 0.1% to about 2% (w / w), from about 0.3% to about 2% (w / w), from about 0.5% to about 2% (w / w), from about 0.7% to about 2% (w / w), from about 1% to about 2% (w / w), from about 1.3% to ATTORNEY DOCKET NO.43081-0032WO1 about 2% (w / w), from about 1.5% to about 2% (w / w), from about 1.7% to about 2% (w / w), from about 0.3% to about 1% (w / w), from about 0.3% to about 1.3% (w / w), from about 0.3% to about 1% (w / w), from about 0.5% to about 1% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.5% to about 1% (w / w), from about 0.5 to about 1.5% (w / w), from about 0.5% to about 2% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.7% to about 1% (w / w), from about 1% to about 1.3 % (w / w), from about 1.3% to about 1.5% (w / w), from about 1.5% to about 2% (w / w), about 0.1% (w / w), about 0.2% (w / w), about 0.3% (w / w), about 0.4% (w / w), about 0.5% (w / w), about 0.6% (w / w), about 0.7% (w / w), about 0.8% (w / w), about 0.9% (w / w), about 1% (w / w), about 1.3% (w / w), about 1.5% (w / w), about 1.7% (w / w), or about 2% (w / w). In some instances, the muscarinic cholinergic receptor agonist can be pilocarpine. In some instances, the pilocarpine can be in salt form, such as, for example pilocarpine hydrochloride. In some instances, the pilocarpine can be in salt form, such as, for example pilocarpine nitrate. In some instances, the pilocarpine can be in free base form. In some instances, the pilocarpine can be present in an amount of from about 0.1% to about 2% (w / w), from about 0.1% to about 1.5% (w / w), from about 0.1% to about 1% (w / w), from about 0.1% to about 0.5% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.7% (w / w), from about 0.1% to about 2% (w / w), from about 0.3% to about 2% (w / w), from about 0.5% to about 2% (w / w), from about 0.7% to about 2% (w / w), from about 1% to about 2% (w / w), from about 1.3% to about 2% (w / w), from about 1.5% to about 2% (w / w), from about 1.7% to about 2% (w / w), from about 0.3% to about 1% (w / w), from about 0.3% to about 1.3% (w / w), from about 0.3% to about 1% (w / w), from about 0.5% to about 1% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.5% to about 1% (w / w), from about 0.5 to about 1.5% (w / w), from about 0.5% to about 2% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.7% to about 1% (w / w), from about 1% to about 1.3 % (w / w), from about 1.3% to about ATTORNEY DOCKET NO.43081-0032WO1 1.5% (w / w), from about 1.5% to about 2% (w / w), about 0.1% (w / w), about 0.2% (w / w), about 0.3% (w / w), about 0.4% (w / w), about 0.5% (w / w), about 0.6% (w / w), about 0.7% (w / w), about 0.8% (w / w), about 0.9% (w / w), about 1% (w / w), about 1.3% (w / w), about 1.5% (w / w), about 1.7% (w / w), or about 2% (w / w). In some instances of the compositions provided herein, the API can be a co- drug that includes a muscarinic agonist moiety and an alpha2 adrenergic agonist moiety, or a pharmaceutical salt thereof. The muscarinic agonist moiety and the alpha2 adrenergic agonist moiety are connected covalently via a linker, and the linker comprises an amide bond. In some instances, the co-drug can be a compound of Formula (III), an enantiomer, a diastereoisomer, a hydrate, a solvate, a crystal form, or a tautomer thereof, Formula (III) In Formula (III), R is H, -CO-C1-18 alkyl, -CO-C1-18 alkyloxy; -CO-aryl, -CO- aryloxy, -CO-C1-18alkylaryl, or -CO-C1-18alkylaryloxy; and Z is: In some instances, the API can be a co-drug selected from the group consisting of (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5-yl)amino)-4,5-dihydro-lH- ATTORNEY DOCKET NO.43081-0032WO1 imidazole-lcarbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3- (2-((4-bromo-lHbenzo[d]imidazol-5-yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)- 2-((l-methyl-1Himidazol-5-yl)methyl)pentyl propionate; (2R,3S)-3-(2-((4-bromo-lH- benzo[d]imidazol-5- yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl- lH-imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2-((4-bromo-lH- benzo[d]imidazol-5-yl)amino)-4,5-dihydro-lH-imidazolel-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3- (2-((4-bromo-lH- benzo[d]imidazol-5-yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((lmethyl-lH- imidazol-5-yl)methyl)pentyl oleate; (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5- yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl (9Z,12Z)-octadeca-9,12-dienoate; (2R,3S)-3-(2-((5- bromoquinoxalin-6-yl)amino)-4,5-dihydrolH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2- ((5-bromoquinoxalin-6-yl)amino)- 4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lHimidazol-5-yl)methyl)pentyl propionate; (2R,3S)-3-(2-((5-bromoquinoxalin-6-yl)amino)-4,5- dihydro-lH- imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)- 3-(2-((5-bromoquinoxalin-6-yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2- ((lmethyl-lH-imidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((5- bromoquinoxalin-6-yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl- lHimidazol-5-yl)methyl)pentyl oleate; (2R,3S)-3-(2-((5-bromoquinoxalin-6- yl)amino)-4,5-dihydrolH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl (9Z,12Z)-octadeca- 9,12-dienoate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-lcarbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5- yl)methyl)pentyl propionate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydrolH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2- ((4-amino-2,6- ATTORNEY DOCKET NO.43081-0032WO1 dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl- lHimidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5- yl)methyl)pentyl oleate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lHimidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl (9Z,12Z)-octadeca-9, 12-dienoate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2- ((l-methyl-lH- imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2-((2,6-dichlorophenyl)amino)- 4,5- dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl propionate; (2R,3S)-3-(2-((2,6-dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l- carbonyl)-2- ((l-methyl-lH-imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)- 4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazolel-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl oleate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)-4,5- dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl (9Z,12Z)-octadeca-9,12-dienoate, and (2R,3S)-3-((Z)-2-((5-bromoquinoxalin-6- yl)imino)imidazolidine-1-carbonyl)-2-((1-methyl-1H-imidazol-5-yl)methyl)pentyl pivalate or any of the compounds described in WO2022 / 221071 (incorporated herein by reference). In some instances of the compositions provided herein, the API can be riboflavin or a riboflavin derivative. In some instances of the compositions provided herein, the API can be a compound that has the general Formula (I): ATTORNEY DOCKET NO.43081-0032WO1 In Formula (I) R1, R2, and R3 are each independently selected from hydrogen or -C(O)R5; R4 is selected from hydrogen, -C(O)R5, a phosphate, or a salt thereof; and R5 is a linear or branched or cyclic alkyl having 1 to 26 carbon atoms (e.g., methyl, ethyl, propyl, butyl, sec-butyl, tert-butyl, and the like). In some embodiments of Formula (I), R1, R2, R3, and R4 are each independently selected from hydrogen or -C(O)R5. In some embodiments of Formula (I), at least one of R1, R2, R3, and R4 is -C(O)R5, at least two of R1, R2, R3, and R4 are -C(O)R5, or at least three of R1, R2, R3, and R4 are -C(O)R5, or all of R1, R2, R3, and R4 are -C(O)R5. In some embodiments each of R1, R2, R3, and R4 can be the same groups or can have different groups. In some embodiments of Formula (I), R1, R2, R3, and R4 are each independently selected from hydrogen or -C(O)R5; and at least one of R1, R2, R3, and R4 is -C(O)R5, at least two of R1, R2, R3, and R4 is -C(O)R5, or at least three of R1, R2, R3, and R4 is -C(O)R5. In some embodiments, R1, R2, R3, and R4 are each independently -C(O)R5. In some embodiments of Formula (I), R1, R2, R3, and R4 are each independently selected from hydrogen or -C(O)R5; at least one of R1, R2, R3, and R4 is -C(O)R5, at least two of R1, R2, R3, and R4 are -C(O)R5, or at least three of R1, R2, R3, and R4 are -C(O)R5; and R5 can be a linear or branched alkyl having 1 or 3 carbon atoms. ATTORNEY DOCKET NO.43081-0032WO1 In some embodiments, R1, R2, R3, and R4 are each independently -C(O)R5, and R5 can be a linear or branched alkyl having 1 or 3 carbon atoms. In some embodiments, exemplary compounds of Formula (I) can include selected from riboflavin tetraacetate, riboflavin tetrapropionate, riboflavin tetrabutyrate, riboflavin tetrapalmitate, or combinations thereof. In some embodiments, exemplary compounds of Formula (I) can include riboflavin, riboflavin-5-phosphate, riboflavin tetraacetate: (2R,3S,4S)-5-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)- yl)pentane-1,2,3,4-tetrayl tetraacetate, riboflavin tetrapropionate: (2R,3S,4S)-5-(7,8- dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)pentane-1,2,3,4-tetrayl tetrapropionate, riboflavin tetrabutyrate: (2R,3S,4S)-5-(7,8-dimethyl-2,4-dioxo-3,4- dihydrobenzo[g]pteridin-10(2H)-yl)pentane-1,2,3,4-tetrayl tetrabutyrate, riboflavin tetrapalmitate: (2R,3S,4S)-5-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin- 10(2H)-yl)pentane-1,2,3,4-tetrayl tetrapalmitate, or combinations thereof. In some embodiments, the compound of Formula (I) can be present in the compositions in an amount of from about 0.01% to about 10% (w / w), from about 0.01% to about 9% (w / w), from about 0.01% to about 8% (w / w), from about 0.01% to about 7% (w / w), from about 0.01% to about 6% (w / w), from about 0.01% to about 5% (w / w), from about 0.01% to about 4% (w / w), from about 0.01% to about 3% (w / w), from about 0.01% to about 2% (w / w), from about 0.01% to about 1% (w / w), from about 0.01% to about 0.9% (w / w), from about 0.01% to about 0.8% (w / w), from about 0.01% to about 0.7% (w / w), from about 0.01% to about 0.6% (w / w), from about 0.01% to about 0.5% (w / w), from about 0.01% to about 0.4% (w / w), from about 0.01% to about 0.3% (w / w), from about 0.01% to about 0.2% (w / w), from about 0.01% to about 0.1% (w / w), from about 1% to about 10% (w / w), from about 1% to about 9% (w / w), from about 1% to about 8% (w / w), from about 1% to about 7% (w / w), from about 1% to about 6% (w / w), from about 1% to about 5% (w / w), from about 1% to about 4% (w / w), from about 1% to about 3% (w / w), from about 1% to about 2% (w / w), from about 0.01% to about 1%, 0.01% to about 0.95% (w / w), ATTORNEY DOCKET NO.43081-0032WO1 0.01% to about .9% (w / w), 0.01% to about 0.85% (w / w), 0.01% to about 0.8% (w / w), 0.01% to about 0.75% (w / w), 0.01% to about 0.7% (w / w), 0.01% to about 0.65% (w / w), 0.01% to about 0.6% (w / w), 0.01% to about 0.55% (w / w), 0.01% to about 0.5% (w / w), 0.01% to about 0.45% (w / w), 0.01% to about 0.4% (w / w), 0.01% to about 0.35% (w / w), 0.01% to about 0.3% (w / w), 0.01% to about 0.25% (w / w), 0.01% to about 0.2% (w / w), 0.01% to about 0.15% (w / w), 0.01% to about 0.1% (w / w), 0.01% to about 0.09% (w / w), 0.01% to about 0.08% (w / w), 0.01% to about 0.07% (w / w), 0.01% to about 0.06% (w / w), 0.01% to about 0.05% (w / w), 0.01% to about 0.04% (w / w), 0.01% to about 0.03% (w / w), 0.01% to about 0.02% (w / w), from about 0.001% to about 1% (w / w), 0.001% to about 0.95% (w / w), 0.001% to about .9% (w / w), 0.001% to about 0.85% (w / w), 0.001% to about 0.8% (w / w), 0.001% to about 0.75% (w / w), 0.001% to about 0.7% (w / w), 0.001% to about 0.65% (w / w), 0.001% to about 0.6% (w / w), 0.001% to about 0.55% (w / w), 0.001% to about 0.5% (w / w), 0.001% to about 0.45% (w / w), 0.001% to about 0.4% (w / w), 0.001% to about 0.35% (w / w), 0.001% to about 0.3% (w / w), 0.001% to about 0.25% (w / w), 0.001% to about 0.2% (w / w), 0.001% to about 0.15% (w / w), 0.001% to about 0.1% (w / w), 0.001% to about 0.09% (w / w), 0.001% to about 0.08% (w / w), 0.001% to about 0.07% (w / w), 0.001% to about 0.06% (w / w), 0.001% to about 0.05% (w / w), 0.001% to about 0.04% (w / w), 0.001% to about 0.03% (w / w), 0.001% to about 0.02% (w / w), 0.001% to about 0.01% (w / w), from about 0.01% to about 1%, 0.01% to about 0.95% (w / w), 0.01% to about .9% (w / w), 0.01% to about 0.85% (w / w), 0.01% to about 0.8% (w / w), 0.01% to about 0.75% (w / w), 0.01% to about 0.7% (w / w), 0.01% to about 0.65% (w / w), 0.01% to about 0.6% (w / w), 0.01% to about 0.55% (w / w), 0.01% to about 0.5% (w / w), 0.01% to about 0.45% (w / w), 0.01% to about 0.4% (w / w), 0.01% to about 0.35% (w / w), 0.01% to about 0.3% (w / w), 0.01% to about 0.25% (w / w), 0.01% to about 0.2% (w / w), 0.01% to about 0.15% (w / w), 0.01% to about 0.1% (w / w), 0.01% to about 0.09% (w / w), 0.01% to about 0.08% (w / w), 0.01% to about 0.07% (w / w), 0.01% to about 0.06% (w / w), 0.01% to about 0.05% (w / w), 0.01% to about 0.04% ATTORNEY DOCKET NO.43081-0032WO1 (w / w), 0.01% to about 0.03% (w / w), 0.01% to about 0.02% (w / w), from about 0.05% to about 0.5% (w / w), from about 0.05% to about 0.45% (w / w), from about 0.05% to about 0.4% (w / w), from about 0.05% to about 0.35% (w / w), from about 0.05% to about 0.3% (w / w), from about 0.05% to about 0.25% (w / w), from about 0.05% to about 0.2% (w / w), from about 0.05% to about 0.15% (w / w), from about 0.05% to about 0.1% (w / w), from about 0.05% to about 0.09% (w / w), from about 0.05% to about 0.08% (w / w), from about 0.05% to about 0.07% (w / w), from about 0.05% to about 0.06% (w / w), from about 0.06% to about 0.5% (w / w), from about 0.07% to about 0.5% (w / w), from about 0.08% to about 0.5% (w / w), from about 0.09% to about 0.5% (w / w), from about 0.1% to about 0.5% (w / w), from about 0.15% to about 0.5% (w / w), from about 0.2% to about 0.5% (w / w), from about 0.25% to about 0.5% (w / w), from about 0.3% to about 0.5% (w / w), from about 0.35% to about 0.5% (w / w), from about 0.4% to about 0.5% (w / w), from about 0.45% to about 0.5% (w / w), about 0.01% (w / w), 0.02% (w / w), 0.03% (w / w), 0.04% (w / w), 0.05% (w / w), 0.06% (w / w), 0.07% (w / w), 0.08% (w / w), 0.09% (w / w), 0.1% (w / w), 0.15% (w / w), 0.2% (w / w), 0.25% (w / w), 0.3% (w / w), 0.35% (w / w), 0.4% (w / w), 0.45% (w / w), 0.5% (w / w), 0.55% (w / w), 0.6% (w / w), 0.65% (w / w), 0.7% (w / w), 0.75% (w / w), 0.8% (w / w), 0.85% (w / w), 0.9% (w / w), 0.95% (w / w), or 1% (w / w). In some instances, the compositions described herein can be pharmaceutical compositions comprising an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or combinations thereof; a semi-fluorinated alkane and one or more of the excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid as described herein. In some instances, the compositions can be topical compositions. In some instances, the compositions can be topical ocular compositions. In some instances, the API can be a tyrosine kinase inhibitor. In some instances, the tyrosine kinase inhibitor can be a multi-kinase inhibitor (MKI) that inhibits one or more selected from the group consisting of Vascular Endothelial ATTORNEY DOCKET NO.43081-0032WO1 Growth Factor Receptors (VEGFR) 1, 2, and 3 and Platelet-derived Growth Factor Receptor (PDGFR), α, β, and Lyn. In some instances, the API can be a multikinase inhibitor selected from afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib, or combinations thereof. In some instances, the multikinase inhibitor can be selected from axitinib, nintedanib, and pazopanib. In some instances, the multikinase inhibitor can be axitinib, and optionally can be present in the compositions described herein in an amount of from about 0.0001% to about 5% (w / w), from about 0.0005% to about 2% (w / w), or from about 0.001% to about 1% (w / w). In some instances, the multikinase inhibitor can be nintedanib, and optionally can be present in the compositions described herein in an amount of from about 0.0001% to about 5% (w / w), from about 0.0005% to about 2% (w / w), from about 0.001% to about 1% (w / w), or from about 0.01% to about 1% (w / w). In some instances, the multikinase inhibitor can be pazopanib, and optionally can be present in the compositions described herein in an amount of from about 0.0001% to about 5% (w / w), from about 0.0005% to about 2% (w / w), or from about 0.001% to about 1% (w / w). In some instances, the API can be present in the compositions described herein in an amount of from about 0.0001% to about 5% (w / w), from about 0.1% to about 2.5% (w / w), from about 0.1% to about 2% (w / w), from about 0.1% to about 1.5% (w / w), from about 0.1% to about 1% (w / w), from about 0.001% to about 0.01% (w / w), from about 0.001% to about 0.009% (w / w), from about 0.001% to about 0.008% (w / w), from about 0.001% to about 0.007% (w / w), from about 0.001% to about 0.006% (w / w), from about 0.001% to about 0.005% (w / w), from about 0.001% ATTORNEY DOCKET NO.43081-0032WO1 to about 0.004% (w / w), from about 0.001% to about 0.003% (w / w), from about 0.001% to about 0.002% (w / w), from about 0.0001% to about 0.001% (w / w), from about 0.0001% to about 0.0009% (w / w), from about 0.0001% to about 0.0008% (w / w), from about 0.0001% to about 0.0007% (w / w), from about 0.0001% to about 0.0006% (w / w), from about 0.0001% to about 0.0005% (w / w), from about 0.0001% to about 0.0004% (w / w), from about 0.0001% to about 0.0003% (w / w), from about 0.0001% to about 0.0002% (w / w), from about 0.15% to about 0.5% (w / w), from about 0.15% to about 0.45% (w / w), from about 0.15% to about 0.4% (w / w), from about 0.15% to about 0.35% (w / w), from about 0.15% to about 0.3% (w / w), from about 0.15% to about 0.25% (w / w), from about 0.15% to about 0.2% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.5% (w / w), from about 0.1% to about 0.45% (w / w), from about 0.1% to about 0.4% (w / w), from about 0.1% to about 0.35% (w / w), from about 0.1% to about 0.3% (w / w), from about 0.1% to about 0.25% (w / w), from about 0.1% to about 0.2% (w / w), from about 0.15% to about 0.5% (w / w), from about 0.15% to about 0.45% (w / w), from about 0.15% to about 0.4% (w / w), from about 0.15% to about 0.35% (w / w), from about 0.15% to about 0.3% (w / w), from about 0.15% to about 0.25% (w / w), from about 0.15% to about 0.2% (w / w), from about 0.1% to about 1.7% (w / w), from about 0.1% to about 1.3% (w / w), from about 0.1% to about 0.7% (w / w), from about 0.1% to about 2% (w / w), from about 0.3% to about 2% (w / w), from about 0.5% to about 2% (w / w), from about 0.7% to about 2% (w / w), from about 1% to about 2% (w / w), from about 1.3% to about 2% (w / w), from about 1.5% to about 2% (w / w), from about 1.7% to about 2% (w / w), from about 0.3% to about 1% (w / w), from about 0.3% to about 1.3% (w / w), from about 0.3% to about 1% (w / w), from about 0.5% to about 1% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.5% to about 1% (w / w), from about 0.5 to about 1.5% (w / w), from about 0.5% to about 2% (w / w), from about 0.5% to about 0.7% (w / w), from about 0.7% to about 1% (w / w), from about 1% to about 1.3 % (w / w), from about 1.3% to about 1.5% (w / w), ATTORNEY DOCKET NO.43081-0032WO1 from about 1.5% to about 2% (w / w), about 0.1% (w / w), about 0.2% (w / w), about 0.3% (w / w), about 0.4% (w / w), about 0.5% (w / w), about 0.6% (w / w), about 0.7% (w / w), about 0.8% (w / w), about 0.9% (w / w), about 1% (w / w), about 1.3% (w / w), about 1.5% (w / w), about 1.7% (w / w), about 2% (w / w), about 2.5% (w / w), about 3% (w / w), about 3.5% (w / w), about 4% (w / w), about 4.5% (w / w), about 5% (w / w), about 5.5% (w / w), about 0.001%(w / w), about 0.002% (w / w), about 0.003%(w / w), about 0.004% (w / w), about 0.005%(w / w), about 0.0011% (w / w), about 0.0012% (w / w), about 0.0013% (w / w), about 0.0014% (w / w), about 0.0015% (w / w), about 0.0016% (w / w), about 0.0017% (w / w), about 0.0018% (w / w), about 0.0019% (w / w), about 0.002% (w / w), about 0.0021% (w / w), about 0.0022% (w / w), about 0.0023% (w / w), about 0.0024% (w / w), about 0.0025% (w / w), about 0.0026% (w / w), about 0.0027% (w / w), about 0.0028% (w / w), about 0.0029% (w / w), about 0.0030% (w / w), about 0.0031% (w / w), about 0.0032% (w / w), about 0.0033% (w / w), about 0.0034% (w / w), about 0.0035% (w / w), about 0.0036% (w / w), about 0.0037% (w / w), about 0.0038% (w / w), about 0.0039% (w / w), about 0.0001% (w / w), about 0.0002% (w / w), about 0.0003% (w / w), about 0.0004% (w / w), about 0.0005% (w / w), about 0.0006% (w / w), about 0.0007% (w / w), about 0.0008% (w / w), or about 0.0009% (w / w). In some instances, the API can be present in the compositions described herein in an amount of about 0.02% (w / w). In some instances, the API can be present in the compositions described herein in an amount of about 0.04% (w / w). In some instances, the API can be present in the compositions described herein in an amount of about 0.05% (w / w). In some instances, the API can be present in the compositions described herein in an amount of about 1% (w / w). In some instances, the API compounds, for example, compounds such as those of Formula (I), and their salts can be in the form of a solvate. Such solvates include for example hydrates, alcoholates (e.g., ethanol solvate), and the like. API compounds as described herein may exist in different polymorphic forms. ATTORNEY DOCKET NO.43081-0032WO1 In some instances of the compositions described herein, the API in the composition is chemically stable for at least 6 months, at least 1 year, at least 18 months, or at least 2 years. The compositions described herein can include a semi-fluorinated alkane (SFA). A semi-fluorinated alkane is an amphiphilic liquid with two mutually immiscible moieties (hydrocarbon segment and perfluorinated segment) bound covalently. In some instances, the semifluorinated alkane can be a partially fluorinated alkane compound having a formula CF3(CF2)m(CH2)nCH3. In some instances, m is an integer from 1 to 10, and n is an integer from 1 to 10. For example, m can be 1, 2, 3, 4, 5, or 6. In another example, n can be 1, 2, 3, 4, 5, or 6. Suitable examples of semifluorinated alkane compounds include perfluorobutylpentane (F4H5), perfluorobutylhexane (F4H6), perfluorohexylbutane (F6H4), perfluorohexylhexane (F6H6), perfluorohexyloctane (F6H8), and perfluorohexyl decane (F6H10). In some instances, the SFA is perfluorohexyloctane (F6H8). The structure of F6H8 is shown below: In some instances, the SFA can be present in the compositions in an amount of from about 1% to about 99.9% (w / w), from about 1% to about 30% (w / w), from about 1% to about 25% (w / w), from about 1% to about 20% (w / w), from about 5% to about 20% (w / w), from about 5% to about 15% (w / w), from about 10% to about 99.9% (w / w), from about 20% to about 99.9% (w / w), from about 30% to about 99.9% (w / w), from about 40% to about 99.9% (w / w), from about 50% to about 99.9% (w / w), from about 60% to about 99.9% (w / w), from about 65% to about 99.9% (w / w), from about 70% to about 99.9% (w / w), from about 75% to about 99.9% (w / w), from about 80% to about 99.9% (w / w), from about 85% to about 99.9% (w / w), from about 90% to ATTORNEY DOCKET NO.43081-0032WO1 about 99.9% (w / w), from about 95% to about 99.9% (w / w), from about 98% to about 99.9% (w / w), from about 20% to about 80% (w / w), from about 20% to about 70% (w / w), from about 20% to about 60% (w / w), from about 20% to about 50% (w / w), from about 20% to about 40 % (w / w), from about 20% to about 30% (w / w), from about 30% to about 80% (w / w), from about 40% to about 80% (w / w), from about 50% to about 80% (w / w), from about 60% to about 80% (w / w), from about 70% to about 80% (w / w), from about 50% to about 90% (w / w), from about 60% to about 90% (w / w), from about 70% to about 90% (w / w), about 99.9% (w / w), about 99% (w / w), about 98% (w / w), about 97% (w / w), about 96% (w / w), about 95% (w / w), about 94% (w / w), about 93% (w / w), about 92% (w / w), about 91% (w / w), about 90% (w / w), about 85% (w / w), about 80% (w / w), about 75% (w / w), about 70% (w / w), about 65% (w / w), about 60% (w / w), about 55% (w / w), about 50% (w / w), about 45% (w / w), about 40% (w / w), about 35% (w / w), about 30% (w / w), about 25% (w / w), about 20% (w / w), about 15% (w / w), about 10% (w / w), about 9% (w / w), about 8% (w / w), about 7% (w / w), about 6% (w / w), about 5% (w / w), about 4% (w / w), about 3% (w / w), about 2% (w / w), about 1% (w / w), about 0.5% (w / w), or about 0.1% (w / w). The compositions described herein can include one or more excipient compound(s) that are oils with certain ester functionality. The one or more excipient compound(s) can be selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid; and combinations thereof. Applicant has surprisingly found that the addition of these excipient compounds (or combinations thereof) can result in solubility of APIs in the composition, e.g., in SFAs. Without being bound by theory, it is believed that the ester functionality of the excipient compound(s) allows good solubility, miscibility, and / or emulsifying capability in the SFA of the compositions. Applicant has surprisingly found that the inclusion of the excipient compound(s) in the compositions described herein can create a suitable delivery system for APIs, including both water soluble and water insoluble APIs. The compositions described herein can thus provide suitable delivery ATTORNEY DOCKET NO.43081-0032WO1 compositions for water insoluble APIs for which there were, prior to the present invention disclosed herein, very limited ways to formulate, or APIs that have low solubility in aqueous formulations. Nonlimiting examples of APIs that have limited or no solubility in aqueous formulations that can be suitably formulated in compositions described herein include, APIs such as steroids, tyrosine kinase inhibitor class compounds, and compounds containing one or more aromatic heterocyclic functionalities. In some instances, the excipient compound(s) are oils with certain ester functionality and can be selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid; and combinations thereof. In some instances, the excipient compound(s) can comprise more than one ester group. Where more than one ester group is present in the excipient compound, each acyl group in the compound can independently derive from a same or different fatty acid. In some instances, the excipient compound(s) can be a mixture of two or more different excipient compounds selected from hydroxyalkyl esters of an aliphatic fatty acid, hydroxyacid alkyl esters, alkyl esters of fatty acids, or combinations thereof. In some instances, at least one of the one or more excipient compound(s) has a hydrophilic-lipophilic balance (HLB) value of less than or equal to 3.4 as calculated according to the formula: HLB = 20(1-(S / A)), wherein S is number of ester saponification, and A is the acid number of the fatty acid. In some instances, the excipient compound(s) can be a hydroxyalkyl ester of an aliphatic fatty acid. In some instances, the hydroxyalkyl ester of an aliphatic fatty acid can be a propylene glycol mono or di-ester of C4-C20 fatty acid, or a glycerol of 1, 2 or 1, 3 di-ester of C4-C20 fatty acid, or a glycerol of a mono ester of a C4-20 fatty acid. The fatty acid can be saturated or unsaturated, linear or branched. In some instances, the hydroxyalkyl ester of an aliphatic fatty acid is a compound of any one of Formulas (II)-(VIII): ATTORNEY DOCKET NO.43081-0032WO1 ; ; ; ; ATTORNEY DOCKET NO.43081-0032WO1 ; ; and . In some instances, R6and R7can each, independently, be a linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl having 3 to 19 carbon atoms. In some instances, R6and R7can each, independently, be a linear or branched alkyl having 7 to 17 carbon atoms. In some instances, R can be H or an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-6 carbon atoms, optionally wherein one H atom on each carbon atom can independently be replaced with one -OH group. In some instances, R can be H or an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-4 carbon atoms. In some instances, for R, one H atom on each carbon atom can independently be replaced with one -OH group. In some instances, n is an integer from 1 to 12, optionally from 2 to 3. For example, n can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12. In some instances, the excipient compound(s) can be an alkyl ester of a fatty acid. In some instances, the alkyl ester of a fatty acid is a compound of Formula (IX): ATTORNEY DOCKET NO.43081-0032WO1 . In some instances, x is an integer from 2 to 3. In some instances, y is an integer from 4 to 7. For example, x can be 2 or 3. In another example, y can be 4, 5, 6, or 7. In some instances, the excipient compound(s) can be a hydroxyacid alkyl ester. In some instances, the hydroxyacid alkyl ester can be a medium-chain alkyl C12 to C15 lactate or glycolate. In some instances, the hydroxyacid alkyl ester can be a compound of any one of Formulas (X)-(XII): ; ; and . ATTORNEY DOCKET NO.43081-0032WO1 In some instances, R6and R7can each, independently, be a linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl having 3 to 19 carbon atoms. In some instances, R6and R7can each, independently, be a linear or branched alkyl having 7 to 17 carbon atoms. In some instances, R can be H or an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-6 carbon atoms, optionally wherein one H atom on each carbon atom can independently be replaced with one -OH group. In some instances, R can be H or an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-4 carbon atoms. In some instances, for R, one H atom on each carbon atom can independently be replaced with one -OH group. In some instances, R8can be a linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl having 6 to 20 carbon atoms. In some instances, R8can be a linear or branched alkyl having 12 to 15 carbon atoms. Exemplary, non-limiting excipient compounds include3-hydroxypropane-1,2-diyl bis(icosanoate); 3-hydroxypropane-1,2-diyl dinonadecanoate; 3-hydroxypropane-1,2- diyl distearate; 3-hydroxypropane-1,2-diyl diheptadecanoate; 3-hydroxypropane-1,2- diyl dipalmitate; 3-hydroxypropane-1,2-diyl dipentadecanoate; 3-hydroxypropane- 1,2-diyl ditetradecanoate; 3-hydroxypropane-1,2-diyl ditridecanoate; 3- hydroxypropane-1,2-diyl didodecanoate; 3-hydroxypropane-1,2-diyl diundecanoate; 3-hydroxypropane-1,2-diyl bis(decanoate); 3-hydroxypropane-1,2-diyl dinonanoate; 3-hydroxypropane-1,2-diyl dioctanoate; 1-(heptanoyloxy)-3-hydroxypropan-2-yl octanoate; 3-hydroxypropane-1,2-diyl diheptanoate; 2-(heptanoyloxy)-3- hydroxypropyl octanoate; 1-(hexanoyloxy)-3-hydroxypropan-2-yl heptanoate; 3- hydroxypropane-1,2-diyl dihexanoate; 1-hydroxy-3-(pentanoyloxy)propan-2-yl hexanoate; 1-(butyryloxy)-3-hydroxypropan-2-yl hexanoate; 1-(butyryloxy)-3- hydroxypropan-2-yl pentanoate; 3-hydroxypropane-1,2-diyl dibutyrate; 1- (butyryloxy)-3-hydroxypropan-2-yl octanoate; 2-(butyryloxy)-3-hydroxypropyl octanoate; 2-hydroxypropane-1,3-diyl bis(icosanoate); 2-hydroxypropane-1,3-diyl dinonadecanoate; 2-hydroxypropane-1,3-diyl distearate; 2-hydroxypropane-1,3-diyl ATTORNEY DOCKET NO.43081-0032WO1 diheptadecanoate; 2-hydroxypropane-1,3-diyl dipalmitate; 2-hydroxypropane-1,3-diyl dipentadecanoate; 2-hydroxypropane-1,3-diyl ditetradecanoate; 2-hydroxypropane- 1,3-diyl ditridecanoate; 2-hydroxypropane-1,3-diyl didodecanoate; 2- hydroxypropane-1,3-diyl bis(decanoate); 2-hydroxy-3-(octanoyloxy)propyl decanoate; 2-hydroxypropane-1,3-diyl dioctanoate; 3-(hexanoyloxy)-2-hydroxypropyl octanoate; 2-hydroxypropane-1,3-diyl dihexanoate; 3-(hexanoyloxy)-2-hydroxypropyl octanoate; 3-(butyryloxy)-2-hydroxypropyl octanoate; 3-(butyryloxy)-2- hydroxypropyl hexanoate; 2-hydroxypropane-1,3-diyl dibutyrate; 2-hydroxyoctyl icosanoate; 2-hydroxyheptyl icosanoate; 2-hydroxyhexyl icosanoate; 2-hydroxypentyl icosanoate; 2-hydroxypentyl stearate; 2-hydroxypropyl stearate; 2-hydroxybutyl stearate; 2-hydroxybutyl palmitate; 2-hydroxypentyl palmitate; 2-hydroxypentyl tetradecanoate; 2-hydroxybutyl tetradecanoate; 2-hydroxypropyl tetradecanoate; 2- hydroxypentyl dodecanoate; 2-hydroxybutyl dodecanoate; 2-hydroxypropyl dodecanoate; 2-hydroxypropyl decanoate; 2-hydroxybutyl decanoate; 2- hydroxypentyl decanoate; 2-hydroxypentyl octanoate; 2-hydroxybutyl octanoate; 2- hydroxypropyl octanoate; 2-hydroxypropyl hexanoate; 2-hydroxypropyl butyrate; 2- hydroxybutyl butyrate; 1-hydroxyoctan-2-yl icosanoate; 1-hydroxyoctan-2-yl stearate; 1-hydroxyhexan-2-yl stearate; 1-hydroxypentan-2-yl stearate; 1-hydroxypentan-2-yl palmitate; 1-hydroxypropan-2-yl stearate; 1-hydroxypropan-2-yl palmitate; 1- hydroxypropan-2-yl tetradecanoate; 1-hydroxypropan-2-yl dodecanoate; 1- hydroxypropan-2-yl decanoate; 1-hydroxypropan-2-yl octanoate; 1-hydroxypropan-2- yl hexanoate; 1-hydroxypropan-2-yl butyrate; 1-hydroxybutan-2-yl butyrate; 1- hydroxypentan-2-yl butyrate; 1-hydroxyoctan-2-yl butyrate; 2-hydroxyethyl icosanoate; 2-hydroxyethyl stearate; 2-hydroxyethyl palmitate; 2-hydroxyethyl tetradecanoate; 2-hydroxyethyl dodecanoate; 2-hydroxyethyl decanoate; 2- hydroxyethyl octanoate; 2-hydroxyethyl hexanoate; 2-hydroxyethyl butyrate; 3- hydroxypropyl butyrate; 3-hydroxypropyl hexanoate; 3-hydroxypropyl pentanoate; 3- hydroxypropyl heptanoate; 3-hydroxypropyl octanoate; 3-hydroxypropyl decanoate; ATTORNEY DOCKET NO.43081-0032WO1 3-hydroxypropyl dodecanoate; 3-hydroxypropyl tetradecanoate; 3-hydroxypropyl palmitate; 3-hydroxypropyl stearate; 3-hydroxypropyl icosanoate; pentadecyl 2- hydroxypropanoate; pentadecyl 2-hydroxyacetate; tetradecyl 2-hydroxypropanoate; tetradecyl 2-hydroxyacetate; tridecyl 2-hydroxyacetate; tridecyl 2- hydroxypropanoate; dodecyl 2-hydroxypropanoate; dodecyl 2-hydroxyacetate; decyl 2-hydroxyacetate; decyl 2-hydroxypropanoate; octyl 2-hydroxypropanoate; 2,3- dihydroxypropyl icosanoate; 2,3-dihydroxypropyl stearate; 2,3-dihydroxypropyl palmitate; 2,3-dihydroxypropyl tetradecanoate; 2,3-dihydroxypropyl dodecanoate; 2,3-dihydroxypropyl decanoate; 2,3-dihydroxypropyl octanoate; 2,3-dihydroxypropyl hexanoate; 2,3-dihydroxypropyl butyrate; 1,3-dihydroxypropan-2-yl butyrate; 1,3- dihydroxypropan-2-yl pentanoate; 1,3-dihydroxypropan-2-yl hexanoate; 1,3- dihydroxypropan-2-yl heptanoate; 1,3-dihydroxypropan-2-yl octanoate; 1,3- dihydroxypropan-2-yl nonanoate; 1,3-dihydroxypropan-2-yl decanoate; 1,3- dihydroxypropan-2-yl dodecanoate; 1,3-dihydroxypropan-2-yl tetradecanoate; 1,3- dihydroxypropan-2-yl palmitate; 1,3-dihydroxypropan-2-yl stearate; 1,3- dihydroxypropan-2-yl icosanoate; 2,3-dihydroxypropyl nonanoate; 2,3- dihydroxypropyl heptanoate; 2,3-dihydroxypropyl pentanoate; dodecyl octanoate; tetradecyl octanoate; hexadecyl octanoate; octadecyl octanoate; octadecyl decanoate; hexadecyl decanoate; tetradecyl decanoate; and dodecyl decanoate; propane-1,2-diyl dibutyrate; 2-(butyryloxy)propyl pentanoate; propane-1,2-diyl dipentanoate; 2- (pentanoyloxy)propyl hexanoate; propane-1,2-diyl dihexanoate; 2- (hexanoyloxy)propyl heptanoate; 2-(heptanoyloxy)propyl octanoate; 2- (heptanoyloxy)propyl nonanoate; 2-(octanoyloxy)propyl nonanoate; propane-1,2-diyl dinonanoate; 2-(nonanoyloxy)propyl decanoate; propane-1,2-diyl bis(decanoate); 2- (decanoyloxy)propyl dodecanoate; propane-1,2-diyl didodecanoate; 2- (dodecanoyloxy)propyl tetradecanoate; propane-1,2-diyl ditetradecanoate; 1- (tetradecanoyloxy)propan-2-yl palmitate; propane-1,2-diyl dipalmitate; 1- (palmitoyloxy)propan-2-yl stearate; propane-1,2-diyl distearate; 2- ATTORNEY DOCKET NO.43081-0032WO1 (stearoyloxy)propyl icosanoate; propane-1,2-diyl bis(icosanoate); 2-methylpropane- 1,3-diyl bis(icosanoate); 2-methyl-3-(stearoyloxy)propyl icosanoate; 2- methylpropane-1,3-diyl distearate; 2-methyl-3-(palmitoyloxy)propyl stearate; 2- methylpropane-1,3-diyl dipalmitate; 2-methyl-3-(tetradecanoyloxy)propyl palmitate; 2-methylpropane-1,3-diyl ditetradecanoate; 3-(dodecanoyloxy)-2-methylpropyl tetradecanoate; 2-methylpropane-1,3-diyl didodecanoate; 3-(decanoyloxy)-2- methylpropyl dodecanoate; 2-methylpropane-1,3-diyl bis(decanoate); 2-methyl-3- (nonanoyloxy)propyl decanoate; 2-methylpropane-1,3-diyl dinonanoate; 2-methyl-3- (octanoyloxy)propyl nonanoate; 2-methylpropane-1,3-diyl dioctanoate; 3- (heptanoyloxy)-2-methylpropyl octanoate; 3-(hexanoyloxy)-2-methylpropyl octanoate; 3-(hexanoyloxy)-2-methylpropyl heptanoate; 2-methyl-3- (pentanoyloxy)propyl hexanoate; 3-(butyryloxy)-2-methylpropyl pentanoate; 2- methylpropane-1,3-diyl dibutyrate; a cetostearyl alcohol; a cetyl alcohol; docosanol; ethylhexyl hydroxystearate; glyceryl 1-stearate; glyceryl dibehenate; glyceryl distearate; glycerylricinoleate; lauryl lactate; a lauroyl polyoxylglyceride; a myristyl alcohol; octyldodecanol; polyoxyl 35 castor oil; polyoxyl 40 hydrogented castor oil; polyoxyl 40 stearate; sorbitan monolaurate; sorbitan monooleate; sorbitan monopalmitate; sorbitan monostearate; sorbitan sesquioleate; sorbitan trioleate; sorbitan tristearate; trihydroxystearin; and combinations of two or more thereof. In some embodiments, the excipient compound(s) can be present in the compositions in an amount of from about 0.1% to about 99% (w / w), from about 0.1% to about 80% (w / w), from about 0.1% to about 50% (w / w), from about 0.1% to about 30% (w / w), from about 0.1% to about 20% (w / w), from about 0.1% to about 15% (w / w), from about 0.1% to about 10% (w / w), from about 0.1% to about 5% (w / w), about 20% (w / w), about 15% (w / w), about 10% (w / w), about 5% (w / w), about 3% (w / w), or about 1% (w / w), from about 1% to about 30% (w / w), from about 1% to about 25% (w / w), from about 1% to about 20% (w / w), from about 1% to about 30%, from about 1% to about 40%, from about 5% to about 40%, from about 5% to about ATTORNEY DOCKET NO.43081-0032WO1 30%from about 5% to about 20% (w / w), from about 5% to about 15% (w / w), from about 10% to about 99.9% (w / w), from about 20% to about 99.9% (w / w), from about 30% to about 99.9% (w / w), from about 40% to about 99.9% (w / w), from about 50% to about 99.9% (w / w), from about 60% to about 99.9% (w / w), from about 65% to about 99.9% (w / w), from about 70% to about 99.9% (w / w), from about 75% to about 99.9% (w / w), from about 80% to about 99.9% (w / w), from about 85% to about 99.9% (w / w), from about 90% to about 99.9% (w / w), from about 95% to about 99.9% (w / w), from about 98% to about 99.9% (w / w), from about 40% to about 80% (w / w), from about 40% to about 70% (w / w), from about 40% to about 60% (w / w), from about 40% to about 50% (w / w), from about 20% to about 40 % (w / w), from about 20% to about 30% (w / w), from about 30% to about 80% (w / w), from about 40% to about 80% (w / w), from about 50% to about 80% (w / w), from about 60% to about 80% (w / w), from about 70% to about 80% (w / w), from about 50% to about 90% (w / w), from about 60% to about 90% (w / w), from about 70% to about 90% (w / w), about 99.9% (w / w), about 99% (w / w), about 98% (w / w), about 97% (w / w), about 96% (w / w), about 95% (w / w), about 94% (w / w), about 93% (w / w), about 92% (w / w), about 91% (w / w), about 90% (w / w), about 85% (w / w), about 80% (w / w), about 75% (w / w), about 70% (w / w), about 65% (w / w), about 60% (w / w), about 55% (w / w), about 50% (w / w), about 45% (w / w), about 40% (w / w), about 35% (w / w), about 30% (w / w), about 25% (w / w), about 20% (w / w), about 15% (w / w), about 10% (w / w), about 9% (w / w), about 8% (w / w), about 7% (w / w), about 6% (w / w), about 5% (w / w), about 4% (w / w), about 3% (w / w), about 2% (w / w), about 1% (w / w), about 0.5% (w / w), or about 0.1% (w / w), from about 1% to about 30% (w / w), from about 1% to about 25% (w / w), from about 1% to about 20% (w / w), from about 1% to about 15% (w / w), from about 1% to about 10% (w / w), from about 5% to about 20% (w / w), from about 5% to about 15% (w / w), from about 10% to about 15% (w / w), from about 10% to about 20% (w / w), from about 10% to about 30% (w / w), about 30% (w / w), about 25% (w / w), about 20% (w / w), about 15% (w / w), about 10% (w / w), about 9% (w / w), ATTORNEY DOCKET NO.43081-0032WO1 about 8% (w / w), about 7% (w / w), about 6% (w / w), about 5% (w / w), about 4% (w / w), about 3% (w / w), about 2% (w / w), or about 1% (w / w). The compositions disclosed herein may, in some instances, also comprise one or more additional therapeutic agents, excipients, or diluents including, but not limited to, absorbents, anti-irritants, preservatives, antioxidants, coloring agents / pigments, emollients (moisturizers), emulsifiers, film-forming / holding agents, prescription drugs, surfactants / detergent cleansing agents, penetration enhancers, viscosity enhancers, and thickeners. In some instances, the compositions herein can include a surfactant. In some instances, the surfactant can be an ionic surfactant or a non-ionic surfactant. The compositions of the present application can include those suitable for any acceptable route of administration. Suitable examples of acceptable routes of administration include ocular, topical ocular, ocular injection, inhalation, dermal, topical dermal, oral, and the like. In some instances, the compositions described herein can be prepared and used in the form of an aerosol spray, cream, emulsion, solid, liquid, dispersion, foam, oil, gel, hydrogel, lotion, mousse, ointment, pomade, or solution. In some instances, the composition is in any form commonly employed in the art of cosmetic and skin care formulation. In some instances, the compositions can be in an emulsion or nano- emulsion form. In some instances, the compositions can be in the form of an emulsion solution. In some instances, the compositions can be in the form of an organic composition without aqueous components. In some instances, the compositions described herein can be an ophthalmic composition, e.g., for intraocular administration. Suitable examples of ophthalmic compositions include eye drops, suspensions, ointments, emulsions, nanoemulsions, emulsion solutions, oils, gels, hydrogels, and solutions. Any one of these ophthalmic compositions can be administered directly to the cornea or other portion of the eye, ATTORNEY DOCKET NO.43081-0032WO1 using, for example, a plastic or latex applicator (e.g., a single-use applicator), an eye dropper, a glass pipette, syringe, or a rubber bulb. In some instances, the compositions described herein have a pH of about 6 to about 8. In some instances, the compositions described herein are absorbed transcorneally or are selectively absorbed transcorneally. The phrases “absorbed via the transcorneal route,” “absorbed via transcorneal pathway,” and “absorbed transcorneally” are used interchangeably and relate to transcorneal absorption. In transcorneal absorption, a drug typically penetrates the eye through cornea to the aqueous humor to the iris. In the periorbital absorption, drug typically penetrates the eye through the conjunctival to the scleral to the ciliary body. In some instances, a composition described herein is absorbed transcorneally (e.g., at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% of the composition is absorbed transcorneally, e.g., as determined by an assay known in the art or described in the working examples herein). In some instances, a composition described herein is selectively absorbed transcorneally (e.g., at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% more of the composition is absorbed transcorneally as compared to the amount absorbed periorbitally, e.g., as determined by an assay known in the art or described in the working examples herein, or at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, or at least 20-fold more of the composition is absorbed transcorneally as compared to the amount absorbed periorbitally, e.g., as determined by an assay known in the art or described in the working examples herein). In some instances, the amount of the composition that is absorbed transcorneally is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% greater than the amount that is absorbed periorbitally. ATTORNEY DOCKET NO.43081-0032WO1 In some instances, the API of a composition of the present application is absorbed transcorneally or is selectively absorbed transcorneally. In some instances, an API described herein is absorbed transcorneally (e.g., at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% of the API is absorbed transcorneally, e.g., as determined by an assay known in the art or described in the working examples herein). In some instances, an API described herein is selectively absorbed transcorneally (e.g., at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% more of the API is absorbed transcorneally as compared to the amount absorbed periorbitally, e.g., as determined by an assay known in the art or described in the working examples herein, or at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, or at least 20-fold more of the API is absorbed transcorneally as compared to the amount absorbed periorbitally, e.g., as determined by an assay known in the art or described in the working examples herein). In some instances, the amount of the API that is absorbed transcorneally is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% greater than the amount that is absorbed periorbitally. In some instances, the compositions described herein can be a cosmetic composition, e.g., for topical administration to e.g., epidermal tissue, nails, or hair. Suitable examples of cosmetic compositions include suspensions, ointments, emulsions, nanoemulsions, emulsion solutions, oils, gels, creams, mousse, sprays, hydrogels, and solutions. Any one of these cosmetic compositions can be administered directly to the skin, hair, or nails, using, for example, a plastic or latex applicator (e.g., a single-use applicator), a dropper, a cotton or fabric applicators, a sponge, a glass pipette, or a rubber bulb. In some instances, the compositions are prepared by uniformly and intimately bringing into association the API as disclosed herein with the excipient compound(s) and SFA as disclosed herein. In some instances, the compositions can be solutions. In ATTORNEY DOCKET NO.43081-0032WO1 some instances, the compositions can be emulsions. In some instances, the emulsions can be micro-emulsions or nano-emulsions. In some instances, the compositions can be in the form of emulsion solutions. In some instances, the methods for making the compositions described herein can comprise combining an API with one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof to form a first solution; and combining said first solution with a semi-fluorinated alkane compound to form a mixture. Optionally, the mixture can be further mixed, suspended, or emulsified, and / or droplet particle size D90 reduced within said mixture to less than 100 nm, by physical agitation selected from high speed stirring, vortexing, sonicating, heating and stirring, or homogenizing the mixture. In some instances, the methods for making the nano emulsions can comprise uniformly and intimately bringing into association the API as disclosed herein with the excipient compound(s) and SFA as disclosed herein, and, optionally, emulsifying said mixture and reducing droplet particle size D90 within said mixture to less than 100 nm by physical agitation as described herein. In some instances, the methods can further comprise measuring the droplet particle size of the mixture during or following said physical agitation. In some instances, the compositions can be in the form of an organic composition without aqueous components. Also provided herein are methods of formulating a topical ophthalmological composition for transcorneal absorption, the method comprising combining an API, one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof, and a semi-fluorinated alkane compound. Also provided herein are dispensers comprising the compositions described herein. In one example of Fig.1, an example dispenser 10 contains a liquid 14 of the compositions described herein. Applicant discovered that the compositions described ATTORNEY DOCKET NO.43081-0032WO1 herein can, in some instances, be less stable in low density polyethylene (LDPE) and in poplypropylene (PP) than in other materials such as glass or polyethylene terephthalate (PET). Without being bound by theory it is believed that LDPE and PET material absorb one or more components of the compositions described herein, thereby reducing the content of the active pharmaceutical ingredient (API) over time. The dispenser 10 includes a container portion 18 having an interior wall 22 defining an interior volume 26 and adapted to contact and store a liquid 14 within at least a portion of the interior volume 26; a dispensing portion 30 adapted to dispense one or more drops of a liquid 14 out of the container portion 18; and, contained within the interior volume 26, a liquid 14 comprising compositions as described herein, or a composition comprising an active pharmaceutical ingredient (API), a semi-fluorinated alkane (SFA), and one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof. In some instances, the interior wall 22 of the dispenser 10 comprises less than about 10%, less than about 5%, or less than about 1% of one or more of low density polyethylene (LDPE) or polypropylene (PP). In some instances, the interior wall 22 does not comprise low density polyethylene (LDPE) or polypropylene (PP). In some instances, the interior wall 22 comprises glass or polyethylene terephthalate. In some instances, the interior wall 22 consists essentially of glass or polyethylene terephthalate (PET). In some instances, the concentration of the API in the compositions of the liquid 14 remains more than 90% of the initial API concentration after storage in the dispenser 10 for a period of 6 months. In some instances, the concentration of the API in the compositions of the liquid 14 remains more than 90% of the initial API concentration after storage in the dispenser 10 for a period of 12 months. In some instances, the container portion 18 and the dispensing portion 30 can each, independently, comprise or consist of the same material or different materials. ATTORNEY DOCKET NO.43081-0032WO1 In some instances, the container portion 18 and the dispensing portion 30 can each, independently, consist essentially of glass or polyethylene terephthalate (PET). In some instances, the dispensing portion 30 can comprise low density polyethylene (LDPE) or polypropylene (PP), particularly where the compositions of the liquid 14 do not typically come into contact with the dispensing portion 30 during normal storage of the compositions of the liquid 14, but come into contact with the dispensing portion 30 briefly during dispensation, such as when a drop is passing through the dispensing portion 30 from the container portion 18 during administration to an eye of a subject. Without being bound by theory, it is believed such limited contact of the compositions of the liquid 14 with LDPE or PET will have little or no effect on the compositions of the liquid 14. In some instances, the dispenser 10 is adapted to dispense drops each independently having a volume of from about 5 µl to about 40 µl. The compositions described herein can, in some instances, be conveniently presented in a unit dosage form or a multi-dosage form (e.g., the dispenser 10). In some embodiments, compositions and formulations described herein can be conveniently presented in a dosage form (unit or multiple) that can be used with or in an automated dosing apparatus or regimen. In some instances, the dispenser 10 may optionally have a cap 34 that is removable from the container portion 18. For example, the cap 34 can cover the dispensing portion 30 during storage. This disclosure also includes pharmaceutical kits useful, for example, in the treatment of disorders, diseases and conditions referred to herein, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present disclosure. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc. Instructions, either as inserts or as ATTORNEY DOCKET NO.43081-0032WO1 labels, indicating quantities of the components to be administered, guidelines for administration, and / or guidelines for mixing the components, can also be included in the kit. The kit may optionally include an additional therapeutic agent as described herein. In some embodiments, a kit can comprise a dispensing device preloaded with a composition as described herein. Also provided herein are methods for treating diseases or conditions using the compositions, dispensers, and methods described herein. In some instances, the diseases or conditions can be related to skin or dermal tissues, mucosal membranes, oral tissues, esophageal tissues, lung tissues, or other bodily tissues. Also provided herein are methods for treating ocular diseases or conditions using the compositions, dispensers, and methods described herein. In some instances, the ocular diseases or conditions can be related to the cornea or corneal tissues. In some instances, the ocular disease or condition is preferably treated with a composition that is absorbed (e.g., selectively absorbed) transcorneally. Also provided herein are methods for inducing one or more symptoms of miosis in a subject using the compositions, dispensers, and methods described herein. Also provided herein are methods for inducing miosis in a subject using the compositions, dispensers, and methods described herein. Exemplary, nonlimiting ocular diseases that can be treated with the compositions, dispensers, and methods described herein include chemical burns or a disease selected from keratoconus, thin corneas, keratitis, infectious keratitis including bacterial or fungal keratitis, corneal ulcer, bullous keratopathy and other forms of corneal edema, keratolysis, an autoimmune disease, a cicatricizing disease such as Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Rheumatoid Arthritis, corneal ectasia including cornea ectasia appearing after laser-assisted in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK), post-refractive ectasia, corneal degeneration, brittle cornea ATTORNEY DOCKET NO.43081-0032WO1 syndrome, Ehlers-Danlos Syndrome Type VI, corneal neovascularization, corneal melting including Corneal Melting in Boston Keratoprosthesis Type I, hyperopia, hyperopic astigmatism, myopia, astigmatism, myopic astigmatism, myopic regression, keratopathy, corneal astigmatism, unstable cornea, or pellucid marginal degeneration (PMD). In some instances, the disease or condition can be a front of eye disease or condition. Exemplary, nonlimiting front of eye diseases or conditions that can be treated with the compositions, dispensers, and methods described herein include neurotrophic keratitis, glaucoma, elevated intraocular pressure, ocular hypertension, presbyopia, myopia, ocular rosacea, dry eye disease, meibomian gland dysfunction, blepharitis, allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, pterygium, pinguecula, corneal transplant rejection, graft versus host disease, ocular allergy, uveitis, anterior uveitis, Behcet's disease, Sjogren's syndrome, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, chronic ocular surface inflammation caused by viral infection, herpes simplex keratitis, atopic conjunctivitis, Lyell’s syndrome, neovascularization induced by viral, bacterial, fungal, or parasitic infection, contact lens induced neovascularization, ulceration, alkali burns, stem cell deficiency, neovascular glaucoma, Steven Johnson syndrome, tumor in the eye, aphakia, pseudophakia, astigmatism, blepharospasm, cataract, conjunctival diseases, corneal diseases, corneal ulcer, eyelid diseases, lacrimal apparatus diseases, pupil disorders, refractive disorders, and strabismus. In some instances, the disease or condition can be a back of eye disease or condition. In some instances, the methods can include a method for treating, slowing the progression of, or reducing one or more symptoms of an ocular condition in a subject, or inducing one or more symptoms of miosis in a subject, comprising administering the compositions described herein to the eye of a subject. In some instances, the methods can include a method of delivering an API to an eye of a subject comprising ATTORNEY DOCKET NO.43081-0032WO1 administering the compositions or topical ophthalmological compositions described herein. Administering can in some instances include contacting the eye with the composition. In some instances, the methods can include a method for slowing myopia progression in a subject or for relieving vitreous floater symptoms in a subject, comprising administering the topical ophthalmological compositions described herein to the subject, wherein the API is a muscarinic receptor antagonist, such as, for example, atropine, an atropine mimetic or analog, or a free base or salt form thereof. In some instances, compositions described herein can contain APIs, such as, e.g., a co-drug as described herein, or, e.g., a muscarinic cholinergic receptor agonists such as, for example, aceclidine, pilocarpine, or combinations thereof, that can treat ocular diseases or conditions such as presbyopia, refractive errors of the eye, Sjogren's syndrome, glaucoma, conjunctivitis, lacrimal gland disease, or esotropia. Also provided herein are methods for treating ocular diseases or conditions using the compositions and methods described herein. In some instances, the ocular diseases or conditions can be presbyopia. In some instances, the ocular diseases or conditions can be refractive errors of the eye, Sjogren's syndrome, glaucoma, conjunctivitis, lacrimal gland disease, or esotropia. In some instances, methods are providing for administering, to the eye of a subject, an effective amount of a muscarinic cholinergic receptor agonist as API using the compositions described herein. In some instances, the compositions described herein can be in the form of an eye drop. In some instances, the methods can further comprise applying the eye drop to an eye of the subject. In some instances, a subject treated in accordance with a method described herein is in need of transcorneal absorption of an API. In some instances, a subject treated in accordance with a method described herein has failed to respond to treatment with an aqueous composition comprising the API or a salt thereof. In some instances, a subject treated in accordance with a method described herein has had an ATTORNEY DOCKET NO.43081-0032WO1 adverse side effect from the API or a salt thereof after receiving an aqueous composition comprising the API or a salt thereof. In some instances, a subject treated in accordance with a method described herein is highly sensitive to an aqueous composition comprising the API or a salt thereof. In some instances, compositions described herein can contain APIs, such as, e.g., riboflavin or a riboflavin derivative, that can facilitate photo-crosslinking of structural proteins such as collagen. In some instances, provided herein are methods for crosslinking structural proteins, such as collagen and keratin, using compositions described herein. In some instances, the structural protein can be in a tissue or in or on a body of a subject such as a mammal, e.g., a human. Structural proteins that can be photo-crosslinked using compositions or methods described herein, such as those in which the API is riboflavin or a riboflavin derivative, can include any structural proteins that are photo-crosslinkable in the presence of a reactive oxygen facilitator. Exemplary structural proteins include, without limitation, collagens and collagen derivatives, keratins and keratin derivatives, elastins and elastin derivatives, and the like. As used herein, “collagen” includes, without limitation, collagen fibers or fibrils. As used herein, “keratin” includes, without limitation, keratin fibers or fibrils. In some instances, the methods can comprise contacting the structural proteins or a biological tissue comprising the structural proteins with an effective amount of one or more compounds of Formula (I), or with an effective amount of a composition comprising one or more compounds of Formula (I); and irradiating the structural proteins or the tissue comprising the structural proteins. In some instances, methods are provided for crosslinking collagen in a tissue of a subject. In some embodiments, the methods can comprise administering to the tissue of the subject an effective amount of a composition described herein, wherein the API is one or more compounds of Formula (I); and irradiating the tissue. ATTORNEY DOCKET NO.43081-0032WO1 In some instances, the irradiation can include irradiating with UV light (e.g., UVA light), or with blue light. In some instances, contacting the structural proteins or a biological tissue comprising the structural proteins can include, without limitation, topically applying the compositions to the proteins or tissues, immersing the proteins or tissues in the compositions, spraying the proteins or tissues with the compositions, injecting the compositions into the tissue or into a matrix comprising the structural proteins, and the like. In some instances, contacting the structural proteins or a biological tissue comprising the structural proteins can include administering an effective amount of a composition described herein comprising as API one or more compounds of Formula (I) to a tissue in the body of a subject. Effective amounts of a composition described herein comprising as API one or more compounds of Formula (I) can be administered to various bodily tissues or biological tissues. In some embodiments, exemplary bodily tissues or biological tissues can include, without limitation, collagenous tissues, keratinous tissues, corneal tissue, epithelial tissues, epidermal tissues, pericardial tissues, skin, hair, or nails. In some instances, the tissues can be in or on the body of a subject. In some instances, the tissues can be ex vivo or in vitro. In some instances, the tissues can be bovine or porcine tissues. Also provided herein are methods for treating ocular diseases or conditions using the compounds, compositions, and methods described herein. In some instances, the ocular diseases or conditions can be related to the cornea or corneal tissues. Exemplary, nonlimiting ocular diseases that can be treated with compositions and methods described herein include chemical burns or a disease selected from keratoconus, thin corneas, keratitis, infectious keratitis including bacterial or fungal keratitis, corneal ulcer, bullous keratopathy and other forms of corneal edema, keratolysis, an autoimmune disease, a cicatricizing disease such as Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Rheumatoid Arthritis, corneal ectasia including cornea ectasia appearing after laser-assisted in situ ATTORNEY DOCKET NO.43081-0032WO1 keratomileusis (LASIK) and photorefractive keratectomy (PRK), post-refractive ectasia, corneal degeneration, brittle cornea syndrome, Ehlers-Danlos Syndrome Type VI, corneal neovascularization, corneal melting including Corneal Melting in Boston Keratoprosthesis Type I, hyperopia, hyperopic astigmatism, myopia, astigmatism, myopic astigmatism, myopic regression, keratopathy, corneal astigmatism, unstable cornea, or pellucid marginal degeneration (PMD). Also provided herein are methods for inducing miosis in a subject using the compounds, compositions, and methods described herein. In some instances, methods are providing for administering, to the eye and / or corneal tissue of a subject, a composition described herein comprising an effective amount of a compound of Formula (I) as API; and irradiating at least a portion of the eye and / or corneal tissue with, e.g., UV light or blue light. In some instances, the compositions comprising Formula (I) as API can be in the form of an eye drop. In some instances, the methods can further comprise applying the eye drop to an eye of the subject. In some instances, the methods can further comprise de-epithelializing at least a portion of the cornea. In some instances, the crosslinking method can be performed without de-epithelializing any portion of the cornea. The compositions described herein comprising Formula (I) as API, and corresponding methods described herein can, in some instance, be useful for crosslinking structural proteins in biological tissues or other formats ex vivo. Exemplary ex vivo applications include, without limitation compositions, biomaterials, biological matrices, and biological tissues for experimental or in vitro use or for biomaterials, tissues, hydrogels, and matrices intended for wound healing, tissue regeneration, tissue engineering, or drug delivery applications, and, for example, compositions, biological matrices, and biological tissues intended for use in hydrogels, biological scaffolds, surgical implants, bioprosthetics, grafts, and transplants and the like. Exemplary biomaterials include, without limitation, natural or synthetic variants of heart valves, corneal transplants, arterial prostheses, arterial ATTORNEY DOCKET NO.43081-0032WO1 grafts, wound healing matrices or grafts, skin grafts, vascular grafts, transdermal drug delivery devices or patches, and the like. In some instances, these biomaterials can also be subject to photo-crosslinking using the compositions described herein comprising one or more compounds of Formula (I) as API, and corresponding methods described herein within or on the body of a subject, for example, during or after delivery of the biomaterials to the subject such as through surgery or other delivery methods. In some instances, the methods further comprise (a) (i) selecting a subject in need of transcorneal absorption of an API; or (ii) selecting a subject having an ocular condition, wherein the ocular condition is in need of transcorneal absorption of an API. In some instances of the methods, the API is selectively delivered to the cornea of the subject. In some instances of the methods, the subject has failed to respond to treatment with an aqueous composition comprising the API of the composition. Failure to respond to treatment includes disease progression and failure to achieve clinically significant symptom reduction(s) after treatment. In some instances of the methods, the subject has had an adverse side effect from the API after receiving an aqueous composition comprising the API or a salt thereof. An adverse side effect from the API includes adverse side effects attributed to the API (or the salt thereof) and not to other components or features of a composition comprising the API (e.g., a preservative or pH). In some instances of the methods, the subject is highly sensitive to an aqueous composition comprising the API or a salt thereof. In some instances, the API can be present in an effective amount (e.g., a therapeutically effective amount). Effective doses may vary, depending on the diseases treated, the severity of the disease, the route of administration, the sex, age and general health condition of the subject, excipient usage, the possibility of co- ATTORNEY DOCKET NO.43081-0032WO1 usage with other therapeutic treatments such as use of other agents and the judgment of the treating physician. For example, in some embodiments, where the compositions described herein may be used to treat a disease in an eye of the patient, such as myopia, the treating physician may adjust the dosage and dosage regimen based on the current progression of the disease in the patient, the patient’s age, or other related factors. In some instances, the API is administered at a dose 5-10%, 5-15%, 5-20%, 5- 25%, 5-30%, 10-30%, 10-40%, 10-50%, 10-60%, 10-70%, 20-30%, 20-40%, 20-50%, 20-60%, 20-70%, 30-40%, 30-50%, 30-60%, 30-70%, 40-50%, 40-60%, 40-70%, or 50-70% less than a dose of the API when administered as an aqueous topical ophthalmological composition for the same method of use. The decrease in dose is not due to differences in weight between free base form and acid form of an API. For example, in some instances of a method of treating an ocular condition in a subject, the API is administered to the subject at a dose at least 30% less than a dose of the API in an aqueous topical ophthalmological composition for treating the ocular condition. In some instances, the API dosages can be administered on a daily basis (e.g., as a single dose or as two or more divided doses, e.g., once daily, two times daily, three times daily, or four times daily) or non-daily basis (e.g., every other day, every two days, every three days, once weekly, twice weekly, once every two weeks, once a month). In some instances, the API dosages can be administered once every about 6 to about 8 hours. In some instances, the API dosages can be administered three times a day. In some instances, the API dosages can be administered once a day. The invention will be further described in the following examples, which do not limit the scope of the invention. It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of ATTORNEY DOCKET NO.43081-0032WO1 the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

[0003] ATTORNEY DOCKET NO.43081-0032WO1 EXAMPLES 1. Solubility of Exemplary APIs in Exemplary Excipient Compounds andExemplary Compositions 1.1 Procedure Exemplary API compounds were dissolved in the listed exemplary excipient compound(s) by stirring, homogenizing, heating, sonicating, or a combination of the above described mechanical methods and solubility of the API in the excipient compound was determined by chromatography. After the API was fully dissolved in the excipient compound(s), a SFA, Perfluorohexyloctane (F6H8), was slowly added to the mixture while stirring, homogenizing, heating, sonicating, or a combination of the above described mechanical methods until the final target batch size was reached and solubility of the API in the formulation was determined by chromatography. Exemplary excipients used included: CAPTEX 170 EP, listed as containing coco-caprylate / caprate, and which is a mixture of the following esters: octadecyl octanoate; hexadecyl octanoate; tetradecyl octanoate; dodecyl octanoate; dodecyl decanoate; tetradecyl decanoate; hexadecyl decanoate; and octadecyl decanoate; CAPMUL PG-2L EP / NF, listed as containing propylene glycol dilaurate (24% mono-ester, 76% di-ester), and which is 2-dodecanoyloxypropyl dodecanoate; CAPTEX 200P, listed as containing propylene glycol dicaprylocaprate (70% C-8, 30% C-10), and which is a mixture of propane-1,2-diyl dioctanoate (70%) and propane-1,2-diyl bis(decanoate) (30%). 1.2 Results Results are shown in Table 1 below. ATTORNEY DOCKET NO.43081-0032WO1 8sHi mr6 %o x etF 5.fip%1n u a0ddd d8etm s u n aets edts edts ets / n m P6tFsu etm a tstestststeteteti)Et iel to 07% onibaotototoni108 N MtsN N N Nmi)ly- 6- P)0 dnil0et ax 2ao xretutnias4 u p 988 7 2 q a3.n9 1o C.0 56U( .4.90.00.0 m or-)bd - Ge 5(PtlFa (- Nr2 u / -)mPutpaE 3.as1.5n 8 4 53.4Z(129 02 (- CL 2 1 61U( .3 3. .0 3-))S 0 d 03,0 R 7et1ar2(x etut=pas9 60AaP4.n4d C E 67U( .15.30.0 nuo e p dnm tsareenio s aniesa ue eesadiesesC nabia * geBdiB oetrniB oB B ifeliecreep p cermoF e*so aretem rienirerti exerL F A F C A B A F B F A F ATTORNEY DOCKET NO.43081-0032WO1 Example 2: Solubility of Ivermectin (CBT-273) in Exemplary Formulations 2.1 Experimental An appropriate amount of Ivermectin (CBT-273) was dissolved in various MCT by vortexing. The obtained mixture was filtered through 0.22μm filter and the filtrated solution was analyzed by GC. 2.2 Chromatographic conditions Chromatographic column: SHIMADAU Shim-pack GIST C185um, 4.6 (ID) mm x 250 mm (L), 5 µm Mobile phase: Acetonitrile: Methanol: Water =55:35:10(v:v:v) Flow rate: 1.0 mL / min Wavelength：214 nm Injection volume: 10 µL Column temperature： 45 ℃ 2.3 Results Table 2. Ivermectin（CBT-273) Saturated solubility (mg / g) 6 5 7 2 6 7 6 4 ATTORNEY DOCKET NO.43081-0032WO1 Exemplary Embodiments Embodiment 1. A composition comprising: an active pharmaceutical ingredient (API); one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound. Embodiment 2. The composition of embodiment 1, wherein the composition is non-aqueous. Embodiment 3. The composition of any one of embodiments 1-2, wherein the semi-fluorinated alkane compound is selected from the group consisting of perfluorobutylpentane (F4H5), perfluorobutylhexane (F4H6), perfluorohexylbutane (F6H4), perfluorohexylhexane (F6H6), perfluorohexyloctane (F6H8), and perfluorohexyl decane (F6H10). Embodiment 4. The composition of any one of embodiments 1-3, wherein the hydroxyalkyl ester of an aliphatic fatty acid is a propylene glycol mono or di-ester of C4- C20 fatty acid, or a glycerol of 1, 2 or 1, 3 di-ester of C4-C20 fatty acid, or a glycerol of a mono ester of a C4-20 fatty acid. Embodiment 5. The composition of any one of embodiments 1-4, wherein the fatty acid is saturated or unsaturated, linear or branched. Embodiment 6. The composition of any one of embodiments 1-4, wherein the excipient compound(s) is a mixture of two or more different excipient compounds selected from hydroxyalkyl esters of an aliphatic fatty acid, hydroxyacid alkyl esters, alkyl esters of fatty acids, or combinations thereof. ATTORNEY DOCKET NO.43081-0032WO1 Embodiment 7. The composition of any one of embodiments 1-6, wherein the hydroxyalkyl ester of an aliphatic fatty acid is a compound of any one of Formulas (II)- (VIII): ; ; ; and ; wherein: R6and R7are each, independently, C3-C19 linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl; R is H or an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-6 C atoms, optionally wherein one H atom on each carbon atom can independently be replaced with one -OH group; and n is an integer from 1 to 12. Embodiment 8. The composition of embodiment 7, wherein: R6and R7are each, independently, C7-C17 linear or branched alkyl. Embodiment 9. The composition of any one of embodiments 7-8, wherein: R is an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-4 C atoms. ATTORNEY DOCKET NO.43081-0032WO1 Embodiment 10. The composition of any one of embodiments 7-9, wherein: n is selected from 2 to 3. Embodiment 11. The composition of any one of embodiments 1-6, wherein the alkyl ester of a fatty acid is a compound of Formula (IX): , wherein: x is an integer from 2 to 3; and y is an integer from 4 to 7. Embodiment 12. The composition of any one of embodiments 1-6, wherein the hydroxyacid alkyl ester is a medium-chain alkyl C12 to C15 lactate or glycolate. Embodiment 13. The composition of any one of embodiments 1-6 and 12, wherein the hydroxyacid alkyl ester is a compound of any one of Formulas (X)-(XII): ; ; and , wherein: R6and R7are each, independently, C3-C19 linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl; ATTORNEY DOCKET NO.43081-0032WO1 R8is C6-C20 linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl; and R is H or an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-6 C atoms, optionally wherein one H atom on each carbon atom can independently be replaced with one -OH group. Embodiment 14. The composition of embodiment 13, wherein: R8is C12-C15 linear or branched alkyl. Embodiment 15. The composition of any one of embodiments 13-14, wherein: R is an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-4 C atoms. Embodiment 16. The composition of any one of embodiments 1-15 wherein at least one of the one or more excipient compound(s) has a hydrophilic-lipophilic balance (HLB) value of less than or equal to 3.4 as calculated according to the formula: HLB = 20(1-(S / A)), wherein: S is number of ester saponification; and A is the acid number of the fatty acid. Embodiment 17. The composition of any one of embodiments 1-16, wherein the excipient compound(s) is present in a concentration of from about 0.1% to about 99% (w / w), from about 0.1% to about 80% (w / w), from about 0.1% to about 50% (w / w), from about 0.1% to about 30% (w / w), from about 0.1% to about 20% (w / w), from about 0.1% to about 15% (w / w), from about 0.1% to about 10% (w / w), from about 0.1% to about 5% (w / w), about 20% (w / w), about 15% (w / w), about 10% (w / w), about 5% (w / w), about 3% (w / w), or about 1% (w / w). Embodiment 18. The composition of any one of embodiments 1-17, wherein the semi- fluorinated alkane compound is present in a concentration of from about 1% to about 99.9% (w / w), from about 20% to about 99.9% (w / w), from about 50% to about 99.9% ATTORNEY DOCKET NO.43081-0032WO1 (w / w), from about 70% to about 99.9% (w / w), from about 80% to about 99.9% (w / w), from about 85% to about 99.9% (w / w), from about 90% to about 99.9% (w / w), from about 95% to about 99.9% (w / w), about 80% (w / w), about 85% (w / w), about 90% (w / w), about 95% (w / w), about 97% (w / w), or about 99% (w / w). Embodiment 19. The composition of any one of embodiments 1-18, wherein the API is present in a concentration of from about 0.0001% to about 20%, from about 0.001% to 15% (w / w), from about 0.001% to 10% (w / w), from about 0.001% to 5% (w / w), from about 0.01% to 5% (w / w), or from about 0.01% to 4% (w / w). Embodiment 20. The composition of any one of embodiments 1-19, wherein the API is in a free base, salt, solvate, or hydrate form. Embodiment 21. The composition of any one of embodiments 1-20, wherein the excipient compound(s) is selected from: 3-hydroxypropane-1,2-diyl bis(icosanoate); 3-hydroxypropane-1,2-diyl dinonadecanoate; 3-hydroxypropane-1,2-diyl distearate; 3-hydroxypropane-1,2-diyl diheptadecanoate; 3-hydroxypropane-1,2-diyl dipalmitate; 3-hydroxypropane-1,2-diyl dipentadecanoate; 3-hydroxypropane-1,2-diyl ditetradecanoate; 3-hydroxypropane-1,2- diyl ditridecanoate; 3-hydroxypropane-1,2-diyl didodecanoate; 3-hydroxypropane-1,2- diyl diundecanoate; 3-hydroxypropane-1,2-diyl bis(decanoate); 3-hydroxypropane-1,2- diyl dinonanoate; 3-hydroxypropane-1,2-diyl dioctanoate; 1-(heptanoyloxy)-3- hydroxypropan-2-yl octanoate; 3-hydroxypropane-1,2-diyl diheptanoate; 2- (heptanoyloxy)-3-hydroxypropyl octanoate; 1-(hexanoyloxy)-3-hydroxypropan-2-yl heptanoate; 3-hydroxypropane-1,2-diyl dihexanoate; 1-hydroxy-3-(pentanoyloxy)propan- 2-yl hexanoate; 1-(butyryloxy)-3-hydroxypropan-2-yl hexanoate; 1-(butyryloxy)-3- hydroxypropan-2-yl pentanoate; 3-hydroxypropane-1,2-diyl dibutyrate; 1-(butyryloxy)-3- hydroxypropan-2-yl octanoate; 2-(butyryloxy)-3-hydroxypropyl octanoate; 2- hydroxypropane-1,3-diyl bis(icosanoate); 2-hydroxypropane-1,3-diyl dinonadecanoate; 2-hydroxypropane-1,3-diyl distearate; 2-hydroxypropane-1,3-diyl diheptadecanoate; 2- hydroxypropane-1,3-diyl dipalmitate; 2-hydroxypropane-1,3-diyl dipentadecanoate; 2- ATTORNEY DOCKET NO.43081-0032WO1 hydroxypropane-1,3-diyl ditetradecanoate; 2-hydroxypropane-1,3-diyl ditridecanoate; 2- hydroxypropane-1,3-diyl didodecanoate; 2-hydroxypropane-1,3-diyl bis(decanoate); 2- hydroxy-3-(octanoyloxy)propyl decanoate; 2-hydroxypropane-1,3-diyl dioctanoate; 3- (hexanoyloxy)-2-hydroxypropyl octanoate; 2-hydroxypropane-1,3-diyl dihexanoate; 3- (hexanoyloxy)-2-hydroxypropyl octanoate; 3-(butyryloxy)-2-hydroxypropyl octanoate; 3- (butyryloxy)-2-hydroxypropyl hexanoate; 2-hydroxypropane-1,3-diyl dibutyrate; 2- hydroxyoctyl icosanoate; 2-hydroxyheptyl icosanoate; 2-hydroxyhexyl icosanoate; 2- hydroxypentyl icosanoate; 2-hydroxypentyl stearate; 2-hydroxypropyl stearate; 2- hydroxybutyl stearate; 2-hydroxybutyl palmitate; 2-hydroxypentyl palmitate; 2- hydroxypentyl tetradecanoate; 2-hydroxybutyl tetradecanoate; 2-hydroxypropyl tetradecanoate; 2-hydroxypentyl dodecanoate; 2-hydroxybutyl dodecanoate; 2- hydroxypropyl dodecanoate; 2-hydroxypropyl decanoate; 2-hydroxybutyl decanoate; 2- hydroxypentyl decanoate; 2-hydroxypentyl octanoate; 2-hydroxybutyl octanoate; 2- hydroxypropyl octanoate; 2-hydroxypropyl hexanoate; 2-hydroxypropyl butyrate; 2- hydroxybutyl butyrate; 1-hydroxyoctan-2-yl icosanoate; 1-hydroxyoctan-2-yl stearate; 1- hydroxyhexan-2-yl stearate; 1-hydroxypentan-2-yl stearate; 1-hydroxypentan-2-yl palmitate; 1-hydroxypropan-2-yl stearate; 1-hydroxypropan-2-yl palmitate; 1- hydroxypropan-2-yl tetradecanoate; 1-hydroxypropan-2-yl dodecanoate; 1- hydroxypropan-2-yl decanoate; 1-hydroxypropan-2-yl octanoate; 1-hydroxypropan-2-yl hexanoate; 1-hydroxypropan-2-yl butyrate; 1-hydroxybutan-2-yl butyrate; 1- hydroxypentan-2-yl butyrate; 1-hydroxyoctan-2-yl butyrate; 2-hydroxyethyl icosanoate; 2-hydroxyethyl stearate; 2-hydroxyethyl palmitate; 2-hydroxyethyl tetradecanoate; 2- hydroxyethyl dodecanoate; 2-hydroxyethyl decanoate; 2-hydroxyethyl octanoate; 2- hydroxyethyl hexanoate; 2-hydroxyethyl butyrate; 3-hydroxypropyl butyrate; 3- hydroxypropyl hexanoate; 3-hydroxypropyl pentanoate; 3-hydroxypropyl heptanoate; 3- hydroxypropyl octanoate; 3-hydroxypropyl decanoate; 3-hydroxypropyl dodecanoate; 3- hydroxypropyl tetradecanoate; 3-hydroxypropyl palmitate; 3-hydroxypropyl stearate; 3- hydroxypropyl icosanoate; pentadecyl 2-hydroxypropanoate; pentadecyl 2- hydroxyacetate; tetradecyl 2-hydroxypropanoate; tetradecyl 2-hydroxyacetate; tridecyl 2- hydroxyacetate; tridecyl 2-hydroxypropanoate; dodecyl 2-hydroxypropanoate; dodecyl 2- hydroxyacetate; decyl 2-hydroxyacetate; decyl 2-hydroxypropanoate; octyl 2- ATTORNEY DOCKET NO.43081-0032WO1 hydroxypropanoate; 2,3-dihydroxypropyl icosanoate; 2,3-dihydroxypropyl stearate; 2,3- dihydroxypropyl palmitate; 2,3-dihydroxypropyl tetradecanoate; 2,3-dihydroxypropyl dodecanoate; 2,3-dihydroxypropyl decanoate; 2,3-dihydroxypropyl octanoate; 2,3- dihydroxypropyl hexanoate; 2,3-dihydroxypropyl butyrate; 1,3-dihydroxypropan-2-yl butyrate; 1,3-dihydroxypropan-2-yl pentanoate; 1,3-dihydroxypropan-2-yl hexanoate; 1,3-dihydroxypropan-2-yl heptanoate; 1,3-dihydroxypropan-2-yl octanoate; 1,3- dihydroxypropan-2-yl nonanoate; 1,3-dihydroxypropan-2-yl decanoate; 1,3- dihydroxypropan-2-yl dodecanoate; 1,3-dihydroxypropan-2-yl tetradecanoate; 1,3- dihydroxypropan-2-yl palmitate; 1,3-dihydroxypropan-2-yl stearate; 1,3- dihydroxypropan-2-yl icosanoate; 2,3-dihydroxypropyl nonanoate; 2,3-dihydroxypropyl heptanoate; 2,3-dihydroxypropyl pentanoate; dodecyl octanoate; tetradecyl octanoate; hexadecyl octanoate; octadecyl octanoate; octadecyl decanoate; hexadecyl decanoate; tetradecyl decanoate; and dodecyl decanoate; propane-1,2-diyl dibutyrate; 2- (butyryloxy)propyl pentanoate; propane-1,2-diyl dipentanoate; 2-(pentanoyloxy)propyl hexanoate; propane-1,2-diyl dihexanoate; 2-(hexanoyloxy)propyl heptanoate; 2- (heptanoyloxy)propyl octanoate; 2-(heptanoyloxy)propyl nonanoate; 2- (octanoyloxy)propyl nonanoate; propane-1,2-diyl dinonanoate; 2-(nonanoyloxy)propyl decanoate; propane-1,2-diyl bis(decanoate); 2-(decanoyloxy)propyl dodecanoate; propane-1,2-diyl didodecanoate; 2-(dodecanoyloxy)propyl tetradecanoate; propane-1,2- diyl ditetradecanoate; 1-(tetradecanoyloxy)propan-2-yl palmitate; propane-1,2-diyl dipalmitate; 1-(palmitoyloxy)propan-2-yl stearate; propane-1,2-diyl distearate; 2- (stearoyloxy)propyl icosanoate; propane-1,2-diyl bis(icosanoate); 2-methylpropane-1,3- diyl bis(icosanoate); 2-methyl-3-(stearoyloxy)propyl icosanoate; 2-methylpropane-1,3- diyl distearate; 2-methyl-3-(palmitoyloxy)propyl stearate; 2-methylpropane-1,3-diyl dipalmitate; 2-methyl-3-(tetradecanoyloxy)propyl palmitate; 2-methylpropane-1,3-diyl ditetradecanoate; 3-(dodecanoyloxy)-2-methylpropyl tetradecanoate; 2-methylpropane- 1,3-diyl didodecanoate; 3-(decanoyloxy)-2-methylpropyl dodecanoate; 2-methylpropane- 1,3-diyl bis(decanoate); 2-methyl-3-(nonanoyloxy)propyl decanoate; 2-methylpropane- 1,3-diyl dinonanoate; 2-methyl-3-(octanoyloxy)propyl nonanoate; 2-methylpropane-1,3- diyl dioctanoate; 3-(heptanoyloxy)-2-methylpropyl octanoate; 3-(hexanoyloxy)-2- methylpropyl octanoate; 3-(hexanoyloxy)-2-methylpropyl heptanoate; 2-methyl-3- ATTORNEY DOCKET NO.43081-0032WO1 (pentanoyloxy)propyl hexanoate; 3-(butyryloxy)-2-methylpropyl pentanoate; 2- methylpropane-1,3-diyl dibutyrate; a cetostearyl alcohol; a cetyl alcohol; docosanol; ethylhexyl hydroxystearate; glyceryl 1-stearate; glyceryl dibehenate; glyceryl distearate; glycerylricinoleate; lauryl lactate; a lauroyl polyoxylglyceride; a myristyl alcohol; octyldodecanol; polyoxyl 35 castor oil; polyoxyl 40 hydrogented castor oil; polyoxyl 40 stearate; sorbitan monolaurate; sorbitan monooleate; sorbitan monopalmitate; sorbitan monostearate; sorbitan sesquioleate; sorbitan trioleate; sorbitan tristearate; trihydroxystearin; and combinations of two or more thereof. Embodiment 22. The composition of any one of embodiments 1-21, wherein the semi-fluorinated alkane is perfluorohexyloctane (F6H8). Embodiment 23. The composition of any one of embodiments 1-21, wherein the semi-fluorinated alkane is perfluorobutylpentane (F4H5). Embodiment 24. The composition of any one of embodiments 1-23, wherein the API in the composition is chemically stable for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 1 year, at least 18 months, at least 2 years or longer. Embodiment 25. The composition of any one of embodiments 1-24, wherein the API is selected from alpha agonists, antibiotics, corticosteroids, antinicotinic agents, antiglaucoma agents, antihistamines, antivirals, anti-parasitics, pressure regulators, topical transient receptor potential melastatin 8 (TRPM8) agonists, inhibitors of inflammatory cell binding, cycloplegics / mydriatics, mast cell stabilizers, miotics, ophthalmic NSAIDs, cyclosporine, riboflavin 5'-phosphate ophthalmic compounds, and VEGF inhibitors and VEGF receptor inhibitors. Embodiment 26. The composition of any one of embodiments 1-25 wherein the API has a logP less than or equal to 4.3, optionally less than or equal to 2.0. ATTORNEY DOCKET NO.43081-0032WO1 Embodiment 27. The composition of any one of embodiments 1-26, wherein the composition comprises: from about 0.0001% to about 20% (w / w) of the active pharmaceutical ingredient (API); from about 0.1% to about 40% (w / w) of the one or more excipient compound(s); and from about 60% to about 99.9% (w / w) of the semi-fluorinated alkane compound. Embodiment 28. The composition of embodiment 27, wherein the composition comprises: from about 0.0001% to about 10% (w / w) of the active pharmaceutical ingredient (API); from about 0.1% to about 20% (w / w) of the one or more excipient compound(s); and from about 80% to about 99.9% (w / w) of the semi-fluorinated alkane compound. Embodiment 29. The composition of any one of embodiments 1-28, wherein the composition consists of or consists essentially of: the active pharmaceutical ingredient (API); one or more of the excipient compound(s); and the semi-fluorinated alkane compound. Embodiment 30. A method for delivering an API to a subject comprising dissolving the API in a composition comprising: one or more excipient compound(s) selected from a hydroxyalkyl ester of one or more aliphatic fatty acids, a hydroxyacid alkyl ester, an alkyl ester of one or more fatty acids, and combinations thereof; and a semi-fluorinated alkane compound, to form an API composition, and administering the API composition to the subject. ATTORNEY DOCKET NO.43081-0032WO1 Embodiment 31. The method of embodiment 30 comprising dissolving the API in the one or more excipient compound(s) to form a first composition; and mixing the first composition with the semi-fluorinated alkane compound, to form the API composition. Embodiment 32. The method of embodiment 31, wherein the API is selected from alpha agonists, antibiotics, corticosteroids, anticholinergic agents, antiglaucoma agents, antihistamines, antivirals, anti-parasitics, pressure regulators, topical transient receptor potential melastatin 8 (TRPM8) agonists, inhibitors of inflammatory cell binding, cycloplegics / mydriatics, mast cell stabilizers, miotics, ophthalmic NSAIDs, cyclosporine, riboflavin 5'-phosphate ophthalmic compounds, and VEGF inhibitors and VEGF receptor inhibitors; optionally wherein the API has a logP less than or equal to 4.3, optionally wherein the API has a logP less than 2.0. Embodiment 33. The method of any one of embodiments 31-32, wherein administering the API composition to the subject comprises administering the API composition to skin or mucosal membrane of a subject, to an eye of the subject, or to a lung of the subject. Embodiment 34. A method for delivering an API to a target tissue of a subject, wherein the target tissue is selected from skin, mucosal membrane, eye tissue, lung tissue, or a tissue of the oral cavity or esophagus, comprising administering any one of the compositions of any one of embodiments 1-29 to said target tissue of the subject. Embodiment 35. The method of embodiment 34, wherein the API is selected from alpha agonists, antibiotics, corticosteroids, anticholinergic agents, antiglaucoma agents, antihistamines, antivirals, anti-parasitics, pressure regulators, topical transient receptor potential melastatin 8 (TRPM8) agonists, inhibitors of inflammatory cell binding, cycloplegics / mydriatics, mast cell stabilizers, miotics, ophthalmic NSAIDs, cyclosporine, riboflavin 5'-phosphate ophthalmic compounds, and VEGF inhibitors and VEGF receptor inhibitors. ATTORNEY DOCKET NO.43081-0032WO1 Embodiment 36. A method for treating, slowing the progression of, or reducing one or more symptoms of a condition in a subject, or inducing one or more symptoms of miosis in a subject, comprising administering the composition of any one of embodiments 1-29 to the subject. Embodiment 37. A method for treating, slowing the progression of, or reducing one or more symptoms of an ocular condition in a subject, or inducing one or more symptoms of miosis in a subject, comprising administering the composition of any one of embodiments 1-29 to an eye of the subject. Embodiment 38. The method of embodiment 37, wherein the ocular condition is selected from neurotrophic keratitis, glaucoma, elevated intraocular pressure, ocular hypertension, presbyopia, myopia, ocular rosacea, dry eye disease, meibomian gland dysfunction, blepharitis, allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, pterygium, pinguecula, corneal transplant rejection, graft versus host disease, ocular allergy, uveitis, anterior uveitis, Behcet's disease, Sjogren's syndrome, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, chronic ocular surface inflammation caused by viral infection, herpes simplex keratitis, atopic conjunctivitis, Lyell’s syndrome, neovascularization induced by viral, bacterial, fungal, or parasitic infection or an associated disease or symptom thereof, contact lens induced neovascularization, ulceration, alkali burns, stem cell deficiency, neovascular glaucoma, Steven Johnson syndrome, tumor in the eye, aphakia, pseudophakia, astigmatism, blepharospasm, cataract, conjunctival diseases, corneal diseases, corneal ulcer, eyelid diseases, lacrimal apparatus diseases, pupil disorders, refractive disorders, and strabismus. Embodiment 39. A method for slowing myopia progression in a subject or for relieving vitreous floater symptoms in a subject, comprising administering the composition of any one of embodiments 1-29 to an eye of the subject, wherein the API is a muscarinic receptor antagonist. ATTORNEY DOCKET NO.43081-0032WO1 Embodiment 40. The method of embodiment 39, wherein the API is selected from atropine, an atropine mimetic or analog, or a free base, hydrate, solvate, or salt form thereof. Embodiment 41. A method for treating, slowing the progression of, or reducing one or more symptoms of presbyopia or glaucoma in a subject, or for inducing miosis in a subject, comprising administering the composition of any one of embodiments 1-29 to an eye of the subject, wherein the API comprises a muscarinic cholinergic receptor agonist. Embodiment 42. The method of any one of embodiments 37 to 41, wherein the subject is in need of transcorneal absorption of an API; wherein the subject has had an adverse side effect from the API after receiving an aqueous composition comprising the API; and / or wherein the subject is highly sensitive to an aqueous composition comprising the API; optionally wherein the API is in a free base form; optionally wherein the composition is administered to the eye of the subject about every about 6 to about 8 hours or three times a day, and / or optionally wherein the composition is administered at a dose 5-10%, 5-15%, 5- 20%, 5-25%, 5-30%, 10-30%, 10-40%, 10-50%, 10-60%, 10-70%, 20-30%, 20-40%, 20- 50%, 20-60%, 20-70%, 30-40%, 30-50%, 30-60%, 30-70%, 40-50%, 40-60%, 40-70%, or 50-70% less than a dose of an aqueous topical ophthalmological composition comprising the API used for the same ocular condition or purpose. Embodiment 43. A method of administering to a subject a topical ophthalmological composition for selective transcorneal absorption, the method comprising administering to an eye of the subject the composition of any one of embodiments 1-29; optionally wherein the composition is non-aqueous; and optionally wherein the API is in free base form. ATTORNEY DOCKET NO.43081-0032WO1 Embodiment 44. A method of treating an ocular condition in a subject, the method comprising: (a) (i) selecting a subject in need of transcorneal absorption of an API; or (ii) selecting a subject having an ocular condition, wherein the ocular condition is in need of transcorneal absorption of an API; and (b) administering to an eye of the subject the composition of any one of embodiments 1-29; optionally wherein the composition is non-aqueous; and optionally wherein the API is in free base form. Embodiment 45. A method of selectively delivering an API to a cornea of an eye of a subject, the method comprising administering to the eye of the subject the composition of any one of embodiments 1-29; optionally wherein the composition is non-aqueous; and optionally wherein the API is in free base form. Embodiment 46. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45, wherein the API is selected from the group consisting of aceclidine, pilocarpine, bethanechol, cevimeline, methacholine, xanomeline, and aprolidine. Embodiment 47. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45, wherein the API is riboflavin or a riboflavin derivative, optionally wherein the API is selected from riboflavin, riboflavin tetraacetate, riboflavin tetrapropionate, riboflavin tetrabutyrate, riboflavin tetrapalmitate, or combinations thereof. Embodiment 48. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45, wherein the API is a multikinase inhibitor, optionally wherein the multikinase inhibitor is selected from afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, ATTORNEY DOCKET NO.43081-0032WO1 pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib, or combinations thereof. Embodiment 49. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45, wherein the API is a co-drug selected from the group consisting of (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5-yl)amino)-4,5-dihydro-lH- imidazole-lcarbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2- ((4-bromo-lHbenzo[d]imidazol-5-yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l- methyl-1Himidazol-5-yl)methyl)pentyl propionate; (2R,3S)-3-(2-((4-bromo-lH- benzo[d]imidazol-5- yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5- yl)amino)-4,5-dihydro-lH-imidazolel-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3- (2-((4-bromo-lH- benzo[d]imidazol-5-yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((lmethyl-lH- imidazol-5-yl)methyl)pentyl oleate; (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5- yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl (9Z,12Z)-octadeca-9,12-dienoate; (2R,3S)-3-(2-((5-bromoquinoxalin-6- yl)amino)-4,5-dihydrolH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl acetate; (2R,3S)-3-(2- ((5-bromoquinoxalin-6-yl)amino)-4,5-dihydro- lH-imidazole-l-carbonyl)-2-((l-methyl-lHimidazol-5-yl)methyl)pentyl propionate; (2R,3S)-3-(2-((5-bromoquinoxalin-6-yl)amino)-4,5- dihydro-lH-imidazole-l-carbonyl)-2- ((l-methyl-lH-imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2-((5-bromoquinoxalin- 6-yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((lmethyl-lH-imidazol-5- yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((5- bromoquinoxalin-6- yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lHimidazol-5- yl)methyl)pentyl oleate; (2R,3S)-3-(2-((5-bromoquinoxalin-6-yl)amino)-4,5-dihydrolH- imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl (9Z,12Z)-octadeca- 9,12-dienoate; (2R,3S)-3-(2-((4-amino-2,6-dichlorophenyl)amino)-4,5-dihydro-lH- imidazole-lcarbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2- ((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l- ATTORNEY DOCKET NO.43081-0032WO1 methyl-lH-imidazol-5- yl)methyl)pentyl propionate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydrolH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl butyrate; (2R,3S)-3-(2- ((4-amino-2,6-dichlorophenyl)amino)-4,5- dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lHimidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5- dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl oleate; (2R,3S)-3-(2-((4-amino-2,6-dichlorophenyl)amino)-4,5-dihydro-lHimidazole-l- carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl (9Z,12Z)-octadeca-9,12-dienoate; (2R,3S)-3-(2-((2,6-dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l- carbonyl)-2- ((l-methyl-lH-imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2- ((2,6-dichlorophenyl)amino)- 4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl- lH-imidazol-5-yl)methyl)pentyl propionate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2- ((l-methyl-lH- imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2-((2,6-dichlorophenyl)amino)- 4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazolel-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl oleate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)- 4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl (9Z,12Z)-octadeca-9,12-dienoate; and (2R,3S)-3-((Z)-2-((5- bromoquinoxalin-6-yl)imino)imidazolidine-1-carbonyl)-2-((1-methyl-1H- imidazol-5-yl)methyl)pentyl pivalate, or combinations thereof. Embodiment 50. A method for crosslinking collagen in a tissue of a subject, comprising: administering to the tissue of the subject the composition of any one of embodiments 1-29, wherein the API is a compound of Formula (I): ATTORNEY DOCKET NO.43081-0032WO1 R1, R2, and R3 are each independently selected from hydrogen or -C(O)R5; R4 is selected from hydrogen, -C(O)R5, a phosphate, or a salt thereof; and R5 is a linear or branched or cyclic alkyl having 1 to 26 carbon atoms; and irradiating the tissue with UV radiation or blue light. Embodiment 51. A method for crosslinking a structural protein, comprising: contacting the structural protein or a biological tissue containing the structural protein with the composition of any one of embodiments 1-29, wherein the API is a compound of Formula (I): wherein: R1, R2, and R3 are each independently selected from hydrogen or -C(O)R5; R4 is selected from hydrogen, -C(O)R5, a phosphate, or a salt thereof; and R5 is a linear or branched or cyclic alkyl having 1 to 26 carbon atoms; and irradiating the structural protein or the tissue with UV radiation or blue light. ATTORNEY DOCKET NO.43081-0032WO1 Embodiment 52. The method of any one of embodiments 50 or 51, wherein the API is selected from riboflavin, riboflavin tetraacetate, riboflavin tetrapropionate, riboflavin tetrabutyrate, riboflavin tetrapalmitate, or combinations thereof. Embodiment 53. An excipient system for delivering an API to a subject comprising: one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound. Embodiment 54. A method for making the composition of any one of embodiments 1-29, comprising dissolving the API in a composition comprising: one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound. Embodiment 55. The method of embodiment 54, comprising dissolving the API in the one or more excipient compound(s) to form a first composition; and mixing the first composition with the semi-fluorinated alkane compound. Embodiment 56. The composition of any one of embodiments 1-29, 46-49, 66-67, 69-71, or 73-74, or the method of any one of embodiments 30-52 or 63-74, wherein the composition is in the form of a solution, suspension, emulsion or implant. Embodiment 57. A dispenser comprising: a container portion comprising an interior wall defining an interior volume and adapted to contact and store a liquid within at least a portion of the interior volume; and any one of the compositions of embodiments 1-29, 46-49, 66-67, 69-71, or 73-74, or the excipient system of embodiment 53, contained within the interior volume. ATTORNEY DOCKET NO.43081-0032WO1 Embodiment 58. The dispenser of embodiment 57, wherein the interior wall comprises less than about 10% of one or more of low density polyethylene (LDPE) or polypropylene (PP). Embodiment 59. The dispenser of any one of embodiments 57-58, wherein the interior wall does not comprise low density polyethylene (LDPE) or polypropylene (PP). Embodiment 60. The dispenser of any one of embodiments 57-59, wherein the interior wall comprises glass or polyethylene terephthalate. Embodiment 61. The dispenser of any one of embodiments 57-60, wherein the interior wall consists essentially of glass or polyethylene terephthalate (PET). Embodiment 62. The dispenser of any one of embodiments 57-61, wherein a concentration of the API remains more than 90% of an initial API concentration after storage in the dispenser for a period of at least 6 months, or wherein a concentration of the API remains more than 90% of an initial API concentration after storage in the dispenser for a period of at least 12 months or wherein a concentration of the API remains more than 90% of an initial API concentration after storage in the dispenser for at least a period of 24 months. Embodiment 63. The dispenser of any one of embodiments 57-62, wherein the dispenser further comprises: a dispensing portion adapted to dispense one or more drops of a liquid out of the container portion; and wherein the container portion and the dispensing portion each, independently, consist essentially of glass or polyethylene terephthalate (PET). Embodiment 64. The dispenser of any one of embodiments 57-62, wherein the dispenser further comprises: ATTORNEY DOCKET NO.43081-0032WO1 a dispensing portion adapted to dispense one or more drops of a liquid out of the container portion; and wherein the volume of the one or more drops each independently is from about 5 µl to about 40 µl. Embodiment 65. A method for treating or reducing one or more symptoms of blepharitis, ocular rosacea, rosacea, or eyelid margin redness in a subject, or for improving eyelash health in a subject, or for treating or eradicating Demodex mites, lice, scabies, or bed bugs in a subject, or for treating or preventing a vector-borne disease in a subject, comprising administering the composition of any one of embodiments 1-29 to the subject, to an eye of the subject, or to skin or hair of the subject, wherein the API is an anti-parasitic. Embodiment 66. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45 or 65, wherein the API is an isooxazoline parasiticide or a formamidine parasiticide. Embodiment 67. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45 or 65, wherein the API is one or more of fluralaner, sarolaner, lotilaner, afoxolaner, and / or fluxametamide, a derivative, analogue, enantiomer, racemic mixture, free base, enantiomerically pure composition, or L- and D- isomer thereof. Embodiment 68. A method for treating, slowing the progression of, or reducing one or more symptoms of dry eye disease, meibomian gland disfunction, or inflammatory dry eye in a subject, comprising administering the composition of any one of embodiments 1- 29 to an eye of the subject, wherein the API is selected from one or more of lifitegrast, menthol, AR-15512 ((1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl) cyclohexanecarboxamide), cyclosporine, or derivatives, analogues, pharmaceutically acceptable salts, free base form, racemic mixtures, or diastereomers or enantiomers thereof. ATTORNEY DOCKET NO.43081-0032WO1 Embodiment 69. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45 or 68, wherein the API is lifitegrast, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof. Embodiment 70. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45 or 68, wherein the API is cyclosporine, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof. Embodiment 71. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45 or 68, wherein the API is selected from menthol, AR- 15512 ((1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl) cyclohexanecarboxamide), or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof. Embodiment 72. A method for treating, slowing the progression of, or reducing one or more symptoms of glaucoma, ocular hypertension, or high fluid pressure in an eye of a subject, or a method of lowering fluid pressure in an eye of a subject, comprising administering the composition of any one of embodiments 1-29 to an eye of the subject, wherein the API is a pressure regulator. Embodiment 73. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45 or 72, wherein the API is selected from one or more of Brimonidine, Apraclonidine Iopidine, Dorzolamide, Brinzolamide, Azopt, Timolol, Timoptic / Istalol / Betimol, Betaxolol, Betoptic, Levobunolol, Betagan, Metipranolol, Optipranolol, Latanoprost, Xalatan Green, Bimatoprost, Lumigan, Tafluprost, Zioptan, Latanoprostene, Vyzulta Turquoise, Pilocarpine, Carbachol, Isopto Carbachol, Netarsudil, and Rhopressa, and pharmaceutically acceptable salts or free base forms thereof. ATTORNEY DOCKET NO.43081-0032WO1 Embodiment 74. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45 or 72, wherein the API is Brimonidine. Embodiment 75. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45 or 65, wherein the API is selected from ivermectin or a derivative, analogue, racemic mixture, or diastereomer or enantiomer thereof, optionally wherein the ivermectin is a mixture of ivermectin B1a and ivermectin B1b. Embodiment 76. The method of any one of embodiments 37-49, 56, 65-75, wherein the composition administered to an eye of the subject, and wherein the API is absorbed transcorneally in the eye. Embodiment 77. The method of any one of embodiments 37-49, 56, 65-75, wherein the composition administered to an eye of the subject, and wherein the API is selectively absorbed transcorneally in the eye as compared to periorbitally. Embodiment 78. The method of any one of embodiments 37-49, 56, 65-77, wherein the composition is non-aqueous; optionally wherein the composition is an emulsion. Embodiment 79. The method of any one of embodiments 37-49, 56, 65-78, wherein the composition is non-aqueous, and wherein the composition is administered at a dose 5- 10%, 5-15%, 5-20%, 5-25%, 5-30%, 10-30%, 10-40%, 10-50%, 10-60%, 10-70%, 20- 30%, 20-40%, 20-50%, 20-60%, 20-70%, 30-40%, 30-50%, 30-60%, 30-70%, 40-50%, 40-60%, 40-70%, or 50-70% less than a dose of an aqueous composition comprising the API for treating, slowing the progression of, or reducing one or more symptoms of the ocular condition. Embodiment 80. The method of any one of embodiments 37-49, 56, 65-79, wherein the composition is administered to the subject: (i) every about 6 to about 8 hours or three to four times a day, (ii) once a day, or (iii) twice a day. ATTORNEY DOCKET NO.43081-0032WO1 Embodiment 81. The method of any one of embodiments 37-49, 56, 65-80, wherein the API is in a free base form. Embodiment 82. A method of formulating a topical ophthalmological composition for transcorneal absorption, the method comprising combining an active pharmaceutical ingredient (API); one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound. Embodiment 83. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45, 72, or 75-82, wherein the API is Brimonidine or pharmaceutically acceptable salts or free base forms thereof, optionally wherein at least one excipient compound is a propylene glycol dilaurate or a propylene glycol dicaprylate. Embodiment 84. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45, 68, or 75-82, wherein the API is lifitegrast, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, optionally wherein at least one excipient compound is a propylene glycol dilaurate or a propylene glycol dicaprylate. Embodiment 85. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45, or 75-82, wherein the API is aceclidine, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, optionally wherein at least one excipient compound is a coco-caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate. Embodiment 86. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45, or 75-82, wherein the API is axitinib, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, optionally wherein at least one excipient compound ATTORNEY DOCKET NO.43081-0032WO1 is a coco-caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate. Embodiment 87. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45, or 75-82, wherein the API is atropine, or an atropine mimetic or analog, or a free base, hydrate, solvate, or salt form thereof, optionally wherein at least one excipient compound is a coco-caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate. Embodiment 88. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45, or 75-82, wherein the API is (2R,3S)-3-((Z)-2-((5- bromoquinoxalin-6-yl)imino)imidazolidine-1-carbonyl)-2-((1-methyl-1H-imidazol-5- yl)methyl)pentyl pivalate, or a free base, hydrate, solvate, or salt form thereof, optionally wherein at least one excipient compound is a coco-caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate. Embodiment 89. The composition of any one of embodiments 1-29, or the method of any one of embodiments 30-45, or 75-82, wherein the API is ivermectin or a derivative, analogue, racemic mixture, or diastereomer or enantiomer thereof, optionally wherein the ivermectin is a mixture of ivermectin B1a and ivermectin B1b, optionally wherein at least one excipient compound is a coco-caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate.

Claims

ATTORNEY DOCKET NO.43081-0032WO1 WHAT IS CLAIMED IS:

1. A composition comprising: an active pharmaceutical ingredient (API), optionally wherein the API is in a free base, salt, solvate, or hydrate form; one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof, optionally wherein the fatty acid is saturated or unsaturated, linear or branched; and a semi-fluorinated alkane compound, optionally wherein the composition is in the form of a solution, suspension, emulsion or implant; optionally wherein the composition is non-aqueous.

2. The composition of claim 1, wherein (a) the semi-fluorinated alkane compound is selected from the group consisting of perfluorobutylpentane (F4H5), perfluorobutylhexane (F4H6), perfluorohexylbutane (F6H4), perfluorohexylhexane (F6H6), perfluorohexyloctane (F6H8), and perfluorohexyl decane (F6H10); (b) the hydroxyalkyl ester of an aliphatic fatty acid is a propylene glycol mono or di-ester of C4-C20 fatty acid, or a glycerol of 1, 2 or 1, 3 di-ester of C4-C20 fatty acid, or a glycerol of a mono ester of a C4-20 fatty acid, optionally wherein the hydroxyalkyl ester of an aliphatic fatty acid is a compound of any one of Formulas (II)-(VIII):ATTORNEY DOCKET NO.43081-0032WO1 ;; ; and ; wherein: R6and R7are each, independently, C3-C19 linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl, optionally wherein R6 and R7 are each, independently, C7-C17 linear or branched alkyl; R is H or an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-6 C atoms, optionally wherein one H atom on each carbon atom can independently be replaced with one -OH group, optionally wherein R is an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-4 C atoms; and n is an integer from 1 to 12, optionally wherein n is selected from 2 to 3; (c) the alkyl ester of a fatty acid is a compound of Formula (IX):ATTORNEY DOCKET NO.43081-0032WO1, wherein: x is an integer from 2 to 3; and y is an integer from 4 to 7; (d) the hydroxyacid alkyl ester is a medium-chain alkyl C12 to C15 lactate or glycolate, optionally wherein the hydroxyacid alkyl ester is a compound of any one of Formulas (X)-(XII):; ; and , wherein: R6and R7are each, independently, C3-C19 linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl; R8is C6-C20 linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl, optionally wherein R8is C12-C15 linear or branched alkyl; and R is H or an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1-6 C atoms, optionally wherein one H atom on each carbon atom can independently be replaced with one -OH group, optionally wherein R is an aliphatic linear or branched alkyl, alkenyl, hydroxyalkyl, or hydroxyalkenyl group having 1- 4 C atoms; and / orATTORNEY DOCKET NO.43081-0032WO1 (e) at least one of the one or more excipient compound(s) has a hydrophilic- lipophilic balance (HLB) value of less than or equal to 3.4 as calculated according to the formula: HLB = 20(1-(S / A)), wherein: S is number of ester saponification; and A is the acid number of the fatty acid; and / or the excipient compound(s) is selected from: 3-hydroxypropane-1,2-diyl bis(icosanoate); 3-hydroxypropane-1,2-diyl dinonadecanoate; 3-hydroxypropane-1,2-diyl distearate; 3-hydroxypropane-1,2-diyl diheptadecanoate; 3-hydroxypropane-1,2-diyl dipalmitate; 3-hydroxypropane-1,2-diyl dipentadecanoate; 3-hydroxypropane-1,2-diyl ditetradecanoate; 3-hydroxypropane-1,2- diyl ditridecanoate; 3-hydroxypropane-1,2-diyl didodecanoate; 3-hydroxypropane-1,2- diyl diundecanoate; 3-hydroxypropane-1,2-diyl bis(decanoate); 3-hydroxypropane-1,2- diyl dinonanoate; 3-hydroxypropane-1,2-diyl dioctanoate; 1-(heptanoyloxy)-3- hydroxypropan-2-yl octanoate; 3-hydroxypropane-1,2-diyl diheptanoate; 2- (heptanoyloxy)-3-hydroxypropyl octanoate; 1-(hexanoyloxy)-3-hydroxypropan-2-yl heptanoate; 3-hydroxypropane-1,2-diyl dihexanoate; 1-hydroxy-3-(pentanoyloxy)propan- 2-yl hexanoate; 1-(butyryloxy)-3-hydroxypropan-2-yl hexanoate; 1-(butyryloxy)-3- hydroxypropan-2-yl pentanoate; 3-hydroxypropane-1,2-diyl dibutyrate; 1-(butyryloxy)-3- hydroxypropan-2-yl octanoate; 2-(butyryloxy)-3-hydroxypropyl octanoate; 2- hydroxypropane-1,3-diyl bis(icosanoate); 2-hydroxypropane-1,3-diyl dinonadecanoate; 2-hydroxypropane-1,3-diyl distearate; 2-hydroxypropane-1,3-diyl diheptadecanoate; 2- hydroxypropane-1,3-diyl dipalmitate; 2-hydroxypropane-1,3-diyl dipentadecanoate; 2- hydroxypropane-1,3-diyl ditetradecanoate; 2-hydroxypropane-1,3-diyl ditridecanoate; 2- hydroxypropane-1,3-diyl didodecanoate; 2-hydroxypropane-1,3-diyl bis(decanoate); 2- hydroxy-3-(octanoyloxy)propyl decanoate; 2-hydroxypropane-1,3-diyl dioctanoate; 3- (hexanoyloxy)-2-hydroxypropyl octanoate; 2-hydroxypropane-1,3-diyl dihexanoate; 3- (hexanoyloxy)-2-hydroxypropyl octanoate; 3-(butyryloxy)-2-hydroxypropyl octanoate; 3- (butyryloxy)-2-hydroxypropyl hexanoate; 2-hydroxypropane-1,3-diyl dibutyrate; 2- hydroxyoctyl icosanoate; 2-hydroxyheptyl icosanoate; 2-hydroxyhexyl icosanoate; 2- hydroxypentyl icosanoate; 2-hydroxypentyl stearate; 2-hydroxypropyl stearate; 2-ATTORNEY DOCKET NO.43081-0032WO1 hydroxybutyl stearate; 2-hydroxybutyl palmitate; 2-hydroxypentyl palmitate; 2- hydroxypentyl tetradecanoate; 2-hydroxybutyl tetradecanoate; 2-hydroxypropyl tetradecanoate; 2-hydroxypentyl dodecanoate; 2-hydroxybutyl dodecanoate; 2- hydroxypropyl dodecanoate; 2-hydroxypropyl decanoate; 2-hydroxybutyl decanoate; 2- hydroxypentyl decanoate; 2-hydroxypentyl octanoate; 2-hydroxybutyl octanoate; 2- hydroxypropyl octanoate; 2-hydroxypropyl hexanoate; 2-hydroxypropyl butyrate; 2- hydroxybutyl butyrate; 1-hydroxyoctan-2-yl icosanoate; 1-hydroxyoctan-2-yl stearate; 1- hydroxyhexan-2-yl stearate; 1-hydroxypentan-2-yl stearate; 1-hydroxypentan-2-yl palmitate; 1-hydroxypropan-2-yl stearate; 1-hydroxypropan-2-yl palmitate; 1- hydroxypropan-2-yl tetradecanoate; 1-hydroxypropan-2-yl dodecanoate; 1- hydroxypropan-2-yl decanoate; 1-hydroxypropan-2-yl octanoate; 1-hydroxypropan-2-yl hexanoate; 1-hydroxypropan-2-yl butyrate; 1-hydroxybutan-2-yl butyrate; 1- hydroxypentan-2-yl butyrate; 1-hydroxyoctan-2-yl butyrate; 2-hydroxyethyl icosanoate; 2-hydroxyethyl stearate; 2-hydroxyethyl palmitate; 2-hydroxyethyl tetradecanoate; 2- hydroxyethyl dodecanoate; 2-hydroxyethyl decanoate; 2-hydroxyethyl octanoate; 2- hydroxyethyl hexanoate; 2-hydroxyethyl butyrate; 3-hydroxypropyl butyrate; 3- hydroxypropyl hexanoate; 3-hydroxypropyl pentanoate; 3-hydroxypropyl heptanoate; 3- hydroxypropyl octanoate; 3-hydroxypropyl decanoate; 3-hydroxypropyl dodecanoate; 3- hydroxypropyl tetradecanoate; 3-hydroxypropyl palmitate; 3-hydroxypropyl stearate; 3- hydroxypropyl icosanoate; pentadecyl 2-hydroxypropanoate; pentadecyl 2- hydroxyacetate; tetradecyl 2-hydroxypropanoate; tetradecyl 2-hydroxyacetate; tridecyl 2- hydroxyacetate; tridecyl 2-hydroxypropanoate; dodecyl 2-hydroxypropanoate; dodecyl 2- hydroxyacetate; decyl 2-hydroxyacetate; decyl 2-hydroxypropanoate; octyl 2- hydroxypropanoate; 2,3-dihydroxypropyl icosanoate; 2,3-dihydroxypropyl stearate; 2,3- dihydroxypropyl palmitate; 2,3-dihydroxypropyl tetradecanoate; 2,3-dihydroxypropyl dodecanoate; 2,3-dihydroxypropyl decanoate; 2,3-dihydroxypropyl octanoate; 2,3- dihydroxypropyl hexanoate; 2,3-dihydroxypropyl butyrate; 1,3-dihydroxypropan-2-yl butyrate; 1,3-dihydroxypropan-2-yl pentanoate; 1,3-dihydroxypropan-2-yl hexanoate; 1,3-dihydroxypropan-2-yl heptanoate; 1,3-dihydroxypropan-2-yl octanoate; 1,3- dihydroxypropan-2-yl nonanoate; 1,3-dihydroxypropan-2-yl decanoate; 1,3- dihydroxypropan-2-yl dodecanoate; 1,3-dihydroxypropan-2-yl tetradecanoate; 1,3-ATTORNEY DOCKET NO.43081-0032WO1 dihydroxypropan-2-yl palmitate; 1,3-dihydroxypropan-2-yl stearate; 1,3- dihydroxypropan-2-yl icosanoate; 2,3-dihydroxypropyl nonanoate; 2,3-dihydroxypropyl heptanoate; 2,3-dihydroxypropyl pentanoate; dodecyl octanoate; tetradecyl octanoate; hexadecyl octanoate; octadecyl octanoate; octadecyl decanoate; hexadecyl decanoate; tetradecyl decanoate; and dodecyl decanoate; propane-1,2-diyl dibutyrate; 2- (butyryloxy)propyl pentanoate; propane-1,2-diyl dipentanoate; 2-(pentanoyloxy)propyl hexanoate; propane-1,2-diyl dihexanoate; 2-(hexanoyloxy)propyl heptanoate; 2- (heptanoyloxy)propyl octanoate; 2-(heptanoyloxy)propyl nonanoate; 2- (octanoyloxy)propyl nonanoate; propane-1,2-diyl dinonanoate; 2-(nonanoyloxy)propyl decanoate; propane-1,2-diyl bis(decanoate); 2-(decanoyloxy)propyl dodecanoate; propane-1,2-diyl didodecanoate; 2-(dodecanoyloxy)propyl tetradecanoate; propane-1,2- diyl ditetradecanoate; 1-(tetradecanoyloxy)propan-2-yl palmitate; propane-1,2-diyl dipalmitate; 1-(palmitoyloxy)propan-2-yl stearate; propane-1,2-diyl distearate; 2- (stearoyloxy)propyl icosanoate; propane-1,2-diyl bis(icosanoate); 2-methylpropane-1,3- diyl bis(icosanoate); 2-methyl-3-(stearoyloxy)propyl icosanoate; 2-methylpropane-1,3- diyl distearate; 2-methyl-3-(palmitoyloxy)propyl stearate; 2-methylpropane-1,3-diyl dipalmitate; 2-methyl-3-(tetradecanoyloxy)propyl palmitate; 2-methylpropane-1,3-diyl ditetradecanoate; 3-(dodecanoyloxy)-2-methylpropyl tetradecanoate; 2-methylpropane- 1,3-diyl didodecanoate; 3-(decanoyloxy)-2-methylpropyl dodecanoate; 2-methylpropane- 1,3-diyl bis(decanoate); 2-methyl-3-(nonanoyloxy)propyl decanoate; 2-methylpropane- 1,3-diyl dinonanoate; 2-methyl-3-(octanoyloxy)propyl nonanoate; 2-methylpropane-1,3- diyl dioctanoate; 3-(heptanoyloxy)-2-methylpropyl octanoate; 3-(hexanoyloxy)-2- methylpropyl octanoate; 3-(hexanoyloxy)-2-methylpropyl heptanoate; 2-methyl-3- (pentanoyloxy)propyl hexanoate; 3-(butyryloxy)-2-methylpropyl pentanoate; 2- methylpropane-1,3-diyl dibutyrate; a cetostearyl alcohol; a cetyl alcohol; docosanol; ethylhexyl hydroxystearate; glyceryl 1-stearate; glyceryl dibehenate; glyceryl distearate; glycerylricinoleate; lauryl lactate; a lauroyl polyoxylglyceride; a myristyl alcohol; octyldodecanol; polyoxyl 35 castor oil; polyoxyl 40 hydrogented castor oil; polyoxyl 40 stearate; sorbitan monolaurate; sorbitan monooleate; sorbitan monopalmitate; sorbitan monostearate; sorbitan sesquioleate; sorbitan trioleate; sorbitan tristearate; trihydroxystearin; and combinations of two or more thereof.ATTORNEY DOCKET NO.43081-0032WO1 3. The composition of any one of claims 1-2, wherein the excipient compound(s) is present in a concentration of from about 0.1% to about 99% (w / w), from about 0.1% to about 80% (w / w), from about 0.1% to about 50% (w / w), from about 0.1% to about 30% (w / w), from about 0.1% to about 20% (w / w), from about 0.1% to about 15% (w / w), from about 0.1% to about 10% (w / w), from about 0.1% to about 5% (w / w), about 20% (w / w), about 15% (w / w), about 10% (w / w), about 5% (w / w), about 3% (w / w), or about 1% (w / w); wherein the semi-fluorinated alkane compound is present in a concentration of from about 1% to about 99.9% (w / w), from about 20% to about 99.9% (w / w), from about 50% to about 99.9% (w / w), from about 70% to about 99.9% (w / w), from about 80% to about 99.9% (w / w), from about 85% to about 99.9% (w / w), from about 90% to about 99.9% (w / w), from about 95% to about 99.9% (w / w), about 80% (w / w), about 85% (w / w), about 90% (w / w), about 95% (w / w), about 97% (w / w), or about 99% (w / w); and / or wherein the API is present in a concentration of from about 0.0001% to about 20%, from about 0.001% to 15% (w / w), from about 0.001% to 10% (w / w), from about 0.001% to 5% (w / w), from about 0.01% to 5% (w / w), or from about 0.01% to 4% (w / w).

4. The composition of any one of claims 1-3, wherein the API is selected from alpha agonists, antibiotics, corticosteroids, antinicotinic agents, antiglaucoma agents, antihistamines, antivirals, anti-parasitics, pressure regulators, topical transient receptor potential melastatin 8 (TRPM8) agonists, inhibitors of inflammatory cell binding, cycloplegics / mydriatics, mast cell stabilizers, miotics, ophthalmic NSAIDs, cyclosporine, riboflavin 5'-phosphate ophthalmic compounds, and VEGF inhibitors and VEGF receptor inhibitors.

5. The composition of any one of claims 1-4, wherein the composition comprises: from about 0.0001% to about 20% (w / w) of the API, optionally from about 0.0001% to about 10% (w / w) of the API;ATTORNEY DOCKET NO.43081-0032WO1 from about 0.1% to about 40% (w / w) of the one or more excipient compound(s), optionally from about 0.1% to about 20% (w / w) of the one or more excipient compound(s); and from about 60% to about 99.9% (w / w) of the semi-fluorinated alkane compound, optionally from about 80% to about 99.9% (w / w) of the semi- fluorinated alkane compound.

6. The composition of any one of claims 1-5, wherein the composition consists of or consists essentially of: the active pharmaceutical ingredient (API); one or more of the excipient compound(s); and the semi-fluorinated alkane compound.

7. A method for delivering an API to a subject, the method comprising: dissolving the API in a composition comprising: one or more excipient compound(s) selected from a hydroxyalkyl ester of one or more aliphatic fatty acids, a hydroxyacid alkyl ester, an alkyl ester of one or more fatty acids, and combinations thereof; and a semi-fluorinated alkane compound, to form an API composition, and administering the API composition to the subject; optionally wherein the method comprises dissolving the API in the one or more excipient compound(s) to form a first composition; and mixing the first composition with the semi-fluorinated alkane compound, to form the API composition; optionally wherein the API is selected from alpha agonists, antibiotics, corticosteroids, anticholinergic agents, antiglaucoma agents, antihistamines, antivirals, anti-parasitics, pressure regulators, topical transient receptor potential melastatin 8 (TRPM8) agonists, inhibitors of inflammatory cell binding, cycloplegics / mydriatics, mast cell stabilizers, miotics, ophthalmic NSAIDs, cyclosporine, riboflavin 5'-phosphate ophthalmic compounds, and VEGF inhibitors and VEGF receptor inhibitors; optionallyATTORNEY DOCKET NO.43081-0032WO1 wherein the API has a logP less than or equal to 4.3, optionally wherein the API has a logP less than 2.0; optionally wherein administering the API composition to the subject comprises administering the API composition to skin or mucosal membrane of a subject, to an eye of the subject, or to a lung of the subject; optionally wherein the composition is in the form of a solution, suspension, emulsion or implant.

8. A method for delivering an API to a target tissue of a subject, wherein the target tissue is selected from skin, mucosal membrane, eye tissue, lung tissue, or a tissue of the oral cavity or esophagus, comprising administering any one of the compositions of any one of claims 1-6 to said target tissue of the subject, optionally wherein the API is selected from alpha agonists, antibiotics, corticosteroids, anticholinergic agents, antiglaucoma agents, antihistamines, antivirals, anti-parasitics, pressure regulators, topical transient receptor potential melastatin 8 (TRPM8) agonists, inhibitors of inflammatory cell binding, cycloplegics / mydriatics, mast cell stabilizers, miotics, ophthalmic NSAIDs, cyclosporine, riboflavin 5'-phosphate ophthalmic compounds, and VEGF inhibitors and VEGF receptor inhibitors.

9. A method for treating, slowing the progression of, or reducing one or more symptoms of a condition in a subject, or inducing one or more symptoms of miosis in a subject, comprising administering the composition of any one of claims 1-6 to the subject.

10. A method for treating, slowing the progression of, or reducing one or more symptoms of an ocular condition in a subject, or inducing one or more symptoms of miosis in a subject, comprising administering the composition of any one of claims 1-6 to an eye of the subject, optionally wherein the ocular condition is selected from neurotrophic keratitis, glaucoma, elevated intraocular pressure, ocular hypertension, presbyopia, myopia, ocular rosacea, dry eye disease, meibomian gland dysfunction, blepharitis, allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis,ATTORNEY DOCKET NO.43081-0032WO1 pterygium, pinguecula, corneal transplant rejection, graft versus host disease, ocular allergy, uveitis, anterior uveitis, Behcet's disease, Sjogren's syndrome, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, chronic ocular surface inflammation caused by viral infection, herpes simplex keratitis, atopic conjunctivitis, Lyell’s syndrome, neovascularization induced by viral, bacterial, fungal, or parasitic infection or an associated disease or symptom thereof, contact lens induced neovascularization, ulceration, alkali burns, stem cell deficiency, neovascular glaucoma, Steven Johnson syndrome, tumor in the eye, aphakia, pseudophakia, astigmatism, blepharospasm, cataract, conjunctival diseases, corneal diseases, corneal ulcer, eyelid diseases, lacrimal apparatus diseases, pupil disorders, refractive disorders, and strabismus.

11. A method for slowing myopia progression in a subject or for relieving vitreous floater symptoms in a subject, comprising administering the composition of any one of claims 1-6 to an eye of the subject, wherein the API is a muscarinic receptor antagonist, optionally wherein the API is selected from atropine, an atropine mimetic or analog, or a free base, hydrate, solvate, or salt form thereof.

12. A method for treating, slowing the progression of, or reducing one or more symptoms of presbyopia or glaucoma in a subject, or for inducing miosis in a subject, comprising administering the composition of any one of claims 1-6 to an eye of the subject, wherein the API comprises a muscarinic cholinergic receptor agonist.

13. The method of any one of claims 10 to 12, wherein the subject is in need of transcorneal absorption of an API; wherein the subject has had an adverse side effect from the API after receiving an aqueous composition comprising the API; and / or wherein the subject is highly sensitive to an aqueous composition comprising the API; optionally wherein the API is in a free base form; optionally wherein the composition is administered to the eye of the subject about every about 6 to about 8 hours or three times a day, and / orATTORNEY DOCKET NO.43081-0032WO1 optionally wherein the composition is administered at a dose 5-10%, 5-15%, 5- 20%, 5-25%, 5-30%, 10-30%, 10-40%, 10-50%, 10-60%, 10-70%, 20-30%, 20-40%, 20- 50%, 20-60%, 20-70%, 30-40%, 30-50%, 30-60%, 30-70%, 40-50%, 40-60%, 40-70%, or 50-70% less than a dose of an aqueous topical ophthalmological composition comprising the API used for the same ocular condition or purpose.

14. A method of administering to a subject a topical ophthalmological composition for selective transcorneal absorption, the method comprising administering to an eye of the subject the composition of any one of claims 1-6; optionally wherein the composition is non-aqueous; and optionally wherein the API is in free base form.

15. A method of treating an ocular condition in a subject, the method comprising: (a) (i) selecting a subject in need of transcorneal absorption of an API; or (ii) selecting a subject having an ocular condition, wherein the ocular condition is in need of transcorneal absorption of an API; and (b) administering to an eye of the subject the composition of any one of claims 1- 6; optionally wherein the composition is non-aqueous; and optionally wherein the API is in free base form.

16. A method of selectively delivering an API to a cornea of an eye of a subject, the method comprising administering to the eye of the subject the composition of any one of claims 1-6; optionally wherein the composition is non-aqueous; and optionally wherein the API is in free base form.

17. A method for crosslinking collagen in a tissue of a subject, comprising: administering to the tissue of the subject the composition of any one of claims 1-6, wherein the API is a compound of Formula (I):ATTORNEY DOCKET NO.43081-0032WO1 R1, R2, and R3 are each independently selectedfrom hydrogen or -C(O)R5; R4 is selected from hydrogen, -C(O)R5, a phosphate, or a salt thereof; and R5 is a linear or branched or cyclic alkyl having 1 to 26 carbon atoms; and irradiating the tissue with UV radiation or blue light; optionally wherein the API is selected from riboflavin, riboflavin tetraacetate, riboflavin tetrapropionate, riboflavin tetrabutyrate, riboflavin tetrapalmitate, or combinations thereof.

18. A method for crosslinking a structural protein, comprising: contacting the structural protein or a biological tissue containing the structural protein with the composition of any one of claims 1-6, wherein the API is a compound of Formula (I):ATTORNEY DOCKET NO.43081-0032WO1 wherein: R1, R2, and R3 are each independently selected from hydrogen or -C(O)R5; R4 is selected from hydrogen, -C(O)R5, a phosphate, or a salt thereof; and R5 is a linear or branched or cyclic alkyl having 1 to 26 carbon atoms; and irradiating the structural protein or the tissue with UV radiation or blue light, optionally wherein the API is selected from riboflavin, riboflavin tetraacetate, riboflavin tetrapropionate, riboflavin tetrabutyrate, riboflavin tetrapalmitate, or combinations thereof.

19. An excipient system for delivering an API to a subject comprising: one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound.

20. A method for making the composition of any one of claims 1-6, the method comprising dissolving the API in a composition comprising: one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound; optionally wherein the method comprises dissolving the API in the one or more excipient compound(s) to form a first composition; and mixing the first composition with the semi-fluorinated alkane compound.

21. A method for treating or reducing one or more symptoms of blepharitis, ocular rosacea, rosacea, or eyelid margin redness in a subject, or for improving eyelash health in a subject, or for treating or eradicating Demodex mites, lice, scabies, or bedATTORNEY DOCKET NO.43081-0032WO1 bugs in a subject, or for treating or preventing a vector-borne disease in a subject, comprising administering the composition of any one of claims 1-6 to the subject, to an eye of the subject, or to skin or hair of the subject, wherein the API is an anti-parasitic; optionally wherein the API is an isooxazoline parasiticide or a formamidine parasiticide; optionally wherein the API is one or more of fluralaner, sarolaner, lotilaner, afoxolaner, and / or fluxametamide, a derivative, analogue, enantiomer, racemic mixture, free base, enantiomerically pure composition, or L- and D-isomer thereof; or optionally wherein the API is selected from ivermectin or a derivative, analogue, racemic mixture, or diastereomer or enantiomer thereof, optionally wherein the ivermectin is a mixture of ivermectin B1a and ivermectin B1b.

22. A method for treating, slowing the progression of, or reducing one or more symptoms of dry eye disease, meibomian gland disfunction, or inflammatory dry eye in a subject, comprising administering the composition of any one of claims 1-6 to an eye of the subject, wherein the API is selected from one or more of lifitegrast, menthol, AR- 15512 ((1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl) cyclohexanecarboxamide), cyclosporine, or derivatives, analogues, pharmaceutically acceptable salts, free base form, racemic mixtures, or diastereomers or enantiomers thereof.

23. A method for treating, slowing the progression of, or reducing one or more symptoms of glaucoma, ocular hypertension, or high fluid pressure in an eye of a subject, or a method of lowering fluid pressure in an eye of a subject, comprising administering the composition of any one of claims 1-6 to an eye of the subject, wherein the API is a pressure regulator; optionally wherein the API is selected from one or more of Brimonidine, Apraclonidine Iopidine, Dorzolamide, Brinzolamide, Azopt, Timolol, Timoptic / Istalol / Betimol, Betaxolol, Betoptic, Levobunolol, Betagan, Metipranolol, Optipranolol, Latanoprost, Xalatan Green, Bimatoprost, Lumigan, Tafluprost, Zioptan, Latanoprostene, Vyzulta Turquoise, Pilocarpine, Carbachol, Isopto Carbachol,ATTORNEY DOCKET NO.43081-0032WO1 Netarsudil, and Rhopressa, and pharmaceutically acceptable salts or free base forms thereof; optionally wherein the API is Brimonidine or pharmaceutically acceptable salts or free base forms thereof and wherein at least one excipient compound is a propylene glycol dilaurate or a propylene glycol dicaprylate.

24. The method of any one of claims 10-16 and 21-23, wherein the composition administered to an eye of the subject, and wherein the API is absorbed transcorneally in the eye, optionally wherein the API is selectively absorbed transcorneally in the eye as compared to periorbitally.

25. The method of any one of claims 10-16 and 21-24, wherein the composition is non-aqueous, and wherein the composition is administered at a dose 5- 10%, 5-15%, 5-20%, 5-25%, 5-30%, 10-30%, 10-40%, 10-50%, 10-60%, 10-70%, 20- 30%, 20-40%, 20-50%, 20-60%, 20-70%, 30-40%, 30-50%, 30-60%, 30-70%, 40-50%, 40-60%, 40-70%, or 50-70% less than a dose of an aqueous composition comprising the API for treating, slowing the progression of, or reducing one or more symptoms of the ocular condition.

26. The method of any one of claims 10-16 and 21-25, wherein the composition is administered to the subject: (i) every about 6 to about 8 hours or three to four times a day, (ii) once a day, or (iii) twice a day.

27. A method of formulating a topical ophthalmological composition for transcorneal absorption, the method comprising combining an active pharmaceutical ingredient (API); one or more excipient compound(s) selected from a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, and combinations thereof; and a semi-fluorinated alkane compound.

28. The composition of any one of claims 1-6, or the method of any one of claims 7-16, wherein the API is:ATTORNEY DOCKET NO.43081-0032WO1 (a) selected from the group consisting of aceclidine, pilocarpine, bethanechol, cevimeline, methacholine, xanomeline, and aprolidine; (b) riboflavin or a riboflavin derivative, optionally wherein the API is selected from riboflavin, riboflavin tetraacetate, riboflavin tetrapropionate, riboflavin tetrabutyrate, riboflavin tetrapalmitate, or combinations thereof; (c) a multikinase inhibitor, optionally wherein the multikinase inhibitor is selected from afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib, or combinations thereof; (d) a co-drug selected from the group consisting of (2R,3S)-3-(2-((4-bromo-lH- benzo[d]imidazol-5-yl)amino)-4,5-dihydro-lH-imidazole-lcarbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2-((4-bromo-lHbenzo[d]imidazol-5- yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-1Himidazol-5- yl)methyl)pentyl propionate; (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5- yl)amino)- 4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5-yl)amino)-4,5-dihydro-lH- imidazolel-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3- (2-((4-bromo-lH-benzo[d]imidazol-5-yl)amino)- 4,5-dihydro-lH-imidazole-l-carbonyl)-2-((lmethyl-lH-imidazol-5-yl)methyl)pentyl oleate; (2R,3S)-3-(2-((4-bromo-lH-benzo[d]imidazol-5- yl)amino)-4,5-dihydro-lH-imidazole-l- carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl (9Z,12Z)-octadeca-9,12-dienoate; (2R,3S)-3-(2-((5-bromoquinoxalin-6-yl)amino)-4,5-dihydrolH-imidazole-l-carbonyl)-2- ((l-methyl-lH-imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2- ((5-bromoquinoxalin-6- yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lHimidazol-5- yl)methyl)pentyl propionate; (2R,3S)-3-(2-((5-bromoquinoxalin-6-yl)amino)-4,5- dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2-((5-bromoquinoxalin-6-yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2- ((lmethyl-lH-imidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((5-ATTORNEY DOCKET NO.43081-0032WO1 bromoquinoxalin-6-yl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl- lHimidazol-5-yl)methyl)pentyl oleate; (2R,3S)-3-(2-((5-bromoquinoxalin-6-yl)amino)- 4,5-dihydrolH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl (9Z,12Z)-octadeca- 9,12-dienoate; (2R,3S)-3-(2-((4-amino-2,6-dichlorophenyl)amino)- 4,5-dihydro-lH-imidazole-lcarbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l- carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl propionate; (2R,3S)-3-(2-((4- amino-2,6-dichlorophenyl)amino)-4,5-dihydrolH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2- ((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lHimidazol-5- yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((4-amino-2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol- 5- yl)methyl)pentyl oleate; (2R,3S)-3-(2-((4-amino-2,6-dichlorophenyl)amino)-4,5- dihydro-lHimidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5-yl)methyl)pentyl (9Z,12Z)- octadeca-9, 12-dienoate; (2R,3S)-3-(2-((2,6-dichlorophenyl)amino)-4,5-dihydro-lH- imidazole-l-carbonyl)-2- ((l-methyl-lH-imidazol-5-yl)methyl)pentyl acetate; (2R,3S)-3- (2-((2,6-dichlorophenyl)amino)- 4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l-methyl-lH- imidazol-5-yl)methyl)pentyl propionate; (2R,3S)-3-(2-((2,6-dichlorophenyl)amino)-4,5- dihydro-lH-imidazole-l-carbonyl)-2- ((l-methyl-lH-imidazol-5-yl)methyl)pentyl butyrate; (2R,3S)-3-(2-((2,6-dichlorophenyl)amino)- 4,5-dihydro-lH-imidazole-l-carbonyl)-2-((l- methyl-lH-imidazol-5-yl)methyl)pentyl cyclopropanecarboxylate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)-4,5-dihydro-lH-imidazolel-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl oleate; (2R,3S)-3-(2-((2,6- dichlorophenyl)amino)-4,5-dihydro-lH- imidazole-l-carbonyl)-2-((l-methyl-lH-imidazol-5- yl)methyl)pentyl (9Z,12Z)-octadeca- 9,12-dienoate; and (2R,3S)-3-((Z)-2-((5-bromoquinoxalin-6-yl)imino)imidazolidine-1- carbonyl)-2-((1-methyl-1H-imidazol-5-yl)methyl)pentyl pivalate, or combinations thereof; (e) an isooxazoline parasiticide or a formamidine parasiticide. (f) one or more of fluralaner, sarolaner, lotilaner, afoxolaner, and / or fluxametamide, a derivative, analogue, enantiomer, racemic mixture, free base, enantiomerically pure composition, or L- and D-isomer thereof;ATTORNEY DOCKET NO.43081-0032WO1 (g) lifitegrast, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof; (h) cyclosporine, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof; (i) menthol, AR-15512 ((1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(1- methylethyl) cyclohexanecarboxamide), or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof; (j) selected from one or more of Brimonidine, Apraclonidine Iopidine, Dorzolamide, Brinzolamide, Azopt, Timolol, Timoptic / Istalol / Betimol, Betaxolol, Betoptic, Levobunolol, Betagan, Metipranolol, Optipranolol, Latanoprost, Xalatan Green, Bimatoprost, Lumigan, Tafluprost, Zioptan, Latanoprostene, Vyzulta Turquoise, Pilocarpine, Carbachol, Isopto Carbachol, Netarsudil, and Rhopressa, and pharmaceutically acceptable salts or free base forms thereof; (k) Brimonidine; or (l) selected from ivermectin or a derivative, analogue, racemic mixture, or diastereomer or enantiomer thereof, optionally wherein the ivermectin is a mixture of ivermectin B1a and ivermectin B1b.

29. The composition of any one of claims 1-6, or the method of any one of claims 7-16 or 24-27, wherein the API is: (a) Brimonidine or pharmaceutically acceptable salts or free base forms thereof, optionally wherein at least one excipient compound is a propylene glycol dilaurate or a propylene glycol dicaprylate; (b) lifitegrast, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, optionally wherein at least one excipient compound is a propylene glycol dilaurate or a propylene glycol dicaprylate; (c) aceclidine, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, optionally wherein at least one excipient compound is a coco-caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate;ATTORNEY DOCKET NO.43081-0032WO1 (d) axitinib, or a derivative, analogue, pharmaceutically acceptable salt, free base form, racemic mixture, or diastereomer or enantiomer thereof, optionally wherein at least one excipient compound is a coco-caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate; (e) atropine, or an atropine mimetic or analog, or a free base, hydrate, solvate, or salt form thereof, optionally wherein at least one excipient compound is a coco- caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate; (f) (2R,3S)-3-((Z)-2-((5-bromoquinoxalin-6-yl)imino)imidazolidine-1-carbonyl)- 2-((1-methyl-1H-imidazol-5-yl)methyl)pentyl pivalate, or a free base, hydrate, solvate, or salt form thereof, optionally wherein at least one excipient compound is a coco- caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate; or (g) ivermectin or a derivative, analogue, racemic mixture, or diastereomer or enantiomer thereof, optionally wherein the ivermectin is a mixture of ivermectin B1a and ivermectin B1b, optionally wherein at least one excipient compound is a coco- caprylate / caprate, a propylene glycol dilaurate, or a propylene glycol dicaprylate.

30. A dispenser comprising: a container portion comprising an interior wall defining an interior volume and adapted to contact and store a liquid within at least a portion of the interior volume; and any one of the compositions of claims 1-6, 28, or 27, or the excipient system of claim 19, contained within the interior volume.

Images